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Hereditary diffuse gastric cancer (HDGC) is the familial predisposition to poorly-
differentiated, diffuse gastric adenocarcinoma. It is inherited in an autosomal dominant 
manner and shows high penetrance for diffuse gastric cancer as well as lobular breast 
cancer. Due to the unreliability of endoscopic detection, the primary management strategy 
for HDGC is prophylactic total gastrectomy. There is an urgent need for effective drugs for 
use in conjunction with screening in order to mitigate reliance on surgery.
Germline inactivating mutation of the tumour suppressor gene E-cadherin (CDH1) and its 
functional relatives accounts for the majority of HDGC diagnoses. E-cadherin is a 
transmembrane protein that plays key roles in establishing and maintaining cell-cell 
adhesions, apicobasal polarity and mitosis. Although not amenable to conventional drug 
targeting, the loss of E-cadherin is predicted to create vulnerabilities that can be targeted.
Synthetic lethal interactions occur between two genes where only inactivation of both 
genes is lethal, while inactivation of either gene alone is tolerated. Candidate synthetic 
lethal targets were silenced with shRNA and drugs in an isogenic (CDH1-/- and CDH1+/+) 
MCF10A background. Quantitation of gene expression and analysis of cell viability 
following treatment was used to assess synthetic lethal effect.
In this investigation, microtubule-associated targets MAST2 and MAP1B, and mitotic 
regulators Aurora-A and -B kinase, were identified as vulnerabilities in an E-cadherin-
deficient context. Microtubules have been the targets of many drugs since the advent of 
chemotherapy, and represent a central set of functions that become perturbed in E-
cadherin-deficient cells. Given the role of E-cadherin, it is rational to target microtubule and
mitotic processes and further investigation of agents that target these functions is 
warranted.
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1. Introduction
In the post-genomic era, there is an ever growing understanding of the molecular
mechanisms that drive cancer. This understanding facilitates the development of specific,
targeted treatments that are both increasingly effective and carry reduced side effects.
While this has contributed to a decrease in cancer mortality, incidence has not fallen as
sharply, a trend that reflects focus upon the treatment rather than the prevention of the
disease.
Germline mutation of the tumour suppressor gene E-cadherin (CDH1), predisposes
individuals to hereditary diffuse gastric cancer (HDGC). HDGC is highly penetrant, with a
70% lifetime risk of diffuse gastric cancer and an additional 40% risk of lobular breast
cancer in women (Vogelaar et al., 2015). The primary management strategy for HDGC is
prophylactic gastrectomy due to the unreliability of endoscopic detection (Charlton et al.,
2004). Consequently, there is a need for chemoprevention drugs which can be used in
conjunction with endoscopy to mitigate the reliance on surgery.
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In hereditary cancer syndromes, the molecular driving mechanisms are more predictable
than in sporadic cancers and thus more amenable to a chemoprevention approach. A
multifaceted approach, combining bioinformatics and high-throughput screening, provides
one way to build an unbiased view of the molecular vulnerabilities that could be exploited
for the chemoprevention of familial cancers. A chemoprevention approach will both
decrease the long-term burden on the health system and provide improved outcomes for
at-risk individuals.
Inactivating mutations in tumour suppressor genes are less accessible drug targets due to
the absence of a perturbed protein. However, inactivation of tumour suppressor genes is
predicted to create vulnerabilities that may be targeted with a synthetic lethal approach.
The development of a novel class of 'synthetic lethal' drugs could be used for the
chemoprevention of HDGC and also the improved management of sporadic diffuse gastric




Cancer mortality rates (in the US) have steadily decreased at about 1% per year over the
last decade (AACR, 2012), owing primarily to development of powerful new targeted
therapies and improved screening. While rates are down, the total numbers diagnosed and
dying are increasing (AACR, 2012). While the primary factor for this is an aging population,
the increased exposure to hazardous environmental factors (processed food, atmospheric
pollution, smoking, etc), and increasingly sedentary and high-stress lifestyles also
contribute to increasing incidence (Crew & Neugut, 2006)
Incidence and mortality rates of gastric cancer has fallen significantly over the last 50+
years, though this trend is now flattening as the Western lifestyle prevails (Crew & Neugut,
2006). Although the mortality rate is decreasing, gastric cancer affects almost one million
people annually, and was responsible for 720,000 deaths in 2012 – the second biggest
killer only to lung cancer. Nearly two-thirds of cases occur in developed countries and
incidence rates vary up to ten-fold (Crew & Neugut, 2006; Torre et al., 2012). Countries
with high rates of Helicobacter pylori (H. pylori) infection and consumption of processed
and fermented food show above-average rates of gastric cancer. For example, South
Korea has a rate of 50 per 100,000, while in New Zealand 8 per 100,000 are affected by
the disease (the global average is ~14 per 100,000; Torre et al., 2012). In New Zealand,
males aged 25-44 who died of cancer most commonly died of gastric cancer (NZMOH,
2010).
1.1.2. Gastric cancer
According to Lauren's classification, gastric cancer can be separated into two primary
types: intestinal and diffuse (Lauren, 1965), each with distinct genetic profiles,
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pathogenesis, epidemiology and morphology. In the intestinal type, cohesive cells form a
mass of gland-like tubular structures that form visible lumps and are more amenable to
detection. In the diffuse type, signet ring cell (SRC)-esque cells and associated fibroblasts
thicken the stomach wall without forming a solid mass, making detection more difficult.
Even advanced cancers may go undetected if there is no visible perforation of the lumen
(Hanaoka et al., 2010). Diffuse gastric cancer (DGC) can be discriminated from intestinal
gastric cancer based the absence of CDH1 expression (Becker et al., 1994).
While the intestinal type carries a stronger environmental etiology, the diffuse type shows
a stronger genetic contribution. Only the diffuse type is associated with HDGC, and
because of the difficulty in detecting DGC by endoscopy, more cases are diagnosed at late
stages and carry poorer prognoses (Torre et al., 2012). Recently, gastric adenocarcinoma
has been classified further into four molecular subgroups: tumours positive for Epstein-Bar
virus (EBV); microsatellite unstable tumours; genomically stable tumours; and genomically
unstable tumours (TCGA Research Network, 2014). Genomically stable tumours show
frequent RHOA a n d CDH1 mutations while genomically unstable tumours show
amplifications in receptor proteins and receptor tyrosine kinases (RTKs) linked to abnormal
growth signalling.
1.2. Hereditary diffuse gastric cancer
1.2.1. History
The existence of familial gastric cancer has been known about since the 1800s when
multiple cases of gastric cancer were observed in the Bonaparte family. By some
accounts, while on his deathbed, Napoleon proclaimed that he “has [his] father's stomach”
- although others believe he succumbed to arsenic poisoning (Sokoloff, 1938). The first
link between germline CDH1 mutation and familial DGC was made in 1998 (Guilford,
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1998). It is estimated that inherited cancer predisposition syndromes accounting for 1-3%
of gastric cancer incidence, while the rest is sporadic. Other syndromes associated with
occasional cases of gastric cancer include Li-Fraumeni syndrome, Lynch syndrome and
familial adenomatous polyposis, among others (Vogelaar et al., 2015).
1.2.2. HDGC diagnosis
Hereditary diffuse gastric cancer (HDGC) is inherited in an autosomal dominant manner
(figure 1.1). It is characterised by germline mutation of CDH1, the gene encoding the cell-
cell adhesion protein E-cadherin. HDGC is highly penetrant, with at-risk individuals
harbouring a 70% lifetime risk of developing DGC (figure 1.1). Women carry an additional
42% lifetime risk of developing lobular breast cancer (LBC, Vogelaar et al., 2015). 
Figure 1.1. HDGC family pedigree. Partial pedigree of original HDGC family harbouring
germline CDH1 mutation. Black fill represents those affected by diffuse gastric cancer,
slash indicates individual is deceased (Guilford et al., 1998).
The clinical criteria for HDGC-like families (including second-degree relatives) to be tested
for germline CDH1 mutation is: (1) two or more gastric cancers at any age with one
confirmed DGC; (2) both DGC and LBC with one before age 50; and (3) one confirmed
DGC before age 40 (van der Post et al., 2015). Among families that fit this criteria the
average age of onset is 38 years old, and it is estimated CDH1 mutation will account for
25-40% of cases (Hansford, 2015; Vogelaar et al., 2012). A small number of families
carrying CTNNA1 mutations have also met this criteria, and share many clinical similarities
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with CDH1 mutation-positive familiies (Majewski et al., 2013). HDGC is best defined by
mutations in CDH1 or related genes, both in function (ie, adhesion molecules) or
regulation (ie, transcriptional activator of CDH1; Hansford, 2015). It is likely more genes
associated with HDGC will be identified through whole genome or exome next-generation
sequencing approaches, although to date no additional compelling genes have been found
(P Guilford, pers. comm., 2016).
1.2.3. Pathogenesis
Most HDGC patients with CDH1 mutation develop asymptomatic/preclinical, indolent,
multifocal signet ring cell carcinomas (SRCC), enriched in the body-antral transitional zone
of the stomach (figure 1.2). These early foci sometimes proliferate slowly, evident by the
lack of mitotic cells and low Ki-67 expression (Humar et al., 2009), suggesting E-cadherin-
deficient cells lack a major selective growth advantage. However, further genetic and
epigenetic changes may drive neoplastic growth and fuel the progression of the disease.
Risk factors for DGC are discussed below (chapter 1.4.4) . 
Figure 1.2. Multifocal tumours in early HDGC. Stomach of HDGC individual, showing
the density and localisation of indolent, multifocal stage T1a SRCC. This patient had >125
identified lesions. Adapted from Charlton et al., (2004).
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A proposed model for HDGC development starts with carcinoma in situ, corresponding to
signet ring cell (SRC) presence in the superficial lamina propria that follows a pagetoid
(upwards) spread around the edge of the gland (Humar et al., 2009). The disease may
then spread throughout the lamina propria, followed by thickening of the gastric wall by
sustained tumour cell infiltration in a disease process called linitis plastica. Like sporadic
DGC, advanced HDGC mainly presents as linitis plastica with diffuse infiltration of the
gastric wall. 
The stomach is comprised of distinct role-specific tissue layers (figure 1.3): the upper
mucosa, submucosa, muscularis and serosa. The upper gastric mucosa is the mucous
membrane layer that contains the gastric pits and glands and is comprised of epithelium,
lamina propria and the muscularis mucosae. Epithelium forms the upper layer of structures
such as glands and sits atop a basement membrane, while the rest of the mucosa is
lamina propria. Together, the epithelium and lamina propria sit atop the muscularis
mucosae.
Figure 1.3. Anatomy of the stomach. DGC is thought to originate from hyperproliferative
progenitor cells in the upper neck of the gastric glands in the gastric mucosa. Adapted
from Britannica (2003).
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There are three types of glands: cardiac (proximal part of stomach), oxyntic glands (most
common), and pyloric glands, each with unique secretory roles. DGC is thought to
originate from the hyperproliferative mucous neck progenitor cells in the upper isthmus of
a gastric (most likely oxyntic) gland. The leading hypothesis for the mechanism of cancer
initiation following E-cadherin (CDH1) loss posits that disruption of polarity in gastric
progenitor cells leads to abnormal mitotic spindle orientation and subsequent division out
of the epithelial plane (Humar & Guilford, 2009). 
1.3. E-cadherin
Epithelial tissues line the surfaces and cavities of structures throughout the body. The
primary functions of mammary and gastric epithelium is physical protection, controlling
transport and secretion. E-cadherin is highly expressed in gastric epithelium, playing roles
in maintaining tissue integrity, cell polarity, intercellular signalling and the regulation of
mitosis (Nose et al., 1990). E-cadherin is encoded by CDH1 (16q22.1) and consists of a
single transmembrane domain, a 150-amino acid cytoplasmic domain, and a 550-amino
acid ectodomain comprising five tandem repeats (figure 1.4). 
Figure 1.4. Interactions of E-cadherin. The extracellular domain of E-cadherin forms
adherens junctions with adjacent cells, while the cytoplasmic domain directly links to the
cytoskeleton and facilitates signal transduction. Adapted from Perry et al., (2012).
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The ectodomain of E-cadherin forms Ca2+-dependent adherens junctions with the E-
cadherin of an adjacent cell to facilitate the organisation of polarised tissue monolayers.
Radial actin filaments interact with adherens junctions via a cadherin/catenin complex to
create a dynamic tension-based cytoskeletal plane across the apical surface of epithelial
layers (Vaezi et al., 2002). Adherens junctions bear the force between epithelial cells and
are important for maintaining cell shape and transport physiology while providing a barrier
against microbial infection and gastric secretions (Turner et al., 2009). 
The cytoplasmic tail forms a complex with catenins that are in turn directly linked to the
cytoskeleton. This interaction helps maintain polarity, cellular architecture and aids in
receptor recycling. The tail also stabilises signaling complexes inside the membrane, and
is directly involved in the transduction of pathways including Wnt/β-catenin, PI3K/AKT and
Rho GTPase signalling (van den Bossche et al., 2012). 
E-cadherin mediated cell-cell adhesion provides spatial cues that promote and establish
apical-basal polarity. Cytoskeletal filament interaction with adherens junctions at the
apicolateral corners is central to establishing polarity, though the mechanism is not clearly
understood. Mitotic spindle orientation must be tightly controlled in the Z-axis in order to
preserve the architecture of the tissue (Fleming et al., 2007). E-cadherin acts as a spatial
cue within the cell to direct mitotic spindle orientation from the centrosome (den Elzen et
al., 2009). Ordinarily, cleavage furrow formation is immediately followed by adherens
junction formation, which means apicobasal polarity is maintained during all stages of
mitosis.
E-cadherin is directly involved in signal transduction of pathways such as Wnt/β-catenin
and PI3K/AKT (Lau et al., 2011). Wnt signalling controls stem cell pluripotency and cell
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fate decisions through transcriptional activation by β-catenin (Jamora & Fuchs, 2002),
while PI3K/AKT signalling feeds in to important proliferation and survival pathways (Lau &
Leung, 2012). Once activated, AKT translocates to the nucleus where it regulates
transcription of cell survival, cell cycle and migration genes. AKT signalling is disrupted
following the loss of E-cadherin mediated cell-cell adhesions, leading to retarded cell
proliferation and an increased propensity for transformation (Reddy et al., 2009; Huber et
al., 2005).
β-catenin contains a default nuclear localisation signal, though it is regularly bound at the
cell membrane to the cytoplasmic tail of E-cadherin. In the absence of E-cadherin, β-
catenin can freely migrate towards the nucleus and activates the transcription of Wnt-
controlled genes. Wnt target genes, such as c-MYC or cyclin D1, are associated with
increased growth, invasion and cellular transformation. (Lin et al., 2000, He et al., 1998).
Further, β-catenin is degraded by GSK3B, which is inactivated by active AKT. Constitutive
activation of PI3K/AKT therefore reinforces nuclear β-catenin signalling (Lau et al., 2011).
1.3.1. E-cadherin-deficient tumourigenesis
Early DGCs are frequently signet ring cell carcinoma (SRCC). Lineage markers of early
SRCC foci point towards mucous neck cells that have invaded the basement membrane
as the primary origins (Humar et al., 2007). Early SRCC cells can express markers for a
variety of cell types including pit, neck and chief cells, accordant with defective distribution
of factors that determine cell fate (Humar et al., 2009). E-cadherin loss leads to cell
division outside of the epithelial plane and the formation of early SRCC foci.
In cultured adherent cells, Ca2+-depletion abolishes correct spindle orientation by
disrupting adherens junction-mediated cell adhesion (Yap et al., 2009). Similarly,
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expressing only the endodomain of E-cadherin without the extracellular linker ectodomain,
or inhibiting ectodomain interactions, leads to incorrect spindle orientation (Yap et al.,
2009). As the cytoplasmic anchorage points for the cytoskeleton were not ablated in these
studies, this indicates the loss of adherens junction-mediated cell adhesion alone is
sufficient to affect the mitotic spindle angle. Furthermore, inducible double negative E-
cadherin knockout mice showed increased frequency of epithelial anaphase angles above
10 degrees (den Elzen et al., 2009). Loss of the extracellular linker domain is likely to
account for the majority of E-cadherin-deficient pathogenesis. It is postulated that
disrupted spindle orientation leads to hypertrophy of the gastric crypt epithelium, as
orientation of the preceding cell division tends to be maintained in subsequent divisions
(Humar & Guilford, 2009).
In gastric cancer, the basement membrane must be degraded or otherwise perforated for
a misaligned daughter cell to be displaced into the lamina propria. A potential mechanism
for this involves gastric proteases penetrating the basement membrane due to the loss of
epithelial barrier function. Proteases that are likely responsible for this include pepsinogen,
matrix metalloproteases and collagenases – some of which have been shown to be
upregulated in response to E-cadherin downregulation (Radisky & Radisky, 2010;
Morohara et al., 2006). Cellular invasion through the basement membrane into the lamina
propria is considered evidence for diagnosis of invasive cancer (Okabayashi & Shima,
2013).
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Figure 1.5. Model of early events in HDGC. (Left to right): (i) E-cadherin loss leads to
misaligned division; (i) division out of epithelial plane is maintained; (iii) accumulation of
dividing cells without a mass or perforation; (iv) invasion of submucosa, associated with
EMT and metastasis. Adapted from Humar & Guilford (2009).
E-cadherin downregulation is a hallmark of the epithelial-mesenchymal transition (EMT),
although is insufficient to trigger the event alone (Chen et al., 2014). During an EMT, cells
gain invasive and migratory capabilities that are associated with mesenchymal phenotype
(Huber et al., 2005). Lymphatic and vascular structures reside in the submucosa below the
lamina propria, and growth of the tumour into these circulatory systems can lead to cells
being further displaced into distal tissues, initiating metastasis. Though E-cadherin loss
alone is insufficient to confer a selective growth advantage, the loss of adhesion and
spatial cues for polarity, combined with increased pro-survival signalling, gives rise to an
invasive, poorly-differentiated phenotype.
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1.3.2. Genetic abnormalities of CDH1
The majority of pathogenic CDH1 abnormalities in HDGC are inactivating mutations
(frameshift, splice site, nonsense) although many missense mutations have also been
identified. Germline mutations of CDH1 are found evenly distributed throughout the 16
exons of the gene without regional clustering (Hansford et al., 2014). This is in contrast to
sporadic diffuse gastric cancer, where mutations cluster in exons 7-9 (Fitzgerald, 2004).
Figure 1.6. Genetic abnormalities of CDH1. Mapping of germline CDH1 mutations
described to date by mutation type and location on CDH1 transcript. Adapted from
Hansford et al., (2014).
Although very abundant SRCC foci have been described in particular families, no
correlations between phenotype and location or type of mutation has yet been made
(Guilford et al., 2010). The somatic inactivation of the second CDH1 allele triggers the
initiation of HDGC pathology/pathogenesis and is most commonly gene promoter
hypermethylation (over 50%; Humar et al., 2009). Interestingly, epigenetic downregulation




It remains unclear why DGC and LBC are the only frequent tumours associated with
germline CDH1 mutation. However, risk factors for further genetic and epigenetic damage
in the gastric epithelium include increased carcinogen exposure or activity (particularly
salted, preserved, cured foods; smoking, alcohol), hypoxia, chronic inflammation, obesity,
Helicobacter pylori (H. pylori) and, more recently, Epstein-Barr virus infection (TCGA,
2014; Torre et al., 2012). 
Chronic inflammatory responses such as gastritis lead to an increase of cyclooxygenase-2
(COX-2) and prostaglandin E2 which induce transcriptional repressors of CDH1 (Wild &
Hardie, 2003; Dohadwala et al., 2006). The transcriptional repression of CDH1 may lead to
stable promoter methylation and a long-term reduction in CDH1 expression (Niwa et al.,
2010). 
H. pylori infection is the primary risk factor for sporadic gastric cancer, with geographic
variation of cancer incidence paralleling infection rates, although this factor is more
pertinent to the intestinal subtype than the diffuse (Okabayashi & Shima, 2013). H. pylori
infection leads to cell junction protein translocation away from the membrane – a possible
mechanism for displacement of a daughter cell outside the epithelial plane which is then
maintained in future divisions. This may be a unique mechanism that does not fit the
traditional paradigm of a “second hit” mutation, although sufficient for initiation of the
cancer because out-of-plane division angles are maintained. As gastric progenitor cells
may already have decreased CDH1 expression compared to their differentiated





Because gastric cancer is difficult to treat effectively, the best approach for improving
clinical outcomes is primary prevention. The most modifiable risk factors are salt/nitrite
consumption, fruit/vegetable consumption, alcohol consumption, tobacco smoking, stress
and H. pylori infection (Uemura et al., 1997). Global improvement of sanitary and housing
conditions, as well as use of refrigeration, has led to decreased H. pylori infection (La
Vecchia, 1990). Antioxidant intake such as vitamins C and E and β-carotene may show a
preventive role through protection from DNA damage, though the effect is most
pronounced in populations with low micronutrient intake (Yuan et al., 2004). In white
Americans, it is estimated that between 40-70% of carcinomas may be prevented by
controlling modifiable risk factors, emphasizing the need to prioritise primary prevention
(Song & Giovannucci, 2016).
COX-2 plays roles in the inflammatory response and may be carcinogenic in gastric
cancer (GC) via induction of CDH1 repressors. Expression of COX-2 is induced by
tobacco, acidic conditions and H. pylori infection (McCarthy et al., 1999), therefore COX-2
inhibiting drugs (ie, aspirin, non-steroidal anti-inflammatory drugs) or foods (curcumin from
turmeric) may be chemopreventive in GC (Uefuji et al., 2000). Non-psychotropic
cannabinoids such as cannabigerol (CBG) have potent effects in counteracting intestinal
inflammation (Izzo & Camilleri, 2009), and have also been identified as potential
chemopreventive agents for GC (Borrelli et al., 2014). 
1.4.2. Genetic testing
Genetic counseling is an essential aspect of the clinical management of HDGC families.
Clinical guidelines recommend a full multidisciplinary team comprising expertise in gastric
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surgery, gastroenterology, breast oncology, pathology, psychosocial support and nutrition
(Vogelaar et al., 2015; van der Post et al., 2015). In New Zealand, individuals from
identified or suspected HDGC families undergo genetic testing with informed consent from
age 16 to determine CDH1 mutation status. This analysis is carried out with a combination
of Sanger sequencing and Multiplex Ligation-dependent Probe Amplification to assess the
entire open-reading frame, including exon-intron boundaries, and copy number analysis of
individual exons (van der Post, 2015). Testing of younger family members prior to age of
informed consent is also considered on a case-by-case basis.
However, this analysis is imperfect because CDH1 is large (~5kb) with broad mutation
distribution. In some instances, it may also be difficult to determine whether a mutation is
pathogenic or a benign polymorphism. While over 155 pathogenic germline variants of
CDH1 have been published worldwide (figure 1.6), and many others still unpublished,
there are likely to be further polymorphisms of reduced penetrance or unknown
significance yet to be identified. Further, CDH1-related genes such as catenins (ie,
CTNNA1) or transcriptional activators of CDH1 can contribute to HDGC in clinically similar
ways.
1.4.3. Prophylactic gastrectomy
DGC is difficult to detect in its early stages due to its diffuse phenotype and often absence
of a visible mass. Multiple small SRCC foci have been found in almost all germline CDH1
mutation carriers, even as young as 15 (Charlton et al., 2004). Thus, the only existing
option to eliminate risk of DGC in HDGC families is prophylactic total gastrectomy. This
procedure involves the total removal and resection of the stomach (figure 1.7) and is
curative if there has been no metastatic spread of the disease. The procedure itself reports
a 0-6% mortality risk and is lowest in young, healthy individuals (Haverkamp, 2015).
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Figure 1.7. Surgical overview of total gastrectomy. Prophylactic total gastrectomy is
performed by Roux en y procedure. Aapted from Zanmeel (2014).
Despite laparoscopic techniques, total gastrectomy is a major surgery and leaves patients
with 100% lifetime morbidity (Huscher et al., 2005). Morbid effects commonly include
weight loss, diarrhoea and altered eating habits because of reduced gastric secretions and
transit time. Fat, iron and vitamin A/D/E/K/B12 malabsorption and deficiency also occur
with the resultant nutritional and metabolic problems requiring careful monitoring.
1.4.4. Endoscopic screening 
In Japan, workforce endoscopic screening has led to detection of half of gastric cancers at
an asymptomatic stage, effectively halving the mortality rate for sporadic gastric cancer
since 1970 (Yamaguchi, 2002). Based their level of effectiveness, the current screening
recommendations for individuals with HDGC who decline gastrectomy are upper
endoscopy with multiple biopsies on an annual basis. The endoscopic process can involve
white light gastroscopy or chromoendoscopy (figure 1.8; Shaw et al., 2005; Okabayashi &
Shima, 2013). 
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Figure 1.8. White light endoscopy and chromoendoscopy. (a) White light endoscopy;
and (b) chromoendoscopy with indigo carmine dye. Drawbacks of white light endoscopy
include difficulty identifying lesions in macroscopically normal appearing tissue, where
chromoendoscopy may be used to help highlight the area. Adapted from Okabayashi &
Shima (2013).
The drawbacks of these methods include difficulty in identifying submucosal lesions and
sampling bias in macroscopically normal appearing mucosa. Expert histopathological
identification of early SRCC is recommended and can be achieved with biopsies. 
In one clinical HDGC report, SRCC foci were found in 2/23 patients using preoperative
white light gastroscopy. However, pathological examination of the resected stomach
identified foci in 22/23 patients, highlighting the difficulty of detecting early lesions with
routine endoscopy (Charlton et al., 2004) .
White light endoscopy alone is an imperfect method because DGC infiltrates down without
ulceration or distortion of the epithelium. Consequently, advanced cancer in one individual
of a routinely screened New Zealand cohort of 30 CDH1 mutation carriers escaped
detection and the patient subsequently died (P Guilford, pers. comms., 2015).
Chromoendoscopy relies on a pH-sensitive dye, such as Congo red or indigo carmine, that
allows the visualisation of acid secreting mucosa. Chromoendoscopy with Congo red
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following gastric secretory stimulation by pentagastrin may help highlight areas of interest
(Shaw et al., 2005). Though the method is more sensitive, it has been criticised for being
toxic and is still not able to detect foci <4mm (Marti et al., 2005). Toxicity is even less
desirable in circumstances requiring constant surveillance, such as in HDGC families, and
some have recommended against use of these agents (Marti et al., 2005). Current
surveillance methods may be succeeded by emerging technologies such as narrow band
imaging, blue laser imaging and confocal laser endomicroscopy (Dunbar & Canto, 2008),
to allow detection of sub-luminal foci in vivo.
Mapping of early SRCC foci in some studies has identified densities up to five times higher
in the body-antral transitional zone than in the body or antral zones alone (Charlton et al.,
2004; Fujita et al., 2012). Such a high density of cancer foci, in a zone comprising under
10% of the gastric mucosal surface, supports the use of targeted transitional zone biopsies
in HDGC surveillance. Biopsies targeted to pale areas are also performed, although this is
affected by pale scarification from previous biopsies and may increase the chances of
bleeding and biased sampling (Vogelaar et al., 2015). The current clinical guideline is for
random biopsies to be taken from all areas of the stomach (van der Post, 2015).
Faced with an additional 42% risk of developing breast cancer, it is recommended that
women with a CDH1 mutation undergo annual breast MRI screening and may also
consider prophylactic mastectomy. This option is reviewed on case-by-case basis because
the cancer has a lower penetrance. Some guidelines recommend using selective
oestrogen receptor modulators or aromatase inhibitors for chemoprevention (van der Post,
2015). In Australia, which has a similar cancer picture to New Zealand, it is estimated that
the lives of up to 300 GC patients could be saved per year through widespread uptake of a
simple stool test that tests for the presence of blood, with positive tests warranting further
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investigation (NZSO Physician, 2015). However, it is unclear whether these tests would be
useful for DGC and HDGC in particular.
1.4.5. Psychosocial effects
The psychological toll of concern over a cancer diagnosis is also a factor faced by at-risk
individuals who opt for surveillance over surgical prophylaxis. The main psychosocial
problems include fear and anxiety in coping with cancer, practical (ie, life insurance) and
family issues (Vogelaar et al., 2015). Although the effects are difficult to qualify or quantify,
prophylactic surgery on physically and psychologically fit individuals may mitigate some
concerns. However, surgery-related morbidity can carry its own psychological burden.
1.4.6. Prognosis
Currently, the 5-year survival rate for DGC does not exceed 30% (Correa, 2013; Stiekama
et al., 2013), reflecting the hazards posed by delayed detection of clinically-silent early
disease. This exemplifies the benefit that young, healthy individuals may reap from a
prophylactic total gastrectomy, regardless of the long list of morbidities. As few as 10% of
patients who develop invasive, symptomatic DGC have curable disease (Koea et al.,
2000). DGC is more inclined to spread via peritoneal dissemination, and is considered
invasive disease following growth into the lamina propria. Locally advanced and metastatic
gastric cancer has 5-year survival rates as low as 0% (Ridwelski et al., 2001). As well as
the need to improve detection methods, this highlights the need for better
chemotherapeutic and/or chemopreventive drugs.
1.4.7. Early tumour homogeneity
Tumour heterogeneity – where different cells from the same tumour show distinct
phenotypes and genotypes – presents a significant obstacle in ridding a patient of cancer
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(figure 1.9). This is because additional genetic and epigenetic changes may confer
protection against one or more forms of treatment. In early HDGC, the presence of
synchronous, indolent foci argues against the presence of additional mutation events,
suggesting the earliest disease is attributable to CDH1 silencing alone. 
Figure 1.9. Tumour heterogeneity and post-therapy relapse. Heterogeneous tumours
are difficult to fully treat due to the distinct phenotypes produced through additional genetic
events during tumour progression and evolution. This feature is absent from early HDGC
tumours, suggesting that drug regimentation may elicit a strong, uniform response.
Adapted from Meacham (2013).
Multiple cancer foci in early HDGC should be equally amenable to a given drug treatment
as they are homogeneous and have not yet acquired further genetic changes. With a
chemopreventive approach, early foci could, in principle, be eliminated before further
genetic changes fuel progression. Thus, drugs that are selectively lethal to E-cadherin-
deficient epithelial cells could be administered to at-risk individuals in HDGC families to
prevent or delay the development of advanced disease.
1.5. Chemotherapy
1.5.1. History
The era of chemotherapy began during World War II. Research into agents of chemical
warfare lead to the discovery of a genotoxic (DNA damaging) compound called nitrogen
mustard, which was found to be effective against lymphoma by rapidly killing growing
cancer cells via DNA damage. Since then, a plethora of drugs have been discovered that
target a variety of functions in cancer cells.
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Traditional cytotoxic chemotherapies act by damaging DNA to kill rapidly dividing cells,
exploiting one of the main properties of most cancer cells. However, this also leads to
harm in cells that divide rapidly in normal condition such as cells in the digestive tract and
hair follicles, leading to gastrointestinal toxicity, hair loss and other side effects. In the 20 th
century the focus was cytotoxic drugs, while that has now shifted to targeted therapies
(Baguley 2002). Targeted therapies block the growth of cancer cells by interfering with
specific molecules using specific, targeted drugs. Targeted therapies are chosen or
designed to interact with their target, while traditional chemotherapies were identified
because they kill cells, with little thought for their mechanism of action.
1.5.2. Chemotherapy in diffuse gastric cancer
The most effective treatment for patients with sporadic gastric cancer is perioperative
(before and after surgery) chemotherapy combined with total gastrectomy (Cunningham et
al., 2006). Drug regimentation includes infused cycles of epirubicin, cisplatin and daily
infused 5-fluorouracil (5-FU). This approach was more effective than surgery alone and
reports a 5-year survival rate of 36% for advanced, resectable cancers. This highlights the
utility of effective drugs for further improving patient outcomes, although these first-line
treatment modalities are non-targeted chemotherapies that rely on rapid cell proliferation.
Furthermore, there is little available data on the value of perioperative chemotherapy
specifically in the diffuse subtype (P Guilford, pers. comms., 2016). Drug regimens vary
across countries and providers, and may also include gemcitabine, capecitabine,
carboplatin, oxaliplatin and docetaxel (Cunningham et al., 2006; Barone et al., 2007).
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1.5.3. Side effects
Chemotherapy often involves a raft of side effects including nausea, ulceration, pain,
diarrhoea, appetite/weight loss, fatigue, light sensitivity and hair loss. The common side
effects of GC chemotherapy include severe nausea, mouth sores and appetite
suppression (Cunningham et al., 2006; Chemocare, 2016). Adjuvant anti-emetic, anti-
nausea and chemoprotective drugs such as dexrazoxane (protects from cardiotoxicity) and
amifostine (reduces incidence of infection and fever) are used to reduce side effects of
cancer chemotherapy. Anti-nausea drug ondansetron (Zofran) was voted one of the top 5
advances in modern oncology” (Chustecka, 2014), underpinning the need for
chemotherapies with reduced side effects. Though some effects will pass, late and
potentially permanent side effects of chemotherapy include cataracts, early menopause,
heart problems, liver problems, nerve damage, reduced lung capacity and damaged
vasculature (Janunger et al., 2002). 
1.5.4. Standard targeted drug paradigm
Drug targeting targeting involves inhibiting an aberrant protein that is critical to the biology
of the cancer. For example, in HER2+ breast cancer, where overexpression of the HER2
receptor leads to an increased growth factor signalling, trastuzumab (Herceptin) works by
binding and blocking the receptor on the surface of the breast cancer cell (Verma et al.,
2012). Similarly, vemurafinib (Zelboraf) targets gain of function oncogenic driver
BRAF∆V600E in melanoma (Sosman, 2012). However, as E-cadherin is a tumour suppressor
protein whose function is lost, its absence means it cannot be a conventional drug target
(figure 1.10). Nevertheless, an inactivating mutation in cancer cells but not in normal cells
can create opportunities to selectively kill cancer cells via synthetic lethal targeting.
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Figure 1.10. Loss of function and gain of function mutations drug paradigm. While
gain of function mutations in oncogenes present as clear targets for therapy, loss of
function mutations in tumour suppressor genes leaves no clear targets. Adapted from
Brough et al., (2011).
1.5.5. HDGC chemoprevention
While there is a need for improved detection methods and more effective treatments, there
has been little focus on the chemoprevention of DGC or LBC in HDGC families. Ideally,
the indolent stage T1a foci could be eliminated before their growth is advanced by further
genetic events. Such chemopreventive therapies could be applied every periodically
(perhaps every 2-5 years) in at-risk individuals, supported by annual endoscopic
surveillance. This precautionary approach to chemoprevention may be more cost effective
than surgery and would significantly reduce patient morbidity.
1.6. Synthetic lethality
1.6.1. Synthetic lethal definition
Synthetic lethal interactions were first described almost 100 years ago in Drosophila
melanogaster (D. melanogaster), where the inheritance of two specific mutations led to a
lethal phenotype (Metz & Bridges, 1917). Two genes are 'synthetic lethal' when only their
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simultaneous inactivation leads to death, while individual inactivation leaves cells viable
(figure 1.11). 
Figure 1.11. Synthetic lethal concept. Two genes are synthetic lethal when only their
simultaneous inactivation leads to death. In cancer therapy, the effect implies inhibiting
one gene (B) in a context where the other gene (A) is defective should be selectively lethal
to cancer cells.
Synthetic lethal interactions are attractive targets in loss-of-function cancers, where the
absence of a gene product is the primary driver of tumourigenesis. Investigating synthetic
lethal interactions in E-cadherin-deficient cells may present clinically relevant
vulnerabilities that are amenable to targeted therapy. In this context, 'synthetic' is borrowed
from the Greek synthetikós which means to put together. Indeed, put together, inactivation
of a synthetic lethal partner gene in an E-cadherin-deficient context will lead to selective
killing of the cancer cell while leaving other cells unaffected.
1.6.2. Synthetic lethal screening
Early screening efforts utilised model organisms such as D. melanogaster, and then
Caenorhabditis elegans (C. elegans) and Saccharomyces cerevisiae (S. cerevisiae),
allowing for large mutant crossing matrices and the generation of complex interaction
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networks (Brough et al., 2011). For example, a synthetic genetic array assay in S.
cerevisiae allows strains with a single query gene disruption to be crossed with an array of
yeast strains with over 4700 deletions and any synthetic lethal interactions are
subsequently detected by the absence or poor growth of particular mutant crosses (Tong
et al., 2001). 
Model organism drawbacks and new technology means synthetic lethality screens can
now be performed in human cell lines with RNA-interference (Farmer et al., 2005; Telford
et al., 2015). An unbiased, genome-wide approach to elucidating targets would support the
development of novel classes of synthetic lethal drugs for E-cadherin-deficient tumours.
Uncovered vulnerabilities may also be amenable to existing drugs, and thus merit the
repurposing of existing drugs in new therapeutic applications as well as in combination for
synergistic effect. Furthermore, chemical screens in human cell lines are also important for
identifying pharmacological targets and vulnerabilities. Compound screening in human cell
lines with both known and unknown drug libraries is a potentially rapid method of
elucidating susceptibilities. In this case, lead compounds can be identified, even if their
targets or mechanisms are still unknown. 
1.6.3. Synthetic lethality in action 
Targeting of DNA-repair enzyme poly-ADP ribose polymerase (PARP) illustrates the
clinical utility of a synthetic lethal approach to chemotherapy (Ashworth, 2008). Cells with
inactivating mutations in DNA-repair enzymes BRCA1/2 become reliant on PARP for DNA
repair. Inhibition of PARP ablates essential dsDNA repair and promotes apoptosis in
BRCA1/2-deficient cells (Farmer et al., 2005). Olaparib (Lynparza) is a targeted therapy
targeting PARP and leads to strong clinical responses in breast and ovarian cancer
patients with BRCA1/2 mutations (Tutt et al., 2010). Aligned with the synthetic lethal
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principle, olaparib does not produce as many adverse side effects associated with
conventional chemotherapy (Tutt et al., 2010).
Synthetic lethal interactions can occur between genes acting in the same pathway or in
distinct, compensatory pathways (Hartman et al., 2001). As expected, components of the
same pathway often share the same synthetic lethal partners (Tong et al., 2001).
Reciprocally, there are less likely to be many partners of genetically redundant genes as
systems of functional buffering can mitigate loss of function events. However, it is likely
that some synthetic lethal partners are elements of function buffering networks, as is the
case with PARP and BRCA1/2. There is evidence that PARP is hyperactivated when
BRCA1/2 is lost, most probably to mitigate the loss of a mechanism of functional
compensation for DNA repair (Brough et al., 2011). Thus, the increased expression of
genes following a loss of function event may be used as evidence of a redundant
mechanism to support screening methods.
1.6.4. Rationality of synthetic lethal interaction
E-cadherin-deficient cancers gain a selective advantage from altered cell-cell adhesion,
cytoskeletal organisation and survival signalling. However, it is probable that these
advantages come at the cost of acquired vulnerabilities that may be exploited in a
synthetic lethal manner. For example, the disruption to cytoskeletal interactions promotes
a diffuse phenotype through loss of cell adhesion and altered cytoskeletal organisation.
However, this leaves the disorganised cytoskeleton as a clear vulnerability (figure 1.12). 
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Figure 1.12. Loss of E-cadherin affects cytoskeletal organisation. Apical surface of
isogenic MCF10A (CDH1+/+ and CDH1-/-) cells demonstrating the effect of E-cadherin
deletion on cytoskeletal organisation (Chen et al., 2014). Top row: microtubules; bottom
row: actin; left column: MCF10A CDH1+/+; right column MCF10A CDH1-/-) Adherens
junction protein E-cadherin (red), tight junction protein ZO-1 (magenta), microtubule and
actin cytoskeleton proteins α-tubulin and F-actin, respectively (green). 
E-cadherin loss alters certain signalling pathways and activation of genes that may be
targeted as cells become increasingly reliant on their function for survival. For example,
pro-survival signalling by PI3K/AKT and Wnt pathways, or the components of cytoskeletal
function may be robust synthetic lethal targets. Cells without CDH1 expression are




Preliminary genome-wide siRNA screening has identified a plethora of genes with
evidence of synthetic lethal relationships with CDH1. Gene ontology analysis shows
enrichment in GPCR proteins, PI3K/AKT pathway components and proteins involved with
the cytoskeleton (Telford et al., 2015), such as microtubule-associated proteins.
Microtubule-associated proteins are involved in a wide range of functions, from
organisation and dynamics to transport and mitosis, with both structural and signalling
roles.
Microtubule-associated serine/threonine kinase 2 (MAST2) plays a part in modulating
microtubule interactions and dynamics, and was identified in the preliminary screen as
potentially synthetic lethal. MAST2 interacts with dystrophin/utrophin networks to facilitate
dynamics between microtubules and the cell membrane (Garland et al., 2008). In epithelial
cells, utrophin particularly interacts with adherens junctions proteins, leading to a stable
cytoskeleton and cell structure (Belkin & Burridge, 1995). RNA sequencing data shows an
upregulation of MAST2 in E-cadherin-deficient cells, implying it may be a mechanism of
compensation for cytoskeletal disorganisation. 
Additional biologically relevant genes identified in the preliminary screen included
microtubule-associated protein 1B (MAP1B) and the mitosis regulating family of Aurora
kinases (AURKA and AURKB). In epithelial biogenesis, MAP1B plays a role in polarised
growth and maintenance of plasma membrane domains, and silencing show been shown
to affect polar morphogenesis (Spiliotis et al., 2008). While MAP1B is not upregulated, it is
possible that further dysregulation of polarised epithelial morphogenesis is intolerable in an
E-cadherin-deficient context. The Aurora kinase family regulate centrosome function and
control chromatid segregation and microtubule polymerisation. Similarly, it is expected that
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further defects to bipolar assembly and chromosome alignment may be lethal to E-
cadherin-deficient cells.
There is a well-described arsenal of drugs targeting signalling pathways and the
cytoskeleton such as the taxanes paclitaxel and docetaxel. Plant-derived compounds
targeting microtubule dynamics represents some of the oldest targeted functions in cancer
therapy (Wani et al., 1971). Terpene alkaloids the taxanes from the Pacific Yew tree
(Taxus brevifolia) and vinca alkaloids such as vinchristine and vinblastine from the
Madagascan periwinkle (Catharanthus roseus, formerly Vinca roseus) target microtubule
disassembly and assembly, respectively. Historically, the advent of these drugs has been
responsible for some of the most significant increases in cancer survival rates (Rowinsky
et al., 1992). 
1.6.6. Translational synthetic lethality
Synthetic lethal drugs may be used in the chemoprevention and/or treatment of early
CDH1-deficient tumours in HDGC families. This would reduce reliance on morbid surgical
prophylaxis, instead allowing at-risk individuals to manage the cancer syndrome with the
administration of drugs supported by routine screening. As well as improved physical
outcomes, chemopreventive methods would heavily mitigate the psychological burden of a
cancer predisposition throughout a lifetime. As CDH1 loss is also common feature of
sporadic adenocarcinoma, associated with epithelial-mesenchymal transition and poor
prognosis, these synthetic lethal drugs may also improve the management of sporadic
DGC and LBC, and possibly other advanced adenocarcinoma.
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2. Materials & methods
In cancer therapy, a synthetic lethal effect implies that inhibiting one gene in a context
where an other (eg, CDH1-/-) is defective should be selectively lethal to the cancer cells.
This work aims to investigate the presence of synthetic lethal interactions between CDH1
and putative partner genes. To do this, query partner genes are silenced in two isogenic
epithelial cell lines with and without CDH1 expression (CDH1+/+ and CDH1-/-)). In principle,
a synthetic lethal interaction will manifest as a selective reduction in viability in cells lacking
CDH1 expression following partner gene silencing. To interrogate synthetic lethal effect,
selected candidate genes are silenced by shRNA knockdown, followed by time-course




0.22 µm hydrophillic syringe filter – Sartorius, Madrid, Spain
0.45 µm PVDF syringe filter – Sigma-Aldrich, St. Louis, USA
0.5% EDTA trypsin – Invitrogen, Waltham, USA
2-Mercaptoethanol – Sigma-Aldrich, St. Louis, USA
30% 37.5:1 acrylamide:bis solution – Bio-Rad, Hercules, USA
5X Cell Culture Lysis Reagent – Promega, Fitchburg, USA
Actrapid Penfil Neutral insulin – Novo Nedvark, Denmark
Amersham ECL Plus Western Blotting Substrate – GE Healthcare Life Sciences, Little
Chalfont, USA
Ammonium persulfate (APS) – Sigma-Aldrich, St. Louis, USA
Anti-α-tubulin monoclonal antibody T6199 (mouse) – Sigma-Aldrich, St. Louis, USA
Anti-actin polyclonal antibody A2066 (rabbit) – Sigma-Aldrich, St. Louis, USA
Anti-E-cadherin polyclonal antibody sc7870 (rabbit) – Santa Cruz, Santa Cruz, USA
Anti-mouse Alexa Fluor 555 – Thermo Fisher Scientific, Waltham, USA
Anti-mouse Alexa Fluor 647 – Thermo Fisher Scientific, Waltham, USA
Anti-mouse HRP-conjugated antibody NA934 (rabbit) – Amersham Biosciences,
Buckinghamshire, UK
Anti-pericentrin polyclonal antibody ab4448 (rabbit) – Abcam, USA
Anti-rabbit Alexa Fluor 488 – Thermo Fisher Scientific, Waltham, USA
Anti-rabbit HRP-conjugated antibody NA931 (mouse) – Amersham Biosciences,
Buckinghamshire, UK
Antibody diluting buffer – prepared in lab (appendix 5.1.8)
Agar bacteriology grade – Applichem, St. Louis, USA
Agar plates – prepared in lab (appendix 5.1.3)
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Alisertib – Applichem, Houston, USA
Ampicillin sodium salt – Sigma-Aldrich, St. Louis, USA
BCA Protein Assay Kit – Thermo Fisher Scientific, Waltham, USA
Blocking buffer – prepared in lab (appendix 5.1.8)
Calcium chloride – Scharlau, Barcelona, Spain
CellTiter-Glo – Promega, Fitchburg, USA
Custom oligonucleotide primers – Integrated DNA Technologies, Coralville, USA
Cholera toxin – Sigma-Aldrich, St. Louis, USA
Danusertib – Applichem, Houston, USA
Dimethyl sulfoxide (DMSO) – Sigma-Aldrich, St. Louis, USA
Dulbecco's Modified Eagle Medium (DMEM) – Invitrogen, Waltham, USA
Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12) – Invitrogen,
Waltham, USA
ECL Plus Western Blotting Substrate – Amersham Biosciences, Buckinghamshire, UK
Electrophoresis protein gel – prepared in lab (appendix 5.1.7)
Epidermal growth factor (EGF) – PeproTech, Rocky Hill, USA
Fast EvaGreen qPCR Master Mix – Bio-Rad, Hercules, USA
Fetal bovine serum (FBS) – Invitrogen, Waltham, USA
Fibronectin – Thermo Fisher Scientific, Waltham, USA
Fixing buffer – prepared in lab (appendix 5.1.8)
Freezing media – prepared in lab (chapter 2.2.6)
Gel running buffer – prepared in lab (appendix 5.1.6)
GIPZ lentiviral shRNA vector – Thermo Fisher Scientific, Waltham, USA
Glycerol – Scharlau, Barcelona, Spain
Glycine – Sigma-Aldrich, St. Louis, USA
Goat serum – Invitrogen, Waltham, USA
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Hoechst 33342 – Thermo Fisher Scientific, Waltham, USA
Horse serum – Invitrogen, Waltham, USA
Hydrocortisone – Sigma-Aldrich, St. Louis, USA
L-glutamine – Invitrogen, Waltham, USA
Laemmli sample buffer – prepared in lab (appendix 5.1.6)
Lipofectamine 2000 – Thermo Fisher Scientific, Waltham, USA
Lower buffer – prepared in lab (appendix 5.1.6)
Lysogeny broth (LB) – prepared in lab (appendix 5.1.3)
MEM non-essential amino acids – Invitrogen, Waltham, USA
NucleoBond Xtra Midi Plus – Machery-Nagel, Düren, Germany
NucleoSpin EasyPure – Machery-Nagel, Düren, Germany
PageRule prestained protein ladder – Thermo Fisher Scientific, Waltham, USA
Paraformaldehyde (PFA) – BDH, UK
Penicillin-streptomycin – Invitrogen, Waltham, USA
Permeabilisation buffer – prepared in lab (appendix 5.1.8)
Phosphate buffered saline (PBS) solution – prepared in lab (appendix 5.1.1)
Phosphate buffered saline (Dulbecco A) tablets – Oxoid Limited, Surrey, UK
PrimeScript RT Reagent Kit – Takara Bio, Otsu, Japan
Propan-2-ol – Scharlau, Barcelona, Spain
Propidium iodide (PI) – Thermo Fisher Scientific, Waltham, USA
psPAX2 lentiviral packaging plasmid – Addgene, Cambridge, UK
Puromycin – InvivoGen, San Diego, USA
Quick-RNA MiniPrep – Zymogen, Tustin, USA
Reduced serum media (optiMEM) – Thermo Fisher Scientific, Waltham, USA
Resazurin dye – prepared in lab (appendix 5.1.5)
RNAGEM Tissue Plus – Zygem, Auckland, New Zealand
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Running buffer – prepared in lab (appendix 5.1.6)
Skim milk powder – Pams, Auckland, New Zealand
Super optimal broth with catabolite repression (SOC) – prepared in lab (appendix 5.1.4)
Sodium chloride – Scharlau, Spain
Sodium dodecyl sulfate (SDS) – Sigma-Aldrich, St. Louis, USA
Sodium pyruvate – Invitrogen, Waltham, USA
Stripping buffer – prepared in lab (appendix 5.1.6)
Tetramethylethylenediamine (TEMED) – Thermo Fisher Scientific, Waltham, USA
Top10 Dh5α Escherichia coli (E. coli) – Invitrogen, Waltham, USA
Transfer buffer – prepared in lab (appendix 5.1.6)
Tris-buffered saline and tween-20 (TBST) – prepared in lab (appendix 5.1.6)
Tris ultrapure – Applichem, St. Louis, USA
Triton X-100 – Sigma-Aldrich, St. Louis, USA
Tryptone – Scharlau, Barcelona, Spain
Tween-20 – Sigma-Aldrich, St. Louis, USA
Upper buffer – prepared in lab (appendix 5.1.6)
Vectashield Mounting Medium with DAPI – Vector Labs, USA
VSVG lentiviral envelope plasmid – Addgene, Cambridge, UK
Yeast extract – Merck, Darnstadt, Germany
2.1.2. Equipment
0.22 µm polyethersulfone vacuum filter system – Corning, Corning, Corning, USA
0.6 mL microtube – Axygen, Union City, USA
1 mL cryovial – Nunc, Rochester, USA
1 mL syringe – BD, Singapore
1.5 mL microtube – Axygen, Union City, USA
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20 G needle – Terumo, Tokyo, Japan
6-well, clear, flat-bottom tissue culture plate – Greiner Bio-One, Frickenhausen, Germany
10 mL serological pipette – Greiner Bio-One, Frickenhausen, Germany
10 mL syringe – BD, Singapore
100x20 mm cell culture dish with vent – Greiner Bio-One, Frickenhausen, Germany
15 mL Falcon tube – BD Biosciences, San Jose, USA
22x22 mm glass cover slip – Menzel-Glaser, Germany
25 mL cell culture flask – Greiner Bio-One, Frickenhausen, Germany
25 mL serological pipette – Greiner Bio-One, Frickenhausen, Germany
50 mL falcon tube – BD Biosciences, San Jose, USA
5390 Centrifuge – Eppendorf, Hamburg, Germany
5810 R Centrifuge – Eppendorf, Hamburg, Germany
60 mL syringe – BD, Singapore
75 mL cell culture flask – Greiner Bio-One, Frickenhausen, Germany
75x25 mm Gold Seal glass slide – Thermo Fisher Scientific, Waltham, USA
96-well tissue culture plate 3603 – Corning, Corning, USA
7900HT Fast Real-Time PCR system – Applied Biosystems, Carlsbad, USA
Avanti J-25 Centrifuge – Beckman, Brea, USA
Centra 3C centrifuge – International Equipment Company, Oakbrook, USA
Cell culture incubator with carbon dioxide – Binder, Tuttlingen, Germany
Cell scraper – Corning, Corning, USA
CFX-Connect Real-Time System – Bio-Rad, Hercules, USA
Cytell Cell Imaging System – GE LifeSciences, Little Chalfont, USA
Double-chambered cell-counting slide – Bio-Rad, Hercules, USA
Eclipse Ti Inverted Microscope System – Nikon, Tokyo, Japan
Fuji LAS-3000 ECL Imaging System – Thermo Fisher Scientific, Waltham, USA
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Immobilon-P 0.45 µm PVDF membrane – Merck Millipore, Darmstadt, Germany
Inoculating loop – Nunc, Rochester, USA
IncuCyte FLR – Essen BioScience, Ann Arbor, USA
MicroAmp Optical 384-well plate – Thermo Fisher Scientific, Waltham, USA
MicroAmp Optical 96-well plate – Thermo Fisher Scientific, Waltham, USA
Milli-Q Ultra Pure Water Purification System – Millipore, Darmstadt, USA
Mini-PROTEAN Cell – Bio-Rad, Hercules, USA
Mr Frosty 5100 Cryo 1˚C Freezing Container – Thermo Fisher Scientific, Waltham, USA
Nanodrop ND-1000 Spectrophotometer – Nanodrop Technologies, Waltham, USA
Pasteur pipette – Hirschmann, Neckartenzlingen, Germany
Pipette aid – Thermo Fisher Scientific, Waltham, USA
POLARstar Microplate Reader – BMG, Berlin, Germany
PowerPac Basic 300 V Power – Bio-Rad, Hercules, USA
TC10 Automated Cell Counter – Bio-Rad, Hercules, USA
Trans-Blot Cell – Bio-Rad, Hercules, USA
Tissue culture hood – EMAIL, Melbourne, Australia
Water bath – Semco, Vista, USA
2.1.3. Software
4peaks – Mekentosj, USA
CellProfiler – Broad Institute, Cambridge, USA
Cytell BioApps – GE Healthcare Life Sciences, Little Chalfont, USA
ImageJ + CellCounter plugin – National Institute of Health, Bethesda, USA
IncuCyte software – Essen BioScience, Ann Arbor, USA
NIS Elements 4.10 – Nikon, Tokyo, Japan
Prism 6 – Prism Software, San Diego, USA
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2.1.4. Cell lines
Isogenic MCF10A (CDH1+/+ & CDH1-/-) cell line – Sigma-Aldrich, St. Louis, USA
HEK293FT cell line – donated by Dr Stephanie Hughes, Otago University, New Zealand
2.2. Cell culture
2.2.1. Cell lines
Isogenic (WT & CDH1-/-) MCF10A breast cell lines were obtained from Sigma-Aldrich.
CDH1 knockout was created by a 4 base-pair homozygous deletion in exon 11
(extracellular adhesion domain) by zinc finger nuclease editing, confirmed by RNAseq
analysis (Beetham, 2014). HEK293FT (Human embryonic kidney cell, transformed with
SV40 large T antigen) cell line was used for lentiviral particle production (chapter 2.5.3).
Upon receipt, lines were thawed and cells from early propagation were aliquoted and
frozen in liquid nitrogen (chapter 2.2.6). Experiments with MCF10A cells were conducted
with cells between passage 6 and 15. HEK293FT cells were used between passage 8 and
20.
2.2.2. Recovery
An aliquot of cells (chapter 2.2.6) was thawed in a 37˚C water bath and resuspended in 9
mL of pre-warmed complete growth media. Cells were pelleted by centrifugation at 1000
rpm for 5 mins and the supernatant was discarded. Pellet was resuspended in 4.5 mL of
complete media (chapter 2.2.3). Cells were transferred to a T25 cell culture flask and
transferred to the incubator at 37˚C with 5% CO2. Media was replaced with warm,
complete media at 24 hrs to remove any trace DMSO and any non-adhered cells.
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2.2.3. Maintenance
MCF10A cells were maintained in Dulbecco's Modified Eagle Medium: Nutrient Mixture F-
12 (DMEM/F-12) supplemented with 5% horse serum, 20 ng/mL EGF, 0.5 µg/mL
hydrocortisone, 100 ng/mL cholera toxin and 10 µg/mL insulin. Pre-mixed media was filter-
sterilised using a 0.22 µm polyethersulfone filter and dispensed into 50 mL aliquots.
HEK293FT cells were maintained in DMEM media supplemented with 10% FBS, 6 mM L-
glutamate, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate and 100 µg/mL
penicillin-streptomycin. Pre-mixed media was filter-sterilised and aliquoted as above. Cell
culture manipulations were performed under sterile conditions using asceptic technique in
a class II hood. Flasks were maintained in a 37˚C humidified chamber with 5% CO2.
2.2.4. Passage
Cells were passaged at 72-96 hr intervals while sub-confluent. Solutions of phosphate
buffered saline (PBS), trypsin (0.05% for MCF10A; 0.025% for HEK293FT), and complete
growth media were pre-warmed in a 37˚C waterbath prior to passage. Media was
aspirated and discarded, cells were gently washed with PBS, PBS was aspirated and
discarded. Typsin was gently added to the flask (1.5 mL for T25; 4.5 mL for T75) and
returned to the incubator for 20 mins for MCF10A; 10 mins for HEK293FT. Following
detachment, trypsin was neutralised with 5 mL complete media and the flask contents
transferred to a 15 mL tube. Cells were pelleted by centrifugation at 1000 rpm for 5 mins.
The supernatant was removed and the cells were resuspended in 1-5 mL complete media
(depending on application). MCF10A cell density was determined (chapter 2.2.5) and cells
were reseeded in new flasks at a density of 1.0 x 105 for WT and 1.5 x 105 for CDH1-/- (3.0
x 105 and 4.5 x 105, respectively, for T75) and returned to the incubator. HEK293FT cells




During passage (chapter 2.2.4), pelleted cells were thoroughly resuspended in 1-5 mL of
complete media. 10 µL of the cell suspension was pipetted onto a dual-chambered
counting slide for cell counter and the cell density determined with a TC10 Automated Cell
Counter.
2.2.6. Freezing
Cells were preserved in liquid nitrogen in freezing media. MCF10A freezing media
comprised of 70% complete media, 20% horse serum and 10% DMSO; and HEK293FT
freezing media comprised of 90% complete media and 10% DMSO. Following passage
(chapter 2.2.4), cells were pelleted and resuspended at 1 x 106 cells/mL in freezing media.
Aliquots of 1 x 106 cells were transferred into cryovials and placed in a Mr Frosty or 5100
Cryo 1˚C Freezing Container in a -80˚C freezer. Cells were refrigerated overnight before
being transferred into liquid nitrogen for long-term storage.
2.3. Characterisation of isogenic MCF10A cell lines
2.3.1. Western blot
2.3.1.1. Protein lysate preparation
Cells were seeded into a 6-well cell culture dish in complete media at 1x105 per well and
harvested prior to reaching confluence. Media was aspirated and the cells washed once
with PBS. Cells were lysed with 1.5 mL 1X passive lysis buffer (5X Cell Culture Lysis
Buffer in PBS). To maximise lysis, cells were scraped with a sterile cell scraper before
being transferred to a microcentrifuge tube. Debris was pelleted by centrifugation at 2000
rpm for 5 mins, the lysate was transferred to a fresh tube and stored at -20˚C until use
within one month of preparation. On the day of blotting, sample was thawed on ice before a
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bicinchoninic acid (BCA) assay was performed to determine protein concentration.
2.3.1.2. SDS-PAGE gel preparation
Electrophoresis gels were prepared with two components: resolving gel and stacking gel. 
For the resolving gel, 2.5 mL 4X lower buffer (appendix 5.1.6) and 3.3 mL 30% pre-mixed
37.5:1 bis:acrylamide was added to 4.2 mL mQH2O. 100 µL ammonium persulfate (APS)
and 10 µL tetramethylethylenediamine (TEMED) was added. The mixture was carefully
poured into a gel mould and covered with 1 mL of isopropanol to prevent desiccation. Prior
to adding the stacking gel, isopropanol was carefully poured off and the gel rinsed with
mQH2O. For the stacking gel, 1 mL 4X upper buffer (appendix 5.1.6) and 0.65 mL 30%
pre-mixed 37.5:1 bis:acrylamide was added to 2.35 mL mQH2O. 30 µL APS and 10 µL
TEMED was added and the mixture carefully poured on top of the resolving gel. A 12 lane
gel comb was used, and complete gels were used immediately or otherwise stored airtight
in moist tissue paper at 4˚C.
2.3.1.3. Gel electrophoresis
Protein samples were mixed 4:1 with 5X DNA loading buffer (appendix 5.1.6) and boiled at
95˚C for 5 mins. Samples were centrifuged at 16k rpm for 1 min to remove bubbles and
pellet residual debris. 25 µg of protein, as determined by BCA assay, was loaded into each
lane of an an SDS-PAGE gel. 10 µL of PageRuler Prestained Protein Ladder was also
loaded onto at least one outer lane. Loaded gel was transferred to gel apparatus and
running buffer (appendix 5.1.6) was added as per instructions of the apparatus. Size
separation electrophoresis was carried out at a constant 200 v for 1 hr.
2.3.1.4. Protein transfer
Polyvinylidene difluoride (PVDF) membrane was cut to shape, briefly activated in 100%
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methanol, and washed once with mQH2O. Protein transfer sandwich components
(membrane, fibre pads and filter paper) were soaked in 1X transfer buffer (appendix 5.1.6)
for 15 mins prior to assembly. The transfer sandwich was assembled as per the
manufacturers instructions and put in to the transfer tank. The assembly was submerged
in transfer buffer and the protein transferred at 100 v for 1 hr. Membrane was washed for 5
mins with mQH2O following transfer.
2.3.1.5. Antibody incubation and imaging
The membrane was washed for 10 mins three times in Tris-buffered saline and tween-20
(TBST; appendix 5.1.6). To block non-specific binding, the membrane was blocked with
5% milk powder in TBST at RT for 1 hr. The membrane was incubated on a shaker at 4˚C
overnight with primary antibody diluted in TBST (see appendix 5.2 for antibody dilutions).
Membrane was washed for 10 mins three times after primary incubation to remove any
unbound antibody. The membrane was incubated on a shaker at RT for 1 hr with
secondary antibody diluted in TBST. The membrane was incubated with enhanced
chemiluminescence (ECL) reagent as per the manufacturers instructions and imaged
using the Fuji ECL Imaging System.
2.3.1.6. Strip and reprobe
Following imaging of the primary probe, membrane was stripped of bound antibodies using
stripping buffer (appendix 5.1.6) at 50˚C for 1 hr. The membrane was then washed with
mQH2O at RT for 1 hr. Antibody incubation and imaging was repeated with secondary





To aid adhesion, sterile 22x22 mm cover slips were placed into a 6-well cell culture dish
and incubated in 200 µg/mL fibronectin (in PBS) at RT for 60 mins. Fibronectin was
aspirated and 1 x 106 cells were seeded per well and incubated in 37˚C with 5% CO2 for at
least 16 hours to allow for complete cell adherence.
2.3.2.2. Fixing/treatment
Blocking and antibody diluting buffers were made up fresh and all steps were performed at
RT. Cells were washed three times with ~5 mL PBS prior to fixing. Cells were fixed in 2 mL
of 4% paraformaldehyde (PFA; appendix 5.1.8) in the dark for 20 mins. Cells were washed
again two times with PBS after fixing and then permeabilised with 2 mL of permeabilisation
buffer (0.5% Triton in PBS) for 10 mins. To block non-specific binding, the cells were
incubated in 2 mL of blocking buffer (5% secondary matched serum, 1% FBS in PBS) for
60 mins.
2.3.2.3. Antibody incubation
Antibodies were diluted in antibody diluting buffer (appendix 5.2 for dilutions) and 40 µL of
the mixture was pipetted onto coverslips. Coverslips were then inverted in a 6-well plate
and kept moist in the dark for 1 hr at RT or overnight at 4˚C. To remove unbound antibody,
the coverslips were washed three times in PBS prior to secondary incubation. Secondary
antibody incubation was performed as above except the incubation was strictly in the dark
for 1 hr at RT.
2.3.2.3. Mounting
To preserve signal strength and to stain nuclei, coverslips were mounted on glass
microscope slides with one drop of Vectashield mounting medium (with DAPI). Slides were
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air-dried at RT for ~20 mins, excess stain wiped away, and stored in the dark at 4˚C. Two
negative controls were included without primary and secondary antibody, respectively.
2.3.2.4. Imaging
Images were captured on the Eclipse Ti Inverted microscope using the fluorophore-
appropriate filter. Images were edited and adjusted using ImageJ.
2.3.3. qPCR
2.3.3.1. RNA extraction
RNA was extracted using RNAGEM Tissue Plus RNA extraction kit according to the
manufacturers instructions for adherent cells, including DNase treatment. 6-, 24-, and 96-
well formats were used, requiring 200, 50, and 20 µL of extraction mixture. RNA was
immediately synthesised into cDNA (chapter 2.3.3.2) while surplus RNA was stored at
-80˚C.
2.3.3.2. cDNA synthesis
cDNA was synthesised using Primescript RT Reagent kit immediately following RNA
extraction (chapter 2.3.3.1), according to the manufacturers instructions for SYBR Green
assay (reaction mixture in appendix 5.4). cDNA synthesis was performed using a PCR
block for 15 mins at 37˚C, followed by a 5 sec deactivation step at 85˚C. No RNA and no
reverse transcriptase (RTase) controls were included. cDNA was immediately analysed
with qPCR (chapter 2.3.3.3) or stored at -20˚C if used the next day. Surplus cDNA was
stored at -80˚C.
2.3.3.3. qPCR
qPCR was performed immediately following cDNA synthesis using Evagreen DNA Binding
44
Dye as per the manufacturers instructions. 6.5 and 13 µL reactions were performed in 384-
and 96-well optically clear reaction plates, respectively (table 5.4), using 7900HT
Sequence Detection System and CFX-Connect Real-Time System, respectively. cDNA
samples were diluted 1/5 in mQH2O. A standard curve was generated using existing and
constant cDNA synthesised from pooled RNA from multiple cell lines.
Using existing RNAseq data (Beetham et al., 2014), reference genes were selected upon
the following criteria being met: (1) high expression (>10,000 normalised reads); and (2)
consistent expression (0.93 > ∆fold-change > 1.10) across isogenic MCF10A cell lines.
qPCR was performed with GAPDH, PPIA, and RPL13a as reference genes to normalise
expression. MAST2 and MAP1B primers (appendix 5.3) were designed to span introns to
mitigate gDNA contamination. qPCR amplification steps included an initial melting and Taq
polymerase activation step for 3 mins at 95˚C, followed by 40 cycles of 5 sec at 95˚C, 10
sec at 55˚C, and 30 sec at 72˚C. No cDNA control and both controls from cDNA synthesis
(chapter 2.3.3.2) were used and each reaction was performed in triplicate.
2.3.3.4. Analysis
GAPDH, RPL13a, a n d PPIA cycle threshold (Ct) were used to normalise mRNA
expression. Efficiency was determined using a standard curve as described by (Larionov,
2005). Fold change was calculated using the method described by Pfaffl (2001). With high
fidelity primers, DNA content within a sample is exactly duplicated, hence log2 fold-
changes can be used to back-calculate relative expression. Relative expression ratio is
calculated from qPCR efficiencies and the crossing point of a sample versus a control.
Efficiencies calculated between 1.95 and 2.05 were acceptable, and Cts later than 38 were
ignored. All experiments included a no cDNA control and a no-template cDNA control.
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2.4. Transfection 
pGIPZ shRNA library was obtained in E. coli Dh5α bacterial glycerol stocks from
Dharmacon. For each candidate SL gene, between 3 and 10 clones containing unique
shRNA sequences were obtained. See appendix 5.5 for shRNA sequence list.
2.4.1. pGIPZ shRNA vector maps
Figure 2.1. pGIPZ lentiviral shRNA vector map with features. Image supplied in
manufacturers catalogue.
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Figure 2.2. pGIPZ lentiviral shRNA detailed vector map. Created using PlasMapper at
UCL Cancer Institute.
2.4.2. Competent cells
Chemically-competent Dh5α E. coli cells were produced by the ice-cold calcium chloride
method described by Inoue (1990) in house. Dh5α cells were streaked onto LB agar and
incubated at 37˚C overnight. A single colony was isolated and transferred to 100 mL LB
and incubated at 37˚C with agitation at 300 rpm for 3 hrs. The culture was crash cooled on
ice for 10 mins before pelleting by 4k rpm centrifugation for 10 mins at 4˚C. The
supernatant was discarded and cells were resuspended in 10 mL ice cold 0.1 M CaCl2
while maintained on ice throughout the protocol. Cells were pelleted as above and then
resuspended in 2 mL ice cold 0.1 M CaCl2. 70 µL glycerol was added, mixed and stored
for 15 mins before a further 70 µL glycerol was added. Chemically competent cells were
aliquoted, snap frozen in liquid nitrogen and stored at -70˚C.
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2.4.3. Heat-shock transformation
Frozen chemically competent cells (chapter 2.4.1) were thawed on ice. 10 µL of cells,
together with no more than 5 µL containing no more than 100 ng of plasmid, were mixed
by flicking in a 1.5 mL microcentrifuge tube and were incubated on ice for 20 mins. Tubes
were heat shocked at 42˚C for 1 min followed by 37˚C for 3 mins before being chilled on
ice for 2 mins. 250 µL of SOC (appendix 5.1.4) was added to the tube and incubated at
37˚C for 45 mins with agitation. Due to varying competence, transformed cells were
spread on LB agar plates at volumes of 1, 50, and 200 µL.
2.4.4. Propagation of bacterial culture
Glycerol stocks of Dh5α E. coli harbouring pGIPZ were streaked onto LB agar plates
(appendix 5.1.3) containing 100 µg/mL ampicillin using asceptic technique and incubated
overnight at 37˚C. To ensure a clonal population, single colonies were isolated using a
sterile loop and inoculated into LB (appendix 5.1.3) with 100 µg/mL ampicillin. LB did not
exceed one third of the maximum volume of the vessel. For cultures over 100 mL, a 1 mL
starter culture was incubated for 4 hrs without antibiotic before being transferred to larger
vessel with antibiotic. Cultures were incubated at 37˚C overnight or until an appropriate
optical density (~1.0 Abs at 600 nm) was reached.
2.4.5. Plasmid extraction
To test which plasmid extraction kit would suit the project, a variety of kits were tested. The
NucleoBond Xtra MidiPrep (Machery-Nagel) was selected from a number of potential kits
(appendix 5.1.9) for moderate plasmid requirements (individual shRNA clones), while the
PureLink MaxiPrep (Invitrogen) was selected for larger requirements (control shRNA
clones). Kits were used as per the manufacturers instructions, however, elution buffer was
slightly warmed prior to the elution step.
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2.4.6. Plasmid quantitation
Plasmid was quantified using NanoDrop and Epoch as per the manufacturers instructions.
Zero-calibration was performed using the respective elution buffer (chapter 2.4.5).
2.4.7. Sanger sequencing
To assess the validity of the plasmid, 200 ng of pGIPZ template and 3.2 pmol of pGIPZ
insert sequence primer was made up to 5 µL with mQH2O and submitted to Genetic
Analysis Services for sequencing. Analysis was carried out using 4Peaks software and
publicly available BLAST database (NCBI).
2.4.8. Neon transfection
The Neon Transfection System (Invitrogen, Waltham, USA; hereon Neon) is an
electroporation method adapted from the novel capillary and electrode-based approach
from Kim et al. (2008) that claims high efficiency. The basis of electroporation is the
application of an electric field to cells to promote physical displacement of lipid molecules,
opening a pore through the bilayer to increase the permeability of the cell membrane. As
the pore fills with water to create a pathway, charged molecules like DNA can passively
diffuse into the cell.
At sub-confluence, cells were passaged (chapter 2.2.4) and transfection was carried out
as per the manufacturers instructions for adherent and suspension cell lines
(Resuspension Buffer R; supplied) with 100 µL Neon Tips (Electrolytic Buffer E2;
supplied). Neon transfection conditions were initially optimised with 5 µg plasmid and 2 x
105 cells, pulsed 3 times at 1600 v for 10 ms (chapter 3.2). For a complete list of conditions
tested, see appendix. Optimal conditions were 30 µg pGIPZ plasmid and 4 x 105 cells.
Neon Tips were changed after each transfection.
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2.5. Lentiviral packaging and transduction
2.5.1. Lentiviral packaging plasmid maps & resource
Figure 2.3. VSV-G lentiviral glycoprotein envelope plasmid detailed vector map.
From biovisualtech.
Figure 2.4. psPAX2 lentiviral packaging plasmid detailed vector map. From
biovisualtech.
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Figure 2.5. Lentiviral packaging overview. (made by the author of this thesis)
ReTrovirus = RTase = RNA genome
γ-retrovirus targets dividing cells; lentivirus targets both dividing/non-dividing cells
replication-incompetent recombinant LV = no life cycle, just payload delivery for controlled 'dosing'
Overview of WT lentiviral genome and plasmid components for producing recombinant particles
Envelope plasmid (pVSVG)
vesicular stomatitis virus G protein (envelope glycoprotein, env)
no Ψ signal = no packaging of envelope/packaging plasmid RNA into lentivirus particle
minimal genome lacking homology to reduce recombination (true for all plasmids)
produces VSV glycoprotein that becomes the outer envelope of the lentivirus
Packaging plasmid (psPAX2)
contains gag (encodes viral capsid, matrix, nucleocapsid)
pol (RTase, Pol III, protease)
rev (binding of Rev to viral RNA containing Rev response element (RRE) allows
mRNA export out of the nucleus by a mechanism different to that of cellular mRNA)
tat (unstalls env transcription)
produces viral core, enzymes (RTase, Pol, protease, integrase), and initiates signal to package
Transfer plasmid (pGIPZ) 
shRNA-containing plasmid – the payload
produces one big polycistronic transcript using WT
5' LTR as promoter
Ψ signal (RNA 2˚ structure) is recognised for
transcript to be packaged into particles
conta ins long 3 ' and 5 ' LTRs to facilitate
integration
tGFP, puromycin resistance markers
pGIPZ → long RNA transcript |5' LTR| Ψ| GFP| puroR| shRNA| 3' LTR| packaged into virus
delivery by transduction, RNA → dsDNA by RTase, integration by LTRs/integrase, switches
to hC MV p r o mo te r , d r i ve s s t ab le tG FP , pu r oR & s h R N A e x p r e s s i o n
→ stable RNAi with selectable GFP and puromycin markers
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2.5.2. Plasmid extraction
VSVG, PAX2, and GIPZ plasmids were prepared from LB cultures as described above
(chapter 2.4.4-5). NucleoSpin MiniPrep kit was used for individual shRNA plasmids while
the NucleoBond Xtra MidiPrep kit was used for plasmids required in higher amount
(VSVG, PAX2, control shRNA). Overall, lentiviral packaging requires significantly less
plasmid than Neon transfection – the plasmid titre from one technical replicate of Neon can
produce enough virus to perform at least 10 viral replicates, up to 20 if aliquoted
appropriately.
2.5.3. Lentiviral packaging
The key elements of pGIPZ, including shRNA and cell markers, are expressed together
and flanked by a Psi packaging sequence and LTRs. The RNA molecule/'genome' is
packed into lentiviral particles in the presence of packaging plasmids that produce coat
proteins and elements for RNA integration (ie, RTase, integrase, etc). Once delivered, the
pGIPZ RNA is reverse transcribed and integrated into the target cell genome, commencing
expression of shRNA and markers. 
HEK293FT cells were seeded at a density of 5.4 x 106 cells in 10 mL complete growth
media in a T75 flask. Allowing 8 mL per flask, optiMEM supplemented with 5% FBS was
filtered through a 0.22 µm filter and warmed to 37˚C. Prior to making a transfection
mixture, all plasmids were quantitated using the NanoDrop (chapter 2.4.6). 24 hrs post-
seeding, a transfection mixture of 18.6 µg of shRNA plasmid (or control), 9.6 µg PAX2,
and 4.8 µg of VSVG was filtered through a 0.22 µm hydrophillic filter directly into a 1 mL
mixture of filtered optiMEM containing 55.8 µL Lipofectamine 2000 and incubated at RT for
20 mins. HEK293FT media was aspirated and the cells washed with PBS, taking care not
to dislodge cells. 8 mL of 5% FBS/optiMEM was added slowly and the transfection mixture
52
added dropwise. 
24 hrs post-transfection, growth media was aspirated, cells washed with PBS, and 6 mL of
pre-warmed, complete growth media was added. 48 hrs post-transfection, HEK293FT
growth media containing lentiviral particles was transferred to 15 mL falcon tubes. Media
was centrifuged at 3000 rpm for 15 mins and filtered through a 0.45 µm PVDF filter.
Lentiviral particles were dispensed into 500 µL aliquots and immediately frozen at -80˚C.
For each subsequent lentiviral experiment, an aliquot was only used once and then
discarded to mitigate repeated freeze-thaw cycles.
2.5.4. Lentiviral titration
Functional viral titre was determined by performing a 2-fold dilution series using
unconcentrated viral particles that were put aside during viral packaging. MCF10A WT
cells were seeded at 4 x 103 cells per well in a black-walled, clear-bottom 96-well plate in
100 µL of complete media. Cells were transduced with 100 µL of each viral serial dilution
to give a final dilution range of 1/2 to 1/32. Mock transduction containing only complete
media was used as the negative control to confirm the absence of any endogenous
fluorescent signal.
At 24 hrs post-transduction, growth media was aspirated and replaced with 100 µL of pre-
warmed, complete MCF10A media. 48 hrs post-transduction, 5 images per well were
captured at 10x magnification using 570 nm filter/GFP channel on the Eclipse Ti Inverted
Microscope System. For further titration analysis, only images from 1/32 final dilution were
used as it was determined that this dilution gave approximately 50% transduction
efficiency. ~50% transduction efficiency was used to increase counting accuracy, as lower
titres increase relative error and higher titres increase multiple particle uptake by cells.
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Counting of transduced, GFP-expressing cells was performed using ImageJ with the Cell
Counter plugin. The average number of transduced cells per field was determined across
5 fields. This number was extrapolated to estimate the average number of transduced cells
per well by adjusting with a factor of well:field size (~46.7; figure 2.6). Back calculation
using transduced cells/well, correcting for dilution and volume, was used to determine the
number of transducing units (TU)/mL.
Figure 2.6. Cytell field surface area to well surface area adjustment. One field
captured at 10x on Cytell 10x image field fits ~46.7 times into a well from a Costar 3603
96-well plate.
2.5.5. Multiplicity of infection
Optimal multiplicity of infection (MOI) needs to achieve high transduction efficiency while
minimising cell death. The optimal MOI was determined by performing a dilution series
using virus that had previously been titred. At 48 hrs post-transduction, viability by total
nuclei count (chapter 2.7.3) and transduction efficiency were assessed. An initial indication
of optimal MOI was up to 15, while any higher lead to early cell death.
2.5.6. Lentiviral transduction
MCF10A WT and MCF10A CDH1-/- cells were seeded at 1,000 cells per well in a black-
walled, clear-bottom 96-well plate in 100 µL of complete media 24 hrs prior to transduction.
Immediately prior to transduction, lentivirus stock was thawed in a 37˚C water bath and
diluted in complete media to adjust the titre. Cells were transduced with 100 µL of
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lentivirus diluted in complete media at an MOI of 15 per seeded cell. Each isogenic cell
line included mock (cell only) transduction and non-silencing shRNA controls.
At 24 hrs post-transduction, growth media was aspirated and replaced with 100 µL pre-
warmed, complete media containing 1 µg/mL of the selective agent puromycin. Puromycin
was omitted from cell only negative control. At 72 hrs post-transduction, cell viability was
assessed as described in chapter 2.7.2-4. Following viability assessment, mRNA
knockdown was confirmed by qPCR (chapter 2.3.3).
2.6. Drug inhibition of Aurora kinases
2.6.1. Drug suspension
Drugs were reconstituted in DMSO at 80 mM, aliquoted and stored at -80˚C. Aliquots were
thawed prior to use and resuspended to 1 mM with complete media. Each aliquot was only
used once.
2.6.2. EC50 curve
EC50 is the effective concentration of a drug that produces the half-maximal (ie, 50%)
response. MCF10A WT and MCF10A CDH1-/- cells were seeded at 4,000 cells per well in
a black-walled, clear-bottom 96-well plate (Costar 3603) in 100 µL of complete media. 24
hrs post-seeding, cells were treated with 10 µL of 11X final drug concentration to yield a
1X drug concentration. An 8-point, 10-fold dilution series was performed for each drug,
ranging between 100 µM and 10 pM. At 48 hrs post-treatment, viability was assessed by
nuclei counting (chapter 2.7.3). EC50 was calculated using non-linear regression in Prism
6.0.
DMSO concentration-matched controls were included, except where DMSO concentration
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was under 0.05% as the effects are negligible (data not shown). A drug free negative
control and high concentration cytotoxic (100 nM taxol) positive control was included in all
drug experiments.
2.6.3. IncuCyte time course confluence assay
MCF10A WT and MCF10A CDH1-/- cells were seeded at 4,000 cells per well in a black-
walled, clear-bottom 96-well plate (Costar 3603) in 100 µL of complete media 24 hrs prior
to treatment and treated with 10 µL of 11X final drug concentration to yield a 1X drug
concentration. Following treatment, plates were transferred to the IncuCyte Imaging
System, which measures total cell surface area as a proxy measure of viability. Imaging
was performed every 2 hrs over 48 hrs from treatment to end-point nuclei counting
(chapter 2.7.3). Data was analysed using IncuCyte software. At 48 hrs post-treatment,
end-point cell viability was assessed (chapter 2.7). This imaging does not require dyes or
additional reagents, and thus the same experimental plate can be further assessed with
end-point metabolic assay or total nuclei count.
2.6.4. Cell cycle analysis
Cell cycle analysis was performed at 10x magnification on the cell cycle BioApp on the
Cytell Cell Imaging System. Gating thresholds were optimised as required for each
experiment and cell cycle stage data was output as .csv files.
2.7. Viability
2.7.1. Manual cell counting
For optimisation of Neon transfection, total and GFP-positive cells were manually counted
from 4x images captured with Eclipse Ti Inverted microscope. Images were counted in
ImageJ with assistance from the CellCounter plugin.
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2.7.2. Metabolic assay
At 72 hrs post-transduction, viability was assessed by oxidation/reduction-based indication
of total ATP/metabolic capacity. Resazurin is a blue, weakly fluorescent dye that is
irreversibly reduced to a pink/red, highly fluorescent resorufin in the presence of
ATP/reducing power. 10% well-volume of Resazurin dye (appendix 5.1.5) was added to
cells in a 96-well plate and incubated in the dark at RT for 30 mins. Following incubation,
plates were scanned using the Optima POLARStar according to the manufacturer's
instructions. Gain was adjusted to maximise the sensitive range for the experiment.
2.7.3. Total nuclei counting
48 hrs post-treatment or 72 hrs post-transduction, viability was assessed by measure of
total nuclei counts. 100 µL of staining mixture containing 1 µg/mL Hoechst 33342 and 0.5
µg/mL propidium iodide (PI) in PBS was added to each well and incubated in the dark at
RT for 30 mins. At least 10 fields of view were automatically imaged at 10x magnification
using the cell viability BioApp on the Cytell Cell Imaging System. DAPI channel was used
to count cells stained by Hoechst. PI-stained cells were counted in the Cy3 channel.
Parameters for nuclei detection were optimised as required for each experiment. 
2.7.4. Viability analysis
Experimental conditions were normalised to their respective controls (non-silencing for
lentiviral transduction and concentration-matched DMSO for drug treatment only if DMSO
> 0.05%) within each cell line. Standard deviation was calculated across technical
replicates. Standard error was calculated across biological replicates.
2.8. Statistical analysis
Because the effects of silencing candidate genes in both cell lines was unknown, a test of
statistical significance was performed using a Student's two-tailed T-test.
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3. Results
The primary aim of this research was to validate the presence of synthetic lethal
interactions between CDH1 and cytoskeletal-associated genes identified via high-
throughput screening (Telford et al., 2015). The approach is summarised in four steps:
characterisation of isogenic MCF10A cell lines, optimisation and testing of Neon
Transfection System, lentiviral knockdown of candidates, and drug inhibition of Aurora
kinases.
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3.1. Characterisation of isogenic MCF10A cell lines
Our laboratory has previously published on the characteristics of the isogenic MCF10A cell
line with and without CDH1 expression (Chen et al., 2014). This chapter describes
additional validation and characteristics carried out by the candidate in isogenic MCF10A
cell lines. MCF10A has normal epithelial characteristics including anchorage-dependent
growth and has minimal chromosomal arrangements and high genomic stability (Soule et
al., 1990). The normal genetic background is an important factor for an early cancer




Loss of E-cadherin leads to visible phenotypic change in MCF10A morphology. While wild-
type (WT) cells grow to full confluence in monolayer culture, CDH1-/- cells never reach
confluence but rather form islands that never fully close (figure 3.1). Other changes include
extended lamellipodia in CDH1-/- cells. (figure 3.1.c). Because E-cadherin indirectly
interacts with integrins to form focal adhesions, the observation is likely a result of altered
migration, as has been previously described (Chen et al., 2014).
          MCF10A WT      MCF10A CDH1-/-
Figure 3.1. Differential growth morphology between isogenic MCF10A.  Cell
monolayers are approximately 50% confluent 48 hrs after passage. (a) 4x WT, (b) 10x WT,
(c) 20x WT; (d) 4x CDH1-/-, (e) 10x CDH1-/-, (f) 20x CDH1-/-. CDH1-/-cells grow in
subconfluent clumps and show larger lamellipodia (arrow) than their WT counterparts.
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3.1.2. Western blot
To confirm the absence of E-cadherin in the CDH1-/- cell line, a western blot (chapter 2.3.1)
was carried out using a specific primary antibody (Ab) against E-cadherin (sc-7870) and a
secondary Ab conjugated to a peroxidase enzyme which allows detection by
chemiluminescent methods. Western blot analysis showed a 135 kDa E-cadherin protein
in the MCF10A WT lysate, while the same band was not observed in the CDH1-/- lysate
(figure 3.2a), confirming the absence of E-cadherin in the CDH1-/- cell line. β-actin was
used as a loading control to show even loading across all the wells (figure 3.2.b).
Figure 3.2. Western blot of E-cadherin in isogenic MCF10A. (A) E-cadherin (135 kDa),
and (B) β-actin (40 kDa). CDH1-/-cell line lacks any detectable E-cadherin protein, while it
is present in WT. Chemiluminescent exposure time was 30 s for both probes.
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3.1.3. Immunofluorescence
To confirm the absence of E-cadherin in the CDH1-/- cell line, immunofluorescent imaging
(chapter 2.3.2) was carried out using a specific primary Ab against E-cadherin (sc-7870).
The secondary Ab is conjugated to a fluorophore to allow imaging of the sub-cellular
presence and localisation of E-cadherin). 
          MCF10A WT      MCF10A CDH1-/-
Figure 3.3. Immunofluorescent imaging of isogenic MCF10A cells. E-cadherin is
present in WT cells and absent in CDH1-/- cells. Primary E-cadherin antibody (sc-7870)
targets histidine-108. (a) WT DAPI, (b) WT E-cadherin sc-7870, (c) a & b overlay; (d)
CDH1-/- DAPI, (e) CDH1-/-E-cadherin sc-7870, (f) d & e overlay; 
As determined by Western blotting, CDH1-/- cells have no E-cadherin present (figure 3.3).
E-cadherin is predominantly localised at the cell membrane, consistent with its role as a
transmembrane adhesion protein. Furthermore, immunofluorescence targeting α-tubulin
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was performed to investigate any differences in cytoskeletal organisation between the
isogenic MCF10A cell lines. 
          MCF10A WT      MCF10A CDH1-/-
Figure 3.4. Immunofluorescence imaging of MCF10A microtubules. Image f shows
CDH1-/- cells lacking microtubule integrity. Prima r y α-tubulin-specific antibody (T6199)
targets and is detected by secondary fluorophore conjugated antibody. (a) DAPI WT, (b)
WT E-cadherin sc-7870, (c) WT α-tubulin T6199; (d) CDH1-/- DAPI, (e) CDH1-/- E-cadherin
sc-7870. (f) CDH1-/- α-tubulin T6199.
While the WT cell line displays coherent microtubule (MT) organisation at the centrosome
and poles, CDH1-/- cells have less organised MTs (figure 3.4; figure 1.12). This is
consistent with similar work observing disrupted microtubule organisation following E-
cadherin disruption (Yap et al., 2009), and provides early evidence that the cytoskeleton
may be a synthetic lethal vulnerability in CDH1-deficient cells.
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3.1.4. qPCR
In conjunction with direct protein detection methods, qPCR (chapter 2.3.3) was used to
confirm E-cadherin knockout at the mRNA level. CDH1 mRNA was significantly (p <
0.0001) reduced in CDH1-/- cells when compared to WT cells (figure 3.5).
Unlike the E-cadherin protein in CDH1-/- cells, expression of E-cadherin mRNA is not null.
The mRNA is still transcribed, although a truncated peptide is translated and probably
rapidly degraded. As the transcript contains a frameshift mutation, it will be rapidly
degraded, through what is termed nonsense-mediated mRNA decay. mRNA decay may
be influenced and maintained via epigenetic modification (Anderson et al., 2009). This
qPCR data is supported by exome sequencing data (Beetham et al., 2014), showing the
CDH1-/- cell line retains transcription of CDH1, but at low abundance. 
Figure 3.5. qPCR of CDH1 expression in isogenic MCF10A cells. CDH1 mRNA
expression in the MCF10A WT and CDH1-/- cell lines (p < 0.0001). Error bar indicates +/- 1
standard deviation, as derived from 3 technical replicates.
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3.2. Optimisation and testing of Neon Transfection System
The primary aim of this research was to validate the presence of synthetic lethal
interaction between CDH1 and the cytoskeletal genes MAST2 and MAP1B. This was
performed by introducing gene silencing constructs against candidate genes into isogenic
MCF10A cells and observing the effect on viability. 
In order to validate the presence of synthetic lethal interactions, candidate genes were
transiently silenced by constitutive shRNA vectors. The first objective was to establish
optimal conditions for the delivery of shRNA expression vectors into MCF10A cells by
electroporation. A balance between transfection efficiency and the maintenance of
sufficient cell survival rates was important. The approach taken can be summarised in two
steps: optimisation of conditions for delivery of shRNA plasmid by electroporation, and
determining the cause of the observed lethality in isogenic cells.
Different electroporation conditions were tested in isogenic cell lines and the
electroporation efficiency was evaluated at 24, 48 and 72 hrs. Optimisation involved
performing parallel transfections and acquiring data on cell morphology, monolayer
confluence, viability and transfection efficiency. All together, 14 conditions were tested for
transfection efficiency and cell viability (see appendix 5.6).
3.2.1. Optimisation of electroporation conditions 
To determine the best parameters for transfection, a range of voltages, pulse widths and
pulse numbers were tested (appendix 5.6). Three conditions were initially tested: T1 (1200
v; 30 ms; two pulses), T2 (three 1600 v, 10 ms pulses), and T3 (1700 v; 10 ms; three
pulses). Condition T2 used was selected based on earlier work by colleagues (B Telford,
pers. comms., 2013) and published research (Kim et al., 2008). Conditions T1 and T2
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showed the highest transfection efficiency at 24 hrs, while T3 showed markedly decreased
transfection efficiency, as observed by GFP expression (figure 3.6). T1 was better-
tolerated by the cells than T2, though T2 showed a higher transfection efficiency. As
maximum transfection efficiency was sought, T2 was selected for further iterations.
Figure 3.6. Initial optimisation of Neon Transfection System conditions. 24 hrs post-
transfection, condition T2 was determined to give rise to the greatest transfection
efficiency and iterated further. Condition parameters listed in appendix; initially optimised
with 5 µg pDNA, 2x105 cells with three 10 ms pulses of 1600 v. 
3.2.2. Optimisation of plasmid titre
The optimal plasmid titre for maximum transfection efficiency was then determined.
Condition T2 was used with a plasmid (pDNA) titre of 5, 10 and 20 µg (T2, T9, and T10,
respectively). 20 µg is the maximum recommended plasmid titre and, as expected,
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increasing pDNA titre correlated with increased transfection efficiency (figure 3.6).
Condition T10 achieved the highest transfection efficiency and was further iterated.
Figure 3.7. Optimisation of plasmid titre for Neon. 24 hrs post-transfection, increasing
plasmid titre correlated with increased transfection efficiency. Though effective in WT cells,
an increased titre is lethal to CDH1-/- cells. Conditions as per T2 (5 µg pDNA); T9 – 10 µg
pDNA, T10 – 20 µg pDNA.
3.2.3. Optimisation of cell density
To determine optimum cell seeding density, three different cell numbers were tested.
Using the T10 condition, 2, 4, and 6 x 105 cells were tested (T10, T11, and T12,
respectively). At 24 hrs post-transfection, T11 and T12 both showed a high number of
positively transfected cells (figure 3.6). Though the highest transfection efficiency, 75%,
was achieved in condition T12 using 6 x 105 cells. As the increasing cell density correlated
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positively with transfection efficiency and reduced lethality, the optimal condition may have
used an even higher cell number. 
Figure 3.8. Optimisation of cell density for Neon. Increasing cell number lead to more
transfected cells, though the transfection efficiency remained stable. Conditions as per T10
with 20 µg pDNA (figure 3.5); T11 with 2x105 cells, T12 with 4x105 cells, T13 with 6x105
cells. 
3.2.4. Attribution of lethality
Despite sufficient transfection efficiency, considerable lethality was observed early post-
transfection. Accordingly, the factors that were contributing to the decrease in cell viability
were investigated. First, the effects of electroporation and plasmid uptake were
investigated next. Conditions with and without 20 µg plasmid and conditions with and
without electroporation were tested, using both silencing and non-silencing inserts. 
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Figure 3.9. Attribution of lethality in Neon transfection. 24 hrs post-transfection and
normalised to untreated (no plasmid or zap) cells, the electroporation alone has minor
effect on lethality, while uptake of the plasmid coupled with electroporation leads to
significant reduction of viability. Error bars show +/- one standard deviation, derived from
at least 2 technical replicates.
The condition with plasmid and electroporation, when normalised to a sample with plasmid
that did not undergo electroporation, demonstrates what reduction in viability is attributable
to the electroporation itself. 24 hrs post-transfection, cells electroporated without plasmid
showed a 20% reduction in viability compared to those that were not electroporated (figure
3.7). This reduction represents the effect of electroporation alone on the viability of the
cells.
In the same experiment, the effect of plasmid uptake on early post-transfection cell viability
was assessed. In conditions with plasmid and electroporation, any further reduction in
viability would be attributed to uptake of the plasmid. 24 hrs post-transfection, cells
electroporated with plasmid showed a ~37% reduction in viability compared to those cells
electroporated without plasmid. This indicates that uptake of 20 µg of plasmid has the
largest contribution to early reduction of cell viability.
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It was not expected that non-silencing control shRNA would cause any reduction in
viability. Because similar reductions in viability were observed with both silencing and non-
silencing plasmids (figure 3.9; also over more than 24 hrs, data not shown), it was
conceived that the non-silencing control plasmid was affecting cell viability via an unknown
method. The non-silencing control pGIPZ was Sanger sequenced to ensure it was not
contaminated or harbouring a silencing insert (chapter 2.4.3). The presence of the correct
non-silencing insert was confirmed (chapter 3.3.1).
Puromycin is an inhibitor of 30S ribosomes, and halting protein translation is lethal to the
cell. The shRNA expression vector, pGIPZ, harbours a gene encoding puromycin N-acetyl
transferase (PAC) that confers resistance to puromycin (PuroR; see chapter 2.4). A
puromycin kill curve for MCF10A indicated that 1 µg/mL eliminated ~all cells after 72 hrs of
treatment, while 2 µg/mL eliminated ~all cells after 24 hrs (data not shown). Puromycin
selection (1 µg/mL) at 24 hrs post-transfection was used to kill non-transfected cells. 
Selection was applied at 24 hrs to allow cell adhesion and a recovery period from
electroporation. As electroporated cells are already vulnerable, early selection may have
an overly damaging effect on cell viability. Perhaps most relevant, key pGIPZ genes
including the shRNA, tGFP and PuroR (PAC) genes are co-transcribed with an internal
ribosomal entry site (IRES) to allow expression from a single transcript. GFP expression is
evident, though far from maximal, at 24 hrs and does not peak until at least 40 hrs (data
not shown). GFP requires post-translational modification for maturation and may thus take
more time to reach a relevant threshold/maximum than PAC. Nonetheless, 24 hrs may be
early enough that puromycin is compounding the effect of the electroporation and plasmid
uptake on cell viability, particularly at higher doses. 
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It is worth noting that even without puromycin, the early effects on cell viability were so
great that experimental data from full-length (72 hr) experiments was poor. Together,
these results indicate that the early reduction in cell viability is most likely to be due to
plasmid uptake rather than the electroporation itself, and the administration of puromycin
is compounding the effect. As the uptake of plasmid is crucial to this research, transfection
by electroporation was abandoned in favour of lentiviral transduction.
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3.3. Lentiviral knockdown of MAST2 and MAP1B
Transfection via the Neon system was deemed sub-optimal for MCF10A due to its toxic
effects and was succeeded by a second generation lentiviral packaging system. Lentiviral
packaging allows the generation of replication-incompetent lentivirus that can be used to
deliver and express a gene of interest (Shimada et al., 1995). pGIPZ lentiviral shRNA
plasmid harbours an shRNA insert based on the miR-30 primary transcript for the efficient
silencing of target genes via the endogenous RNA interference (RNAi) pathway. The
pGIPZ lentiviral vector also contains psi (Ψ) signal for lentiviral packaging, 3' and 5' long
terminal repeats (LTRs) for integration, GFP marker and puromycin resistance (PuroR;
PAC) for selection. For detailed vector map see chapter 2.4.1, and for an overview of
lentiviral packaging and use in this context see appendix 2.5.1. 
3.3.1. Confirmation of shRNA insert sequence
In the Neon experiments (chapter 3.2), non-silencing control shRNA led to decreased
viability similar to that observed in synthetic lethal candidate gene conditions. To ensure
the control shRNA sequence had not acquired a mutation or been mislabeled, sequencing
was carried out (chapter 2.4.3). Sequence quality was sufficiently high despite the tertiary
structure of the hairpin providing interference and low read quality around the shRNA
sequence (data not shown). Analysis confirmed the presence of the correct non-silencing
shRNA insert (figure 3.12). 
Figure 3.10. pGIPZ sequencing analysis. Non-silencing shRNA sequence annotation
confirms the correct shRNA insert sequence. Reads produced by Sanger sequencing at
Genetic Analysis Services, Otago.
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3.3.2. Viral titration
Following production of lentiviral particles, a viral titration was performed to determine viral
titre as transducing units (TU)/mL (chapter 2.5.4). Viral titres were consistent, ranging
between ~7x105 and ~9.5x105 TU/mL (table 3.1). These concentrations were sufficient for
subsequent experiments and did not require further concentrating.
Lentiviral package Functional viral titre (TU/mL)
Non-silencing control shRNA 8.54x105
No insert control shRNA 7.98x105
MAST2 D10 shRNA 8.71x105
MAST2 D11 shRNA 7.01x105
MAST2 D12 shRNA 9.06x105
MAP1B H5 shRNA 9.54x105
MAP1B H6 shRNA 9.04x105
MAP1B H7 shRNA 9.45x105
Table 3.1. Range of functional viral titres. Titres range from 7.01x105 to 9.45x105.
3.3.3. Multiplicity of infection
Creating optimal experimental conditions that maximise transduction efficiency while
minimising toxicity is crucial. The multiplicity of infection (MOI) is the number of viral
particles administered per cell. Optimal MOI for synthetic lethal experiments was
determined by assessing transduction efficiency and total nuclei count over a range of viral
titres. Transduction efficiency was determined from the number of transduced cells over
the total cell count.
Next, the relationship between MOI and viability was assessed. Predictably, increasing
MOI was paralleled by increasing transduction efficiency, up until a point where too many
integration events disrupt cell function and begin to affect viability. At MOI = 15 the viability
was not reduced compared to mock cells, while an MOI = 37.5 lead to some toxic effects
(figure 3.11). Although MOI = 37.5 yielded higher transduction efficiency, reducing early
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cell death was a priority following the Neon experiments. An MOI of 15 lead to at least
50% transduction efficiency (figure 3.12), and together with the little observed lethality was
deemed sufficient for subsequent experiments. 
Figure 3.11. Multiplicity of infection and viability. Up to an MOI of 15, cell viability is
unaffected; As MOI increases (MOI > 15) the cell viability decreases, most likely
attributable to gene disruptions by multiple integrations and an increase in pro-death
signals. Error bars represent +/- 1 standard deviation as derived from at least 2 technical
replicates.
Figure 3.12. Multiplicity of infection and transduction efficiency. As MOI increases,
the transduction efficiency increases in a non-linear manner. At the highest MOI (MOI =
75), transduction efficiency reaches 80% in CDH1-/- cells and 90% in WT cells. Error bars
represent +/- 1 standard deviation, derived from at least 2 technical replicates.
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However, similar studies have not used MOI > 10 (Hao et al., 2008). Although transduction
varies considerably based on cell type (S Hughes, pers. comms., 2015), such a high MOI
yielding such a low transduction efficiency is not supported by mathematical models (figure
3.13). According to the statistical process, at an MOI = 1 the probability of not being
infected P(0) = 36.79%, the probability of being infected by a single particle P(1) = 36.79%,
two particles P(2) = 18.39%, three particles P(3) = 6.13%. As above, at MOI 1 the
probability of a cell being infected by at least one particle P(>1) = 63.2%, at MOI 2 =
86.5%, at MOI 3 = 95%, at MOI 4 = 98.2%, up to MOI 8 = ~100%. 
Figure 3.13. Multiplicity of infection as a statistical process. m is the MOI, n is the
number of infectious agents entering the target, and P(n) is the probability that a target cell
will be infected by n infectious agents. As MOI increases, the percentage of cells infected
with at least one particle (P(>1)) will increase. This application of Poisson's distribution
was adapted from an interpretation by Ellis & Delbrück (1939).
In this investigation, a multiplicity of infection (MOI) of 75 only yielded 80 and 90%
transduction for the CDH1-/- and WT cell lines, respectively (figure 3.12). This highlights the
gap between biology and attempts to model it. There are several possible explanations
that explain the effects of multiplicity (see chapter 4.2.4). Most likely, the viral titre we
derived may be overestimated because cells are transduced and counted 48 hrs later so
GFP signal can mature. During this time, the cells, including transduced cells, are dividing
and leading to overestimate of initial transducing unit/lentiviral particle concentration. It is
likely that the true MOI is much lower than the values in table 3.1. Possible explanations
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for this observation are discussed in chapter 4.2.5. Regardless, the investigation continued
with an MOI of 15 as this method yielded data (chapter 3.3.4-6).
Figure 3.14. Theoretical distribution of lentiviral copy number. Fractions of cells
infected with none, one or multiple particles. As MOI increases, the percentage of cells
infected with multiple particles will increase. Multiple particles per cell result in multiple
integration events, increasing background noise due to disrupted genes. Adapted from
Ellis & Delbrück (1939).
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3.3.4. Knockdown of candidate genes
To confirm the presence of synthetic lethal interactions between CDH1 and cytoskeletal
candidate genes, isogenic cells (WT and CDH1-/-) were transduced with replication-
incompetent lentiviral particles containing unique shRNA sequences from pGIPZ. For a
complete list of shRNA sequences, see appendix 5.5.
MAST2 shRNA targets
Figure 3.15. MAST2 shRNA binding sites. MAST2 (NM_015112) targets. Each shRNA
clone targets a unique sequence of the mRNA, preventing translation and marking the
transcript for degradation. Binding position is designated in brackets. 
MAP1B shRNA targets
Figure 3.16. MAP1B shRNA binding sites. MAP1B (NM_005909) targets. Each shRNA
clone targets a unique sequence of the mRNA, preventing translation and marking the
transcript for degradation. Binding position is designated in brackets. 
This work aimed to assess the effect of shRNA knockdown on isogenic cell line viability.
Figures 3.15 and 3.16 show the position on the transcript that the shRNA sequence
targets on MAST2 and MAP1B, respectively. First, the temporal effects of shRNA
knockdown were investigated at an MOI of 15 as had previously been determined to be
optimal (chapter 3.3.2). For this experiment, control shRNA targeting GAPDH was used,
which is supported by RNA sequencing data showing consistent expression across both
cell lines.
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Figure 3.17. Temporal effect of lentiviral shRNA silencing. Maximum knockdown is
reached at 72 hrs post-transduction, though preexisting protein product may persist. Error
bars represent +/- 1 standard deviation, derived from at least 2 technical replicates.
mRNA expression was assessed by qPCR at 48, 72 and 96 hrs post-transduction to
assess the rate of RNAi knockdown at an MOI of 15. At 48 hrs post-transduction,
knockdown across the isogenic cell lines reached ~55%, and reached the maximum 80%
knockdown at 72 hrs (figure 3.17). There was little additional knockdown between 72 and
96 hrs. 
Figure 3.18. Relative levels of MAST2 expression. Values normalised to non-silencing
shRNA control, 72 hours following treatment with pGIPZ lentivirus containing unique
shRNA sequences targeting MAST2 transcript. Error bars indicate +/- 1 standard
deviation, derived from at least two technical replicates.
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It was considered that 96 hrs post-transduction would be optimal to allow full RNAi effects
to be reached, as well as allowing time for residual protein degradation and/or recycling.
However, WT cells were reaching full confluence by 96 hrs (plated as described in chapter
2.5.6). Attempts to circumvent this by reducing initial seeding density lead to new errors as
seeding became less consistent at low numbers. For subsequent experiments, mRNA was
measured at 72 hrs post-transduction in line with end-point assays. This is discussed
further in chapter 4.2.5.
Figure 3.19. Relative levels of MAP1B expression. Values normalised to non-silencing
shRNA control, 72 hours post-transduction with pGIPZ lentivirus containing unique shRNA
sequences targeting MAP1B transcript. Error bars indicate +/- 1 standard deviation,
derived from at least 2 technical replicates.
Figures 3.18 and 3.19 summarise the level of mRNA silencing for candidate target clones
at 72 hrs post-transduction. For MAST2, clones D10-12; and for MAP1B, clones H5-7
resulted in the greatest level of knockdown (figures 3.18-9), and were thus used for
validation experiments. 
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3.3.5. Assessment of viability following knockdown
To assess the effect of shRNA knockdown of candidate genes, cell viability was measured
over 72 hr time-course experiments with end-point metabolic assay and total nuclei
counts. It is expected that a reduction in fitness caused by a synthetic lethal interaction will
manifest as reduced viability in CDH1-/- cells over time.
3.3.5.1. Metabolic assay
Assessing cell metabolic activity may, under predefined conditions, reflect the viability or
number of viable cells. Resazurin is a blue dye used as a colorimetric assay for cell
viability by measuring total reducing power (ATP content within a sample). Because the
dye irreversibly binds DNA, this metabolic assay is end-point.
Figure 3.20. Metabolic assay of MAST2-silenced cells. Values normalised to non-
silencing shRNA control, 48 and 72 hrs following treatment with pGIPZ lentivirus
containing unique shRNA sequence targeting synthetic lethal candidate gene mRNA. At
48 hrs there is no reduction in viability compared to control, while at 72 hrs the synthetic
lethal effect presents itself. Error bars indicate +/- 1 standard deviation, derived from at
least 3 technical replicates. 
Following silencing of either MAST2 and MAP1B with two different shRNA clones, there is
no discernible difference between WT and CDH1-/- cell viability at 48 hrs post-transduction.
The synthetic lethal effect becomes apparent at 72 hrs post-transduction. For MAST2,
knockdown in the WT cells confers a mild protective effect, while CDH1-/- viability is
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reduced by 10-20% compared to control (figure 3.20). For MAP1B, there is a similar
increase in WT viability at 72 hrs while CDH1-/- cell viability is reduced by 20-40% (figure
3.21). Interestingly, the protective effect of MAST2 silencing on WT cells is not supported
by preliminary siRNA screening data, nor by validation data derived from total nuclei
counting.
Figure 3.21. Metabolic assay of MAP1B-silenced cells. Values normalised to non-
silencing shRNA control, 48 and 72 hrs following treatment with pGIPZ lentivirus
containing shRNA sequence targeting synthetic lethal candidate gene mRNA. At 48 hrs
there is no reduction in viability, while at 72 hrs the synthetic lethal effect presents itself.
Error bars indicate +/- 1 standard deviation, derived from at least 3 technical replicates.
3.3.5.2. Total nuclei and dead cell counting
To build a more accurate representation of viability, total nuclei were counted as a direct
measure of cell numbers 72 hrs post-transduction. For each candidate gene, three shRNA
sequences were investigated for synthetic lethal effect. For MAST2, clones D10-D12 were
used, while for MAP1B, clones H5-7 were used.
72 hrs following MAST2 silencing, WT viability is unaffected while CDH1-/- viability is
reduced by ~20% on average (figure 3.22). Following MAP1B-silencing, WT viability is
also unaffected while CDH1-/- viability is reduced by 30% on average (figure 3.23).
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Figure 3.22. Nuclei counts of MAST2-silenced cells. Values normalised to non-
silencing shRNA control, 72 hrs following treatment with pGIPZ lentivirus containing
unique shRNA sequences targeting MAST2 mRNA. Error bars indicate +/- 1 standard
deviation, derived from at least 2 technical replicates. 
Figure 3.23. Nuclei counts of MAP1B-silenced cells. Values normalised to non-
silencing shRNA control, 72 hrs following treatment with pGIPZ lentivirus containing
unique shRNA sequences targeting MAP1B mRNA. Error bars indicate +/- 1 standard
deviation, derived from at least 2 technical replicates.
After the initial qPCR and knockdown studies on multiple shRNA constructs, the
experiments were repeated on selected shRNAs in an attempt to reduce the errors
associated with each analysis. For final nuclei counting experiments, only one shRNA
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clone was used per candidate gene, MAST2 D11 and MAP1B H6. For MAST2 and
MAP1B, mRNA expression was, on average, reduced by at least 85 and 80%, respectively
(figure 3.24).
Figure 3.24. Relative levels of synthetic lethal candidate gene expression.
Normalised to non-silencing control, 72 hrs following treatment with pGIPZ lentiviral
shRNA. Error bars indicate +/- standard error, derived from at least 2 biological replicates.
Final validation experiments used only one shRNA for each candidate gene. WT viability
was unchanged while CDH1-/- viability was reduced by 20 and 30% in MAST2- and
MAP1B-silenced cells, respectively (figure 3.25).
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Figure 3.25. Combined nuclei counts of candidate-silenced cells for validation.
Values normalised to non-silencing control, 72 hrs following treatment with pGIPZ lentiviral
shRNA. Error bars indicate +/- 1 standard error, derived from 3 biological replicates.
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3.3.6. Cytell field of view coverage comparison
Reproducibility between experimental replicates of high-throughput cell line work can be
affected by inconsistent seeding density and the distribution of cells within the well. While
the former is readily overcome by good experimental technique, there is less control over
the latter. For total nuclei counts, a representative sample of fields is captured to reflect the
conditions of each experimental replicate. The most accurate assessment of cell viability
would cover 100% of surface area of the well for each replicate. However, this would
require some ~50 fields per well of a 96-well plate which renders the approach unfeasible.
Figure 3.26. Comparison of Cytell coverage and accuracy. The dataset comes from an
HDACi experiment (entinostat) provided by A Chen as described in chapter 2.6. 
To investigate the optimal representative number of fields, a dataset of 25 fields per
technical replicate provided by colleague A Chen was broken down into subsets of 5, 10,
15 and 20 fields. These subsets were then compared to the 'most representative' method
of 25 fields. While the relative viability was the same across all subsets, the standard error
increased as the number of fields was decreased (figure 3.26; table 3.2). This showed that
while fewf fields (ie, 5 or 10) were sufficient in representing the trend of the experiment, it
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would be a barrier in reaching statistical significance and perhaps discredit valid findings. It
was determined that 20 fields of view was sufficiently representative.
Figure 3.27. Spread of Cytell viability data. Values are normalised to the value derived
from 25 fields of view. Decreasing the number of fields of view decreases the accuracy
and consistency of the method and increases the deviation and error from the 25 field
approach. Dataset comes from HDACi (entinostat) experiment provided by A Chen.
Cytell (n) fields 20 fields 15 fields 10 fields 5 fields
Max. norm. value 1.089 1.085 1.169 1.288
Min. norm. value 0.894 0.793 0.785 0.628
Mean value 0.991 0.984 0.970 0.939
N < 0.90 2 4 10 21
N > 1.10 0 0 4 6
Table 3.2. Cytell field of view comparison data.
More subtle fold-changes are less likely to reach statistical significance, reducing strength
and validity of the results. For the most informative results, the maximum practical number





















































































3.4. Drug treatment with Aurora kinase inhibitors
The purpose of this chapter was to evaluate known drugs for potential synthetic lethal
effect. While shRNA knockdown of candidate genes will demonstrate the validity of a gene
target, drugs against these targets are often not yet available. Drugs that are already
approved or under clinical investigation for different conditions may be repurposed and
fast-tracked into the clinic and thus make a positive impact in the short-term.
Aurora kinases are a family of protein kinases that play critical roles in mitosis. Disruption
of mitotic machinery is a proven anticancer strategy that is used by multiple
chemotherapeutic agents. Mitotic regulators and cytoskeletal proteins were over-
represented as synthetic lethal candidates in the primary siRNA screen (Telford et al.,
2015), likely stemming from the role E-cadherin plays in cytoskeletal maintenance. 
siRNA knockdown MCF10A WT viability MCF10A CDH1-/- viability Fold change
MAST2 0.65 0.38 0.58
MAP1B 0.84 0.65 0.77
AURKA 0.64 0.58 0.91
AURKB 0.38 0.32 0.84
Table 3.3. MCF10A viability in preliminary siRNA screen (Telford et al., 2015).
In the primary siRNA screen, both AURKA and AURKB siRNAs showed modest levels of
reduced viability in CDH1-/- cells (table 3.3). However, neither met the inclusion criteria for
further validation. This inclusion criteria following candidate knockdown was at least 15%
more reduction in CDH1-/- viability compared to WT and no more than 50% reduction in
WT viability (ie, too toxic for reliable viability measurement). AURKA knockdown lead to
only 9% reduction in relative CDH1-/- viability, while AURKB knockdown lead to 62%
reduction in WT viability. These data suggest that Aurora kinase inhibition in an E-
cadherin-deficient context was worthy of further investigation, given the availability of
Aurora kinase inhibitors.
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3.4.1. Determining optimal drug concentration and EC50
First, the EC50 concentrations of two Aurora kinase inhibitors, alisertib and danusertib,
were determined to measure the potency of each drug after a specified duration of
exposure. Using this result, the optimal experimental dosing range could be determined.
MCF10A WT     MCF10A CDH1-/-
Figure 3.28. EC50 curves for Aurora kinase inhibitors alisertib and danusertib.
Alisertib (A & B, WT & CDH1-/-) and danusertib (C & D, WT & CDH1-/-). EC50, the effective
concentration of drug that gives the half-maximal response, is calculated from a drug
serial-dilution dose-response, utilising the curve fitting method of least squares.
Experiments included three technical replicates, but no biological replicates were
performed.
The EC50 was determined by treating cells with an 8-point, 10-fold dilution series of each
drug, 24 hrs post seeding. At 48 hrs post-treatment, viability was assessed via total nuclei
count (chapter 2.7.4). EC50 was calculated using non-linear regression with a curve fitted
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by least squares. For alisertib, the EC50 was calculated as 11.38 nM for WT and 8.66 nM
for CDH1-/-; for danusertib, the EC50 was calculated as 45.45 nM for WT and 36.03 nM for
CDH1-/- (figure 3.28; table 3.4).
EC50 MCF10A WT MCF10A CDH1-/-
Alisertib (MLN8237) 11.38 nM 8.66 nM
Danusertib (PHA-739358) 45.45 nM 36.03 nM
Table 3.4. EC50 values for Aurora kinase inhibitors alisertib and danusertib. 
The EC50 of both drugs is lower for CDH1-/- cells than WT cells, indicating the potential of
Aurora kinase inhibition in a CDH1-deficient context. This suggests there is a vulnerability
i n CDH1-/- MCF10A cells that may be amenable to inhibition of Aurora kinases in a
synthetic lethal manner.
3.4.2. IncuCyte time course confluence assay
To gather further evidence of a synthetic lethal effect for alisertib, the effect of drug
inhibition on isogenic cell growth was measured in real-time. The IncuCyte live cell
imaging system tracks the confluence of a cell culture monolayer as a proxy measure of
viability in real-time. Cell confluence was measured over 45 hrs post-treatment. Over the
first 24 hrs, WT cells exhibit little decrease in viability across the experimental dosage
range. In contrast, CDH1-/- cells show a dose-dependent inhibition of growth (figure 3.29);
80 nM alisertib shows the greatest growth inhibition, followed by 26.7 nM. 
However, between 24 and 48 hrs post-treatment, WT cells began to show inhibited growth
similar to CDH1-/- cells (figure 3.29); cell proliferation was inhibited in a dose-dependent
manner. This suggests that WT cells can only tolerate Aurora kinase A inhibition for
around 24 hrs. Together these data suggest there may be a short therapeutic window for
Aurora kinase inhibition in a CDH1-deficient context, although the difference between the
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two cell lines was insufficient to be confident that there would significant clinical utility.
Figure 3.29. Time-course confluence assay of alisertib-treated cells. Cells were
drugged at t = 0 hrs and readings taken at 2 hr intervals. While there is marked growth
inhibition only in CDH1-/- cells over the first 24 hrs, both cell lines show a dose-dependent
growth inhibition between 24 and 48 hrs.  
A real-time confluence assay was not performed for danusertib-treated cells due to time
constraints and varying drug potency despite all attempts to correctly aliquot and store the
drug.
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3.4.3. End point nuclei counting
For a more accurate measure of end-point viability, total nuclei counting was performed at
48 hrs post-treatment. For alisertib, all drug dosages lead to preferential reduction in
CDH1-/- viability, though only 25 nM reached statistical significance (p = 0.048). At 25 nM,
WT cells show a 20% reduction in viability compared to untreated, while CDH1-/- cells
show 35% reduction compared to untreated. This equates to an 18% reduction in CDH1-/-
viability compared to WT. This confirms Aurora-A is a valid synthetic lethal target in a E-
cadherin-deficient context, but its additional clinical utility in treating CDH1-deficient
cancers would be marginal.
Figure 3.30. Total nuclei count of alisertib-treated cells. Viability was assessed 48 hrs
post-treatment. Cells were drugged at t = 0 hrs and an end-point staining cocktail was
added at t = 47.5 hrs. CDH1-/- cells show reduced viability compared to WT, though the
effect is the strongest at 25 nM.
Treatment with danusertib also leads to selective reduction in CDH1-/- cell viability. At 25
nM, WT cells show almost unchanged viability (<5%), while CDH1-/- cell viability is reduced
by 25%.This equates to a fold change of about 20% (within inclusion criteria) and confirms
Aurora-B as a synthetic lethal partner of CDH1.
91
Figure 3.31. Total nuclei count of danusertib-treated cells. Viability was assessed 48
hrs post-treatment. Cells were drugged at t = 0 hrs and an end-point staining cocktail was
added at t = 47.5 hrs. CDH1-/- cells show reduced viability compared to WT, though the
effect is the strongest at 25 nM.
These results support the existence of a synthetic lethal relationship between E-cadherin
and components of the cytoskeleton. Although Aurora kinase inhibitors themselves may
not provide a clinical 'advantage', this work encourages further examination of drugs that
target cytoskeletal components and processes.
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4. Discussion
This study investigated the validity of putative synthetic lethal partner genes to E-cadherin
gene CDH1. Candidate genes were identified in a genome-wide siRNA screen (Telford et
al., 2015), performed by PhD student Bryony Telford. Putative synthetic lethal candidates
were validated with shRNA knockdown and drug inhibition of target genes and their
proteins, respectively.
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4.1. Importance of developing a novel strategy for HDGC management
4.1.1. HDGC outlook
Familial cases represent 1-3% of nearly one million annual diagnoses of gastric cancer,
and HDGC attributable to E-cadherin inactivation has been reported in over 155 families
worldwide (Vogelaar et al., 2015; Hansford et al., 2014). A recent study evaluating lifetime
risk for cancer found that by the age of 80 years, the cumulative incidence for gastric
cancer was 70% for males and 56% for females, with an additional 42% risk for breast
cancer (Hansford et al., 2015).
Despite the further understanding of the biology of these tumours and the availability of
increasingly effective drug therapies, late detection results in an overall 5-year survival rate
not exceeding 30%. The survival rates for individuals treated for early gastric cancer are
best, but advanced cancers carry very poor prognoses. The difficulty of early stage
detection is compounded by the lack of luminal perforation in early gastric cancer and
difficulty distinguishing between gastric cancer and benign ulcers or gastritis (Okabayashi
& Shima, 2013). As a result, endoscopic surveillance for HDGC cancer foci is imperfect
and highlights the need for better screening and/or diagnostic tools. 
4.1.2. Emerging technologies
The highlights of emerging technologies for the surveillance of gastrointestinal pathology
include blue laser imaging, narrow-band imaging and confocal laser endomicroscopy
(Meining, 2009; Togashi et al., 2016). Blue laser and narrow-band imaging utilises
monochromatic lasers that allow visualisation of the microarchitecture of specific features
and structures based on powerful colour contrast discrimination. Assessment of changes
to microvasculature and microsurface patterning by magnifying endoscopy with blue laser
and/or narrow-band imaging, allow for in situ diagnoses of foci that are undetectable with
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conventional white-light endscopy (Togashi et al., 2016).
Confocal laser endomicroscopy (CLE) is perhaps the most promising technological
development and would allow submucosal in vivo imaging at a cellular and subcellular
level. Depth-focused lasers increase the spatial resolution and permit the recontruction of
highly-resolved 3D images. However, because CLE relies upon fluorescence, there are
concerns over mutagenic potential of the required contrast agents (Wallace et al., 2010),
and it is unlikely that CLE will allow practical imaging of the entire stomach as required for
HDGC. It is likely that future surveillance will consist of a functionally complementary set of
image-enhanced endoscopic tools, biopsies and histopathological examination.
4.1.3. Chemoprevention
While early detection is an important prognostic factor, prevention is the most effective
management modality. To date, there has been little focus on chemoprevention and the
clinical recommendation for HDGC families is prophylactic total gastrectomy in preference
to annual endoscopic surveillance. Although total gastrectomy is curative in >95% of
HDGC-affected individuals there is significant long-term morbidity, highlighting a need for a
targeted therapy that can efficiently clear early lesions. Eliminating pre-clinical cancer foci
may help prevent or delay tumour progression while reducing the need for surgery.
Loss of function events in tumour suppressor genes are difficult to target because the
encoded protein is lost from the cancer cell. However, loss of CDH1 expression is
predicted to create vulnerabilities that may be exploited in a synthetic lethal manner.
Efficient treatment modalities that can eliminate pre-clinical lesions will both improve
patient outcomes and reduce the public health burden. Further, any synthetic lethal drugs
developed for HDGC may have application across other cancer types. Most pertinently,
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these drugs may be utilised in sporadic E-cadherin-deficient DGC and LBC, but also other
cancers where E-cadherin is silenced, including prostate, endometrial, ovarian carcinomas
and medulloblastoma, among others (Perl et al., 1998).
4.2 Experimental protocol
4.2.1. Cell line selection
The investigation of synthetic lethal partnerships required a cell line model of CDH1 loss.
Isogenic (CDH1+/+ and CDH1-/-) MCF10A non-transformed, mammary epithelial cell line
derived from human fibrocystic tissue were selected (Sigma, St. Louis, USA). The latter
features a homozygous 4 base-pair deletion in CDH1 achieved by zinc-finger nuclease
excision. The model was chosen because breast cancer is part of the HDGC spectrum
and is near to genetically normal,  and there are no equivalent gastric cell lines.
MCF10A has the characteristics of normal breast epithelium with anchorage-dependent
growth, minimal chromosomal rearrangements and high genomic stability (Soule et al.,
1990). With a stable genome and minimal alterations to pathways and functions, MCF10A
closely reflects the biology of the non-malignant cells in vivo. Whereas more advanced
cancers acquire additional genetic changes, the lack of genetic abnormalities in MCF10A
is desirable for its use as part of a chemoprevention model (Chen et al., 2014). Although
MCF10A does have some abnormalities associated with in vitro cultured epithelial cells,
such as MYC amplification and p16 deletion (Debnath et al., 2003), it is considered
genetically 'normal'.
4.2.2. Plasmid selection
Investigation of synthetic lethal interactions requires a method to silence candidate gene
expression. While siRNA was used for preliminary screening, transient and/or stable long-
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term RNAi requires an expression vector. To perform specific and efficient silencing of
candidate genes, lentiviral shRNA vector pGIPZ was selected. pGIPZ features microRNA-
adapted shRNA based on miR-30 that the manufacturers claim delivers efficient silencing
of gene expression with minimal cytotoxicity. The availability of extensive pGIPZ shRNA
libraries (Dharmacon) that specifically target candidate synthetic lethal genes also
supported the selection of this silencing modality.
MicroRNA-adaptors on shRNA sequence increase processing efficiency of shRNA into
siRNA by the endogenous RNAi machinery and promote degradation of target transcript.
Selectable GFP and puromycin markers allow easy identification and selection of cells
harbouring the shRNA vector. Under control of a strong CMV promoter, the shRNA and
reporting markers (turboGFP; tGFP and puromycin N-acetyl transferase; PuroR) are
constitutively expressed in a polycistronic transcript. The single transcript means that the
strength of GFP signal mirrors the level of shRNA expression, acting as a visual indicator
of gene silencing effects. For a vector map of pGIPZ, see chapter 2.4.1.
4.2.3. Electroporation
The simplest method for RNAi is the cytosolic delivery of siRNA, as was performed in
primary screening by liposome transfection (lipofection; Telford et al., 2015). Although
rapid and simple for high-throughput work, caveats including short-term efficacy and lack
of selectable markers underpin the insufficiency of this method for robust validation of
synthetic lethal genes. Transient delivery of a replicative shRNA-vector such as pGIPZ
allows for long-term silencing of the targeted gene and easy visualisation of activity.
MCF10A are notoriously difficult to transfect (P Guilford, pers. comms., 2014) and
consequently, this project explored multiple transfection conditions.
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At the commencement of this project a novel/commercial electroporation method/package
– the Neon transfection system – based on Kim et al., (2008) was tested. The
electroporation itself and the uptake of the plasmid each contributed to significant cell
death early post-transfection (0 – 24 hrs; chapter 3.2.4). Although it was unclear why
plasmid uptake was so poorly tolerated, one explanation was that the plasmid titre is too
high, although lower plasmid titres were ineffective (figure 3.12; chapter 3.3.3), highlighting
the difficulty of MCF10A transfection. It remains possible that additional treatment of cells
with electrocompentence protocols prior to electroporation could have increased
transduction efficiency and decreased cell death.
In untreated MCF10A, it takes between 1-2 hrs for adherence/adhesion and for 2-6 hrs for
anchorage-dependent growth to resume following trypsin-mediated loss of adhesion (Chen
et al., 2014). Although it was not thoroughly investigated, the effects of electroporation and
plasmid uptake together may have delayed the recovery time. It is likely that delayed
recovery, together with rapid puromycin selection 24 hrs post-transfection, may have also
contributed to early cell death (24 hrs+). Standard selection protocols recommend for
puromycin selection to follow a low-dose 7-10 day workflow including serial passage
where necessary. As a lethal phenotype is being sought, it is not possible to run an
experiment of this length. Furthermore, attempts to passage transfected cells were
unsuccessful and therefore the use of short-acting, higher-concentration puromycin is
supported.
Although early transfection efficiency was promising, a significant majority of cells did not
recover from the combined effects of the transfection/electroporation and selection
agents/puromycin, even in non-silencing control conditions (figure 3.9; figure S.1; chapter
3.24). The compromising effects of electroporation, plasmid uptake and early selective
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agents on cell viability produced poor experimental data, leading to the method being
abandoned (data not shown). Although cost did not contribute to the decision to abandon
the method, it is a factor to consider. While good experimental technique would encourage
Neon pipette tip replacement for each technical replicate, it has been demonstrated that
tips may be used up to 10 times before the protocol is compromised (H Beetham, pers.
comms., 2015).
For experimental controls, no insert and non-silencing pGIPZ plasmids were initially
tested. No insert pGIPZ has no miR-30 shRNA sequence and does not activate
endogenous RNAi pathways. Non-silencing pGIPZ produces a scrambled shRNA
sequence with no known targets/homology. It was noted that non-silencing control leads to
some reduction in viability compared to no insert control, but is a more appropriate control
so its continued use was supported. Given the reduction in viability it is likely that the
strong activation of endogenous RNAi machinery has an early impact on cell viability,
rather than just uptake of the plasmid. Higher cell densities should have also been
investigated; while the maximum plasmid titre was used, the kit allows for up to 1 x 10 6
cells and an increased cell density may have reduced toxicity.
The factors contributing to early cell death might have been mitigated with use of an
inducible shRNA-expression vector. To elaborate, an inducible system would remove the
temporal constraints arising from investigating a lethal phenotype because cells could be
transfected, allowed to recover, seeded, and then induced and observed. Furthermore,
mixed or even clonal populations of transfected cells could be propagated and preserved
for later use. Therefore, with an inducible system, in principle, endless replicates of each
experimental condition could be performed from a single electroporation. 
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4.2.4. Lentiviral transduction
To mitigate the cytotoxic effects of vector uptake, validation of synthetic lethal interactions
was performed by lentiviral transduction. For an overview of this process, see chapter
2.5.1. Lentiviral delivery and integration of expression vectors is often followed by
establishment of a stable, clonal populations. However, as the synthetic lethal phenotype
is lethal, surviving stable populations may have confounding integrations/disruptions in the
genome. Instead, experimental protocols were performed on non-clonal, mixed
populations without serial passage following transduction. While this method was
successful, the fold-changes in viability were not as great as those generated in primary
screening, and some candidates did not validate whatsoever. 
Factors affecting the lentiviral protocol may stem back in the experimental pipeline to as
early as viral titration. Here, some possible improvements to the experimental protocol are
discussed. First, the use of polybrene for increased transduction efficiency is standard in
viral transduction protocols (S Hughes, pers. comms., 2015), although it was not used in
this investigation. Future experiments involving viral transduction would likely benefit from
addition of this reagent, as it would decrease the use of viral particles and lead to a more
even distribution throughout a cell population.
It was retrospectively determined that the multiplicity of infection (MOI) was very high –
similar work only rarely exceeded an MOI of 10 (Hao et al., 2008). Theoretically, at MOI =
1, it is expected that ~63% of cells will take up a viral particle, up to MOI = 15 where it is
expected that ~100% of cells will have at least one viral particle (figure 3.14). However, in
the experiments of this investigation, MOI = 15 only resulted in approximately 75%
transduction, representing at least one viral particle for each of those cells. The following
ideas may explain this observation: (1) factors in the media may affect viral particles, (2)
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receptor expression follows uneven distribution, or (3) the initial viral titration was highly
overestimated. 
Viral particles are produced in serum-free DMEM media, and it is possible that
transduction of cells in complete media reduces viral potency as the particles interact with
serum. Lentiviral particles are internalised following docking with low density lipoprotein
receptor (LDLR; Finkelstein et ai., 2013). Transcriptome data suggests the expression of
this protein is not altered following E-cadherin loss (Chen et al., 2014), and both cell lines
are expected to be equally amenable to viral transduction.
In pGIPZ, shRNA and reporters (tGFP and PAC/PuroR) are transcribed together as one
polycistronic transcript, processed, and then translated separately. Therefore, a strong
GFP signal infers a high level puromycin resistance and shRNA expression and, by
extension, target RNAi. 24 hrs following transduction, no GFP was visible and it takes at
least 48 hrs for a strong GFP signal to develop (figure S.2). The delayed end-point for viral
titration may have lead to an over estimation of functional viral titre as cells continue to
divide. This could have been mitigated by using anti-GFP antibodies before the signal had
developed to full strength (~24 hrs), or by serum-starving or otherwise inhibiting growth
with low doses of drugs. It is necessary to count GFP-positive colonies or use antibodies
as described above because the lentivirus used here is replication-incompetent and
therefore cannot be titred with plaque-forming assays or focal forming assays.
Given that the GFP signal does not reach maximum until 48 hrs post-transduction, it is
likely that application of puromycin at 24 hrs is having an effect on cell viability. Meanwhile,
strong GFP signal is already observed 24 hrs following transfection by electroporation,
suggesting electroporation/cytosolic shRNA vector leads to more rapid RNAi and more
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rapid synthetic lethal phenotype than lentiviral transduction/integration. This delay is due
the lentiviral pGIPZ genome being reverse transcribed and integrated while pGIPZ plasmid
will be immediately functional. Given the delay in activity in lentiviral RNAi it is probable
that any synthetic lethal phenotype is delayed, evident by metabolic assay data (chapter
3.3.6.1), where there was no effect at 48 hrs but a detectable effect did present by 72 hrs
post-transduction. Indeed extending experimental duration may lead to a stronger effect –
like those observed in siRNA screening.
However, extending experimental duration leads to different issues. In the current
experimental conditions cells become fully confluent at 96 hrs, and stop dividing due to
contact inhibition. The obvious solution of reducing seeding density is difficult for the 96-
well plate layout that was used. As the density is already relatively low, attempts to further
decrease it introduced higher error. 
To better control density and confluence, amino acid or serum starvation could be used for
growth stasis. This would allow a higher density of cells to be used, and only those that die
are attributed to synthetic lethal effect. This model has drawbacks including that epithelial
cells are dividing in vivo, and some mechanisms of lethality require division for a stress
threshold to be reached. However, cells could be transduced, allowed to recover, and then
returned to complete media to initiate the experiment.
 
Changing the plate format for larger wells is an option, though would require reoptimisation
and increased reagent use. While all published work, including early screens, was
performed in 96-well plates, the use of 24- or 12-well plates would likely reduce seeding
error and allow for longer experiment duration. Again, these potential improvements would
be redundant if an inducible shRNA-expression system were to be used. Replacement of
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the constitutive pGIPZ with an inducible shRNA expression system would allow for the
same improvements/features as discussed for Neon (chapter 4.2). The lentiviral
experiments in this investigation commence at transduction (t = 0 hrs), while an inducible
system would allow for the fine tuning of condition parameters (cell density, cell recovery,
copy number, etc) prior to commencement. Inducible expression vector pTRIPZ is similar
to pGIPZ, though the expression of key genes is controlled by the addition of  doxycycline. 
The pGIPZ shRNA library used for this investigation is not available in pTRIPZ format,
although the presence of multiple cloning sites would allow for shRNA inserts to be cloned
between these vectors. My principle recommendation for improving this experimental
system is to clone pGIPZ shRNA inserts into pTRIPZ and for work to be carried out from
stable cell lines. However, recent attempts in our laboratory to clone fragments of pGIPZ
into pTRIPZ have been very inefficient (A bin Aiderus, pers. comms., 2015).
4.3. Synthetic lethal target validation
4.3.1. MAST2
MAST2 had previously been identified in the primary siRNA screen, where knockdown
elicited a strong synthetic lethal effect (WT 0.65, CDH1-/- 0.38, fold-change 0.58). Using
lentiviral shRNA knockdown to further investigate putative synthetic lethal interactions in
isogenic MCF10A cell lines, MAST2 has been validated as a synthetic lethal partner of
CDH1 (figure 3.25). Four of the seven shRNA clones, D9-11, E2, induced a synthetic
lethal effect, as observed by total nuclei counts (figure 3.22). One shRNA clone, D10, gave
rise to the strongest phenotype and was used for most of the data shown. 
MAST2 (aka MAST205, MTSSK) encodes its namesake protein: microtubule-associated
serine/threonine kinase 2 that plays a part in modulating microtubule interactions and
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dynamics (Clay et al., 2013). MAST2 is expressed in all tissues at low to moderate levels,
where dystrophin and utrophin networks facilitate interaction between the cell membranes
and microtubules to stabilise the cytoskeleton and thus the structure of the cell (Terrien et
al., 2012). MAST2 phosphorylates dystrophin/utrophin to modulate their affinities for
associated proteins, including microtubules. 
In epithelial cells, utrophin interacts with adherens junctions proteins for the role of
modulating microtubule interactions and stabilising the cytoskeleton (Belkin & Burridge,
1995). Loss of E-cadherin-dependent cytoskeletal anchorage leads to a disarrayed
cytoskeleton (figure 1.12). A potential mechanism for synthetic lethality of MAST2 posits
that further destabilisation of an already unstable cytoskeleton will be intolerable and thus
lethal to the cell.
To date, there has been little work characterising the role of MAST2 in cancer. Functional
fusions of MAST2 and NOTCH1 with strong driving/tumourigenic roles have been found in
breast carcinoma and associated pre-invasive lesions (Clay et al., 2013, Robinson et al.,
2011). These fusions drive a subset of breast cancers, albeit rarely (McCarthy 2012,
Robinson et al., 2013) and exhibit unique phenotypic effects in breast epithelial cells.
Overexpression of MAST1 or MAST2 gene fusions has a proliferative effect both in vivo
and in vitro (Robinson et al., 2011). However, MAST2 expression is barely affected by
CDH1 downregulation (Chen et al., 2014).
Protein homologue of tensin (PTEN) is a dual function phosphatase with tumour
suppressor function. PTEN is a negative regulator or PI3K/AKT signalling, and its
downregulation is associated with increased PI3K/AKT signalling (Fournier et al., 2010).
MAST2 interacts with PTEN as negative regulators of cell survival pathways such as
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PI3K/AKT and silencing of either leads to increased survival (Terrien et al., 2012;
Delhommel et al., 2015).
Synthetic lethal targeting of PTEN-deficient cancers identified MAST2 as a target
(Mereniuk et al., 2013), meaning simultaneous silencing of both genes is selectively lethal.
If either PTEN or MAST2 are lost, increased survival signalling is expected to lead to
increased survival. In a PTEN-deficient context, MAST2 silencing leads to selective cell
death via a synthetic lethal phenotype. MAST2 silencing alone is possibly tolerated as it is
rescued by increased survival signalling involving PTEN. However, PTEN co-localises with
E-cadherin at cell-cell contacts, so it is expected E-cadherin loss will displace PTEN. It has
also been shown that E-cadherin expression is positively linked to PTEN expression
(Fournier et al., 2009). In an E-cadherin-deficient context, it is possible that a mechanism
fo r MAST2 synthetic lethality involves decreased PTEN activity leading to insufficient
activation of PI3K/AKT signalling.
Recently, MAST2 knockout mice were demonstrated as viable with a normal phenotype
(Gardin, 2010) This suggests knockdown in humans may be relatively well tolerated.
Indeed, the WT (CDH1+/+) MCF10A cells showed very little reduction in viability (~5%),
while CDH1-/- cells showed a ~20% reduction in viability. This indicates that drugs targeting
MAST2 may produce little side effects in normal cells, while directly targeting E-cadherin-
deficient cells.
Drug inhibition of MAST2 was considered for this project. However, the initial drug of
interest, RB478952, was found to be a pan-kinase inhibitor with insufficient specificity for
MAST2 and not further followed. The ubiquitous nature and conserved catalytic domains
of kinases reflect the difficulty in achieving drug specificity with small molecules. However,
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given the similar functions of some synthetic lethal candidates, the drug may have been
worth investigating.
Inconsistent gene silencing effects between shRNA clones may have been explained by
the mRNA secondary structure around the target sequence preventing the shRNA from
binding the transcript. The lack of access may explain the shRNA clones that had no
effect, while the shRNA clones killing both cell lines may be explained by off-target effects.
Interestingly, one clone, E3, lead to (relatively highly) decreased viability in both isogenic
cell lines. While MAST2 mRNA was reduced by E3 shRNA knockdown, it is possible that
the shRNA is also targeting other genes whose inactivation is not synthetic lethal, but
simply lethal. This is supported because clones E3 and D9 target the identical location on
MAST2 transcript (1381 – 1399; figure 3.15) but have different sequences so one or both
may have off-target effects.
Investigation of synthetic lethal kinase partners of p53 identified MAST2 as a potential
target (Wang & Simon, 2013), though MAST2 expression was significantly increased in
tumours with functional mutations of p53. I n p53-deficient tumourigenesis, tumour
suppressor roles including cell cycle arrest, DNA repair and apoptosis become defective
and an aggressive phenotype is promoted (Aylon & Oren, 2011)
Gene ontology analysis of the synthetic lethal partners of p53 showed a strong
representation of genes involved in cell cycle regulation, cellular growth, polarity and
microtubule dynamics including PLK1, PLK4, CDK1, CDK16, MAST2, MAP3K4, MARK2
and Aurora-A (Wang & Simon, 2013). These candidates show significant crossover with
those identified in CDH1-deficient MCF10A and reflect similar vulnerabilities in
tumourigenesis that are driven by defective cell cycle and microtubule regulation.
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4.3.2. MAP1B
MAP1B was also identified in the primary siRNA screen, with knockdown leading to a good
synthetic lethal effect (WT 0.84, CDH1-/- 0.65, fold-change 0.77). In this study, lentiviral
shRNA knockdown has validated MAP1B as a synthetic lethal partner of CDH1. All three
shRNA clones targeting MAP1B (H5, H6, H7) led to a synthetic lethal phenotype. H5
produced the strongest phenotype and was used for final validation experiments. 72 hrs
post-transduction with H5 shRNA, CDH1-/- cells showed a 30% reduction in viability
compared to WT.
MAP1B encodes a protein belonging to the microtubule-associated protein family that
influences cytoskeletal dynamics and cell fate (Bialik & Kimchi, 2006; Esser et al., 1997)
MAP1B is highly expressed in neuronal regions, and shows a median expression pattern
in the rest of the body (Protein Atlas, 2016). There is a paucity of new research on MAP1B
outside of a neuronal context, where it regulates microtubule organisation, mediates axon
guidance for receptor neurons and contributes to transport of cargo on the microtubules
(Conde & Caceres, 2009; Aoki et al., 1995). 
MAP1B plays a role in polarised growth and maintenance of plasma membrane domains
in epithelial biogenesis (Spiliotis et al., 2008) by coupling microtubules to post-Golgi
vesicle transport. Though not essential for this process, MAP1B silencing may affect
polarised epithelial morphogenesis and downregulation has been associated with epithelial
transition to hyperplasia and dysplasia (Pedrero et al., 2004). Conversely, ectopic MAP1B
expression leads to increased microtubule stability and increased α-tubulin acetylation
(Takemura et al., 1992). Increased microtubule stability can bolster tolerance against
microtubule depolymerising agents such as vinblastine.
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MAP1B interacts with DAPK-1 (death-activated protein kinase), a protein with wide ranging
functions in cell growth control. These two proteins cooperate to induce growth inhibition,
and together form a synthetic lethal interaction (Harrison et al., 2008). MAP1B and DAPK-
1 co-localise in two groups – one with tubulin, the other with cortical F-actin. Reduction of
MAP1B function in this context resulted in attenuated DAPK-1-stimulated autophagy.
MAP1B shows a maturation- and differentiation-dependent expression in retinal epithelium
(Esser et al., 1997). In the same work, MAP1B expression was shown to increase during
pathologic conditions and in cell culture (following multiple passages) resulting in cells
losing epithelial characteristics and altering morphology to more resemble fibroblasts
(Esser et al., 1997). Similarly, MAP1B has been shown to have a similar expression
pattern to vimentin (VIM; also vitronectin (VTN) and fibronectin (FN1)) – associated with
neuronal/mesenchymal/fibroblast (ie, long) characteristics (Aoki et al., 1995). Loss of
epithelial characteristics and increased expression of vimentin is associated with epithelial-
mesenchymal transition (EMT). It is possible MAP1B plays a role in EMT, a de-
differentiation process involving cytoskeletal remodeling that is associated with
invasiveness and poor prognoses. Thus, MAP1B may make an attractive target in
advanced epithelial cancers, where increased MAP1B expression may be involved in lost
epithelial characteristics and/or EMT events. 
MAP1B expression is decreased 10- to 20-fold in CDH1-/- MCF10A compared to CDH1+/+
(Chen et al., 2014). The reduction in expression suggests MAP1B downregulation is well
tolerated in an E-cadherin-deficient context, and makes it difficult to rationalise MAP1B as
a synthetic lethal drug target. It is possible that decreased MAP1B expression and function
contributes to E-cadherin-deficient tumourigenesis through reduced microtubule stability,
and may contribute to the differences in microtubule architecture between the pair of cell
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lines. Interestingly, treatment with low dose of taxol 3 µM lead to a 7- to 8-fold increase of
MAP1B expression in CDH1+/+ cells, likely in response to the pressures of taxol targeting
microtubule stability (unpublished, Telford, Beetham, Chen, Guilford).
Because ectopic expression leads to increased microtubule stability, it is likely that
targeting/silencing MAP1B will reduce microtubule stability. The mechanism for synthetic
lethality between MAP1B and CDH1 is not clear, though it is likely that dysregulation of
microtubule dynamics and decreased stability with an already defective cytoskeleton is not
tolerated by the cell. 
To date, no drugs have been described that specifically target MAP1B. The absence of a
solved crystal structure or absence from compound screening assays do not aid specific
drug development targeting MAP1B. However, MAP1B and CDH1 are synthetic lethal, and
silencing MAP1B is likely to lead to reduced microtubule stability. Therefore, in an E-
cadherin-deficient context, all microtubule destabilising/depolymerising drugs could be
investigated for effect. In isogenic MCF10A, there were no obvious phenotypic changes
following silencing of MAP1B. Due to the role played by MAP1B in controlling microtubule
dynamics, immunofluorescent staining of tubulin or actin may have highlighted some more
subtle phenotypic changes.
Reduced protein content in the cell following shRNA knockdown was inferred from
reduced mRNA measured by qPCR. Logically, as mRNA is translated into protein,
reduced precursor should lead to reduced product. However, the rate of turnover/recycling
varies greatly between proteins and some persist for days. Viability was assessed at 72
hrs post-transfection (in line with the preliminary screen), though the synthetic lethal effect
may have increased with time. Ideally, MAP1B (and MAST2) knockdown would have been
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validated at the protein level, but could be due to a lack of suitable antibodies.
4.3.3. Aurora kinase inhibition
Drug inhibition of Aurora-A and -B kinases (encoded by AURKA and AURKB) in isogenic
E-cadherin-deficient cells found a synthetic lethal effect. (chapter 3.4). The Aurora kinase
family is a collection of related serine/threonine kinases that function as key mitotic
regulators. There are three members of the family, Aurora-A, -B and -C, but only Aurora-A
and -B are expressed at detectable levels in somatic cells undergoing mitosis. Aurora-A
and Aurora-B regulate centrosome function and act by controlling chromatid segregation
and microfilament polymerisaton (Ding et al, 2015; Bolanos-Garcia, 2005). Expression and
activity of Aurora kinases is tightly controlled, and dysregulation leads to genetic instability,
aneuploidy and tumourigenesis (Bolanos-Garcia, 2005; Fu et al., 2007) Overexpression of
Aurora kinases is associated with malignancy (Carvajal et al., 2008) and chromosomal
instability and thus the development of Aurora kinase inhibitors has gained attention.
Aurora-A localises primarily at the spindle poles and transiently along spindle
microtubules, with key roles in bipolar spindle organisation, centrosome formation and
mitotic entry (Fu et al., 2007; Ding et al., 2015). Inhibition of Aurora-A leads to unseparated
chromosomes, and mitosis checkpoint activation, thereby impairing mitotic progression.
(Hirota et al., 2003). Death can occur in mitosis through activation of apoptosis before
escaping mitotic arrest. (Hilton & Shapiro, 2014).
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Figure 4.1. Effects of Aurora kinase inhibition on cell cycle. While Aurora-A inhibition
leads to mitotic arrest and defective spindle assembly, Aurora-B inhibition leads to bypass
to mitotic checkpoints with dysregulated chromosomal segregation leading to polyploidy.
Adapted from Komlodi-Pasztor (2011).
Aurora-B plays important roles in chromosome condensation, spindle-kinetochore
attachment/regulation and cytokinesis (Komlodi-Pasztor, 2011; Hilton & Shapiro, 2014).
Aurora-B inhibition leads to loss of normal chromosomal alignment, chromosomal
segregation and cytokinesis (Hilton & Shaprio, 2014). In mitosis, Aurora-B inhibition results
in failure to activate mitotic checkpoint proteins and rapid exit from mitosis. This leads to
bypass of the checkpoint and cytokinesis failure, which contribute to polyploid cells and
genomic instability (figure 4.1).
Both Aurora kinase inhibitors alisertib and danusertib have demonstrated efficacy in
cancer cell lines, tumour xenograft models and clinical trials (Friedberg et al., 2014; Ding
et al., 2015; ). Alisertib is a small-molecule inhibitor of Aurora-A, with 200-fold selectivity
over Aurora-B (Manfredi et al., 2011) Danusertib is a small molecule inhibitor of all Aurora
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kinases but more so isotype B (IC50 of 13, 79 and 61 nmol/L for A, B, C, respectively;
Carpinelli et al., 2007), as well as other kinases pertinent to cancer such as Bcr-Abl,
FGFR-1 and TrkA tyrosine kinases (Gontarewicz & Brummendorf, 2010; Meulenbeld et al.,
2012). 
4.3.3.1. Aurora-A inhibition
Alisertib has demonstrated potent anticancer effects in epithelial cancer cell lines with
strong growth-inhibiting, proapoptotic, proautophagic and EMT-inhibitory effects (Ding et
al., 2015). Alisertib blocks the cell cycle with G2/M phase arrest and induced mitochondria-
mediated apoptosis and autophagy. Alisertib suppresses PI3K/AKT, mTOR and p38
MAPK pathways but activates 5'-AMPDK, also contributing to proautophagic activity (Ding
et al., 2015). In a tumour xenograft model, alisertib decreased bipolar and aligned
chromosomes and produced strong growth inhibition (Manfredi et al., 2011). 
Elevated levels of Aurora-A are found in about half of colorectal, ovarian and gastric
cancers, and up to 95% of invasive breast duct carcinoma (Fu et al., 2007). Alisertib
clinical trials are currently underway for several uses including gastrointestinal tumours,
metastatic triple-negative breast cancer, urothelial cancer and advanced solid tumours
(clinicaltrials.gov, 2016) and AK inhibitors have demonstrated clinical activity in B- and T-
cell aggressive lymphomas (Friedberg et al., 2014) advanced and/or metastatic solid
tumours (Cohen et al., 2009; Meulenbeld et al., 2013), and platinum-resistant or refractory
epithelial carcinomas (Matulonis, 2012). Chromosomal instability is more common in
advanced tumours, and underpins the use of Aurora kinase inhibition as an advanced
anticancer strategy. In alisertib-treated MCF10A cells, chromatids appear misshapen and
are incorrectly segregated, likely due to defective mitotic spindle machinery.
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For reference, in the primary siRNA screen, Aurora-A showed a relative viability decrease
of 10% (WT viability 0.64; CDH1-/- viability 0.58; Telford et al., 2015). This did not meet the
criteria of 15% viability reduction of CDH1-/-compared to WT. In the same screen, Aurora-B
gave a 15% reduction in CDH1-/- viability (WT 0.39, CDH1-/- 0.32; Telford et al., 2015), but
did not meet the initial inclusion criteria because WT viability was decreased by more than
50% (ie, it is too toxic).
4.3.3.2. Aurora-B inhibition
Danusertib, the pan Aurora kinase inhibitor, has previously shown strong antiproliferative
effects in a wide range of tumour cell lines (Meulenbeld et al., 2012), particularly those with
polyploidy or other anomalies of endoreplication. It has also been used in a small number
of clinical studies including leukaemia, prostate cancer and multiple myeloma
(clinicaltrials.gov, 2016). Danusertib has been used in patients with advanced solid
tumours, generating partial responses and instances of prolonged stable disease in a wide
variety of advanced refractory cancers (Cohen et al., 2009). However, dose-limiting toxicity
is reported with neutropenia, nausea and fatigue as the primary side effects (Steeghs et
al., 2009).
Because cell cycle progression remains unperturbed, Aurora-B-inhibited cells undergo
continued DNA replication, eventually reaching a degree of polyploidy at which death
occurs from massive genome instability (Kops et al., 2005). The instability is intolerable
and cells undergo apoptosis in mitochondria-mediated manner. Aneuploidy, polyploidy and
multinucleation phenotypes make Aurora-B a less attractive therapeutic target, and this is
reflected by the side effects and lower interest in clinical trials. Danusertib reduced viability
more than siRNA treatment, perhaps due to functional overlap of Aurora-C providing
rescue to Aurora-B-silenced multinucleation phenotypes (Balboula et al., 2014).
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Danusertib-treated cells show obvious ploidy and effects on chromosome segregation.
This target is likely not attractive for early DGC prevention or treatment because of
massive genomic instability associated with Aurora-B inhibition (figure S.3).
Tozasertib (VX-680) is a potent inhibitor of Aurora kinases with particular affinity for
isotype B. This compound did not produce any synthetic lethal effects in a known drug
screen of the MCF10A isogenic cell lines (B Telford, unpublished). While danusertib does
preferentially inhibit Aurora kinase B, it does have activity against other isotypes and
perhaps different kinases altogether, so the mild synthetic lethal effect observed may be
attributable to additive or synergistic effects of multiple interactions.
4.3.3.3. Aurora inhibition in HDGC
Reduced cytoskeletal stability in E-cadherin-deficient cells, together with chromosomal
instability caused by defective mitosis following Aurora kinase inhibition may together be
fatal to the cell. Both Aurora-A and Aurora-B are upregulated in CDH1-deficient MCF10A
cells (Chen et al., 2014), though only by ~10%. It is likely that Aurora kinase inhibition
would be well suited for targeting of genomically unstable tumours, a characteristic of more
advanced disease or different subtype altogether (TCGA, 2014). The strategy of targeting
mitosis has drawbacks for HDGC chemoprevention because early SRCC divide slowly.
However, there is evidence that Aurora kinases may help maintain stem cell
characteristics in carcinomas (Yi-Chao Hsu et al., 2016), possibly contributing to the
poorly-differentiated phenotype observed in HDGC.
Alisertib is particularly interesting as it has been used in clinical combination with histone
deactylase (HDAC) inhibitors (HDACi) and microtubule stabilising drugs such as paclitaxel
(Do et al., 2014). HDACs and microtubule-associated genes were well represented in the
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primary screen, suggesting this combination could be effective in E-cadherin-deficient
cells. Targeting microtubules may be a better strategy for HDGC chemoprevention
because tubulin has crucial roles in both mitotic and non-mitotic cells (Komlodi-Pasztor et
al., 2011). Overall, mitosis-specific agents have had less clinical success than microtubule-
targeting agents. While the efficacy of targeting microtubules is usually attributed to
inducing mitotic arrest, other cellular mechanisms are also targeted during interphase.
Targeting mitosis allows interference/inhibition during certain cell cycle stages, while
targeting microtubules impairs functions during all stages. While targeting Aurora kinases
may be a good strategy for advanced carcinoma, it is likely that targeting microtubules is
more effective for early HDGC chemoprevention/chemotherapy.
Aurora kinase inhibition may be more useful in advanced DGC than the early stages of the
disease. Early DGC cells are indolent, so inhibition of Aurora-A leading to attenuated cell
division may not be a good mechanism for HDGC chemoprevention. As well as
suppressing tumour growth, silencing of Aurora-A has been demonstrated to sensitise
cells to more advanced-stage treatment modalities such as conventional chemotherapy
and radiotherapy (Verhejj et al., 2010; Shao et al., 2012). Conversely, inhibition of Aurora-
B forces cells through the mitotic checkpoint and cell division, leading to genomic
instability and polyploid cells. This mechanism is less useful for an early genomically
stable tumour, although may have potential for advanced or genomically unstable tumours.
As discussed above for p53, Aurora-A was identified as a synthetic lethal partner.
Inhibition of Aurora-A leads to cell cycle arrest, a process that is ablated in p53-deficient
tumourigenesis. This highlights the utility of Aurora-A as an amenable target in different
genetic contexts and underscores the therapeutic benefits that may come from further
development of Aurora kinase inhibitors.
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4.3.3.4. Experimental
Treatment with Aurora-A and Aurora-B inhibitors alisertib and danusertib demonstrated
synthetic lethal effect (chapter 3.4). Initial EC50 experiments could have benefited from a
tighter dilution series. This would cause more data points to fall on the curve, leading to a
more accurate result. Despite this, a higher EC50 concentration in WT than CDH1-/- hints at
a synthetic lethal effect and the optimal concentrations for testing were determined.
Aurora kinase inhibitors led to distinct, aberrant nuclear morphologies with some ploidy in
danusertib (figure S.3). Viability assessment of drugs that affect nuclear morphology can
be compromised when nuclei counts are used to measure viability. Dose-dependent
effects of the Aurora kinase inhibitors includes a spectrum of nuclear morphologies
between normalising DMSO control and the maximum drug concentration. The principal
methods of nuclei counting, utilising CellProfiler and/or Cytell analysis package, rely on cell
size/shape parameters defined for each experiment to identify individual nuclei. These
parameters were kept constant within each experiment (though optimised between each
biological replicate), which introduces errors that grow in line with the dose-dependent
effects of the drug.
Assessment of AKi-treated cell viability may therefore be more accurate with assays that
don't rely on morphology, such as metabolic assays (resazurin, MTT, etc). It is possible
that this experiment may have benefited from using two sets of parameters – one for
DMSO control and one for drug-treated. Manual counting is also an option, although
obviously undesirable. Given the role of Aurora kinases in mitosis, it may have been
informative to undertake cell-cycle analysis. Again, the morphological effects of Aurora




This research validated the presence of synthetic lethal interactions identified in
preliminary siRNA screening (Telford et al., 2015). This supports the validity of the screen
and indicates that there is merit in further investigating other candidates. For example,
genes related to PI3K/AKT signalling are enriched for synthetic lethal interactions with
CDH1, suggesting this network is a valuable target.
Although none of the candidate drugs or siRNA produce true synthetic lethality, the
reductions in viability are more reflective of a synthetic sick phenotype, where cells are
selectively impaired or have their fitness reduced. In BRCA1/2-deficient cell lines, the
silencing of PARP leads to a selective ~80% reduction in viability, a much stronger effect
than the 30% reduction observed in this investigation. However, it is worth noting that
simply delaying or slowly progression and development is therapeutically beneficial.
This work warrants the development of targeted therapies against validated synthetic
lethal genes, including serine/threonine kinases MAST2, Aurora-A and Aurora-B kinases
AURKA and AURKB, and microtubule-associated protein MAP1B. The findings also
warrant the investigation of known and approved compounds that target E-cadherin-
deficient vulnerabilities such as cytoskeletal processes or PI3K/AKT signalling, even if they
are not necessarily highly specific. 
The function of both MAST2 and MAP1B is to stabilise microtubules, so it is likely that
microtubule-destabilising agents will elicit strong responses. Investigation of drug activity in
E-cadherin-deficient context provides valuable evidence for combinations of drugs to
increase efficacy while mitigating side effects. Prediction of synthetic lethality and synergy
would be well supported by mapping of gene networks and functional redundancy.
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Although this investigation was primarily focused on chemoprevention of HDGC, findings
may support synthetic lethal targeting in a wider range of sporadic cancers with reduced
CDH1 expression. Most cancers with reduced CDH1 expression are carcinomas, and
include ovary, prostate, lobular breast and colorectal cancers, as well as
medulloblastomas.
Recently, Medsafe-approved drug denosumab has been demonstrated to halt early breast
cancer cells and delay the growth of tumours harbouring BRCA1 mutations (Nolan, 2016).
Denosumab is an antibody drug that is used in the treatment of osteoporosis via targeting
of a surface protein that is also expressed in BRCA1-deficient cells. Although this study
was performed in mice and cell lines, the work has future implications for cancer
chemoprevention in high-risk individuals and aptly highlights three things: (1) the
therapeutic potential of repurposing existing drugs into novel clinical contexts; (2) the value
of targeted therapy with specific antibody-based drugs; and (3) the possibility of reducing
surgical reliance through chemopreventive strategies.
4.4.2. Future research
Although silencing the synthetic lethal partners of CDH1 do not yield viability losses likely
to lead to a revolutionary new therapy, there is value in further investigating the cellular
effects. To better characterise the effects of targeting mitosis or microtubules, some simple
assays such as tetrazolium dye assays or cytostatic activity assays could be used to
assess cytotoxicity or shifts in proliferative capability. Further cell cycle analysis and
immunofluorescent imaging following treatment would provide good evidence on the effect
of targeting mitosis or microtubules.
More biologically relevant models would benefit the further development of synthetic lethal
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drugs or validation of further targets. To represent early in situ development, 3D
cultures/spheroids would be a useful tool for further drug and shRNA experiments.
Cultivation of cells on ECM protein-containing gel or in a suspended/hanging media
droplet are possible options for achieving 3D cultures in MCF10A (A Chen, pers. comms.,
2015). Xenografting and engineered or gastric cancer-prone mouse models are also
powerful tools for studying synthetic lethality in vivo.
The results of this investigation highlight the need to explore further drugs that target
functions and processes of mitosis and the cytoskeleton, especially those identified and
validated in this work. Although antibody-based drugs can achieve the greatest specificity,
they cannot enter a cell and only bind targets on the cell surface. Therefore, specificity of
drugs targeting MAST2 or MAP1B is best achieved with small molecules to allow entry into
the cell. However, the development of these drugs is costly, and it is unlikely that these
findings warrant new drug development. 
Investigation of drugs targeting the cytoskeleton, although unlikely to be a targeted
therapy, are likely to show synthetic lethal activity in E-cadherin-deficient cells. There is a
wide variety of compounds that target the cytoskeleton, and are classed as stabilising or
destabilising agents. Taxol and its derivatives are stabilising agents that impair the
dynamic nature of microtubules by preventing depolymerisation, while destabilising agents
such as vinblastine cause rapid depolymerisation and derangment of microtubules. The
results of this investigation suggest destabilising agents may provide the best clinical
effects, and these drugs should be further explored in more advanced HDGC models.
Despite being a stabilising agent, treatment with taxol leads to selective reduction in
CDH1-/- viability (A Single, pers. comms., 2015). There have been few advancements in
microtubule-targeting drugs in the last decade, although there are many drugs, such as
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pseudolaric acid B, are worth testing (Wong et al., 2005). However, given the clear
vulnerabilities in the cytoskeleton and mitosis, more drugs that target these functions
should be investigated. 
Identifying complementary compounding effects of drugs (ie, synergy) is important for
clinical use and as well as building a more complete understanding of the early cancer
biology. HDACs were identified as targets in siRNA screening, and combined treatment of
taxol and vorinostat/SAHA (high HDAC class I and II specificity) shows an additive effect,
though no synergy (A Single, pers. comms., 2015). Synergistic relationships between
drugs can be rationalised like synthetic lethal effects (ie, related/functional redundancy,
convergent pathways), where targeting two things together elicits a greater response.
Given the success of simultaneous Aurora kinase and microtubule inhibition in the clinic
(Do et al., 2014), this combination should be investigated for further in a CDH1-deficient
context. There is good arsenal of HDAC inhibitors, and may translate well for
chemoprevention because second somatic allele loss of CDH1 is often caused by
hypermethylation. 
Novel drug screening is one method that may yield further useful compounds for HDGC
chemoprevention. Compounds derived from flora have serendipitously evolved to interact
with many facets of  biology, and this underpins the value of sourcing novel drugs from
plants where it is estimated some 95% have yet to be investigated (Balunas, 2005). High-
throughput screening of New Zealand flora for useful compounds has uncovered many
molecules predicted to have relevant bioactivity that warrant further investigation. Methods
of screening for compounds can include mass spectrometry, or functional predictions
based on sequencing data in the case where a reference genome is available, among
others. Screening drugs in isogenic cell lines – as was performed in this investigation –
120
may uncover further E-cadherin-deficient vulnerabilities  and targets for therapy or
chemoprevention.
Other approaches to the clinical management of HDGC include options outside of drug
therapy. In assisted reproduction therapy (ART), pre-implantation genetic diagnosis (PGD)
is the genetic profiling and screening for specific diseases. Embryos are evaluated and
those with certain genetic characteristics may be selected against, while those without the
risk variant are selected for implantation and gestation. In HDGC families, the offspring of
an affected individual carry a 50% chance of inheriting a defective CDH1 allele – higher if
both parents carry a defect in CDH1. In HDGC families, CDH1+/- embryos can be
discarded while CDH1+/+ embryos can be implanted, effectively eliminating inherited
cancer incidence. This approach has been proven (Rechitsky et al., 2002) and would
reduce the public health burden and increase individual wellbeing by effectively and
permanently eliminating the predisposition to highly penetrant cancer for an entire lineage.
Along the same lines, genome editing with precision techniques can be used to reduce
disease penetrance. Engineering of the human genome is a controversial issue that has
generated heated debate, although the practice will inevitably become more prevalent.
The grey area between 'fixing' a pathogenic genome and transhumanist enhancements
will need to be clearly defined. Methods of disease proofing includes creating functional
overlap/redundancy, removing pathogenic gene variants, reducing DNA polymerase
error/mutation rate and/or telomerase activity to delay senescence. For example, cell cycle
regulator p53 is mutated/affected in some 90% of human cancers and it is possible that
engineering functional redundancy could reduce cancer incidence. Recently, approval has
been granted for human studies using the CRISPR/Cas genome editing system to
engineer T-cells for the targeting of immune-evading cancer cells.
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For now, continued effective management of HDGC requires multicentre efforts due to the
rarity of the syndrome. However, this work has shown that CDH1-deficient cells can be
selectively targeted. By further refinement of the synthetic lethal drugs used, particularly in





One PBS tablet was added to 100 mL of mQH2O and autoclaved as per the manufacturers
instructions.
5.1.2. Trypsin
0.5% trypsin was diluted in PBS 1/2 and 1/10 for 0.25% and 0.05% trypsin, respectively,
and stored at 4˚C.
5.1.3. Lysogeny broth (LB)
For 500 mL LB, 5 g tryptone, 2.5 g yeast extract, 5 g NaCl were added to 500 mL mQH 2O
and autoclaved. For LB agar plates, 7.5 g agar was added prior to autoclaving. Following
autoclaving, agar was allowed to cool before being poured into 100 mm plates. For
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selective plates 100 µg/mL ampicillin was added just prior to plate pouring. With asceptic
technique, LB was stored at RT and used for up to one month, while LB plates were stored
at 4˚C and had a usable time of two weeks.
5.1.4. Super optimal broth with catabolite repression (SOC)
For 500 mL of SOC, 10 g tryptone, 2.5 g yeast extract, 0.292 g NaCl, 0.093 g KCl, 0.476 g
MgCl2, 1.233 g MGSO4, 1.8 g glucose were added to a 1 L bottle, made up to 500 mL
with mQH2O and autoclaved. With asceptic technique, SOC was stored at RT and used for
up to one month.
5.1.5. Resazurin metabolic assay reagent
For 400 mL of dye, 0.044 g of resazurin was dissolved with prolonged stirring in 400 mL of
1X PBS pH 7.4 for a final stock concentration of 440 µM. Dye was filtered through 0.22 µm
polyethersulfone filter and aliquoted. Dye was stored at 4˚C for use or -20˚C for long-term
storage.
5.1.6. Western blot buffers
5.1.6.1. Lower buffer
For 1 L of 4X lower buffer (1.5 M Tris-Cl pH 8.8, 0.4% SDS): some number g Tris and 40
mL of 10% SDS was dissolved in 800 mL mQH2O, made up to 1 L, and adjusted to pH 8.8
with 1 M NaOH and HCl. Buffer was stored at RT and used within one year.
5.1.6.2. Upper buffer
For 1 L of 4X upper buffer (0.5 M Tris-Cl pH 6.8, 0.4% SDS): some g Tris and 40 mL of
10% SDS was dissolved in 800 mL mQH2O, made up to 1 L, and adjusted to pH 6.8 with 1
M NaOH and HCl.  Buffer was stored at RT and used within one year.
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5.1.6.3. Running buffer
For 1 L of 10X running buffer: 135.2 g glycine, 24.16 g Tris, and 8 g SDS was dissolved in
800 mL mQH2O and made up to 1 L. For 1 L of 1X buffer: 50 mL of 20X buffer was mixed
with 950 mL mQH2O. Buffer was stored at RT and used within one year.
5.1.6.4. Transfer buffer
For 1 L of 20X transfer buffer without methanol: 150.1 g glycine and 24.16 g Tris was
dissolved in 800 mL mQH2O and made up to 1 L. For 1 L of 1X buffer: 50 mL of 20X buffer
was mixed with 850 mL mQH2O followed by 100 mL methanol. Buffer was made fresh
from 20X concentrate on the day of protein transfer.
5.1.6.5. Tris-buffered saline with tween-20 (TBST)
For 1 L of 10X TBST: 24.23 g Tris, 87.66 g NaCl, and 10 mL tween-20 was dissolved in
200 mL mQH2O and made up to 1 L, adjusted to pH 7.5, and then made up to 1 L. For 1X
TBST: 10X TBST was diluted 1/10 with mQH2O. Buffer was stored at RT and used within
one year.
5.1.6.6. Protein loading Laemmli buffer
For 100 mL of 5X protein loading Laemmli buffer (250 mM Tris-Cl pH 6.8, 10% SDS, 50%
glycerol, 25% 2-mercaptoethanol, 0.05% bromophenol blue): 25 mL Tris-Cl (pH 6.8; upper
buffer), 10 g SDS, and 0.5 g bromophenol blue were combined in 50 mL glycerol. 25 mL 2-
mercaptoethanol was added immediately prior to use (for solution longevity, 750 µL buffer
without 2-mercaptoethanol was combined with 250 µL 2-mercaptoethanol at the
commencement of each experiment). 5X protein loading buffer was diluted with 4 parts
protein lysate for use at 1X.
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5.1.6.7. Stripping buffer
For 100 mL of harsh stripping buffer (2% SDS, 60 mM Tris-HCl, 0.8% 2-mercaptoethanol):
20 mL of 10% SDS, 12.5 mL of 0.5 M Tris-Cl (pH 6.8), and 0.8 mL of 2-mercaptoethanol
was added to 66.7 mL of mQH2O/made up to 100 mL with mQH2O. Buffer was stored at
RT and used within one year.
5.1.7. SDS-PAGE gel
For one 10% resolving gel: a mixture of 4.2 mL ddH2O, 2.5 mL lower buffer, 3.3 mL 30%
acrylamide (37.5:1 bis:acrylamide) and 200 μL of 10% sodium dodecyl sulfate (SDS) was
polymerised by addition of 20 μL tetramethylethylenediamine (TEMED) and 150 μL of 10%
ammonium persulfate (APS) and rapidly cast. To prevent desiccation, resolving gel was
gently covered with isopropanol and prior to the casting of the stacking gel the isopropanol
was carefully removed.
For one stacking gel, a mixture of 2.35 mL ddH2O, 1 mL upper buffer, 0.65 mL 30%
acrylamide (37.5:1 bis:acrylamide) and 80 μL of 10% SDS was polymerised by addition of
20 μL TEMED and 60 μL of 10% APS and rapidly cast atop the resolving gel and the stack
comb carefully added. Once set, gel was used immediately or otherwise stored airtight
inside a moist tissue at 4˚C until use within two weeks.
5.1.8. Immunofluorescent imaging buffers
5.1.8.1. Fixing buffer
For 100 mL fixing buffer, 3.6 g paraformaldehyde (PFA) was slowly added to 90 mL of
PBS with stirring. 1M NaOH was added dropwise until PFA was dissolved. pH was
adjusted to 6.9 with 6M HCl. Fixing buffer was then filtered through 0.22 µm
polyethersulfone filter and frozen in 10 mL aliquots at -20˚C. Aliquotes were thawed at RT
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on day of use, and were used within one week.
5.1.8.2. Permeabilisation buffer
For 100 mL permeabilisation buffer, 5 mL of 10% Triton (final 0.5%) was added to 95 mL
PBS and dissolved with agitation. Bubbles from agitation were allowed to settle before
use, and stored at room temperature under no specific conditions. Buffer was stored at RT
and used within one month.
5.1.8.3. Blocking buffer
For 100 mL of blocking buffer, 5 mL of secondary antibody-matched serum and 1 mL of
fetal bovine serum was added to 94 mL of PBS. Blocking buffer was made fresh on the
day of immunofluorescent imaging.
5.1.8.4. Antibody diluting buffer
For 100 mL of antibody diluting buffer, 1 mL of FBS and 0.5 mL of 10% Triton (final 0.05%)
was added to 94.5 mL PBS. Buffer was stored at RT and used within one month.
5.1.9. Plasmid extraction kits
Zyppy MidiPrep & Zyppy MiniPrep (Zymo, PureLink MaxiPrep & PureLink MidiPrep
(Invitrogen); NucleoSpin MiniPrep & NucleoBond Xtra MidiPrep (Machery-Nagel); and




Western blot 1˚ 2˚
E-cadherin (CDH1) Sc7870 Pc rabbit anti-E-
cadherin 1:200
NA934 Pc α-rabbit HRP-
conjugate 1:5000
α-tubulin (TUBA) T6199 Mc mouse anti-α-
tubulin 1:2500
NA931 Pc α-mouse HRP-
conjugate 1:5000
Table 5.1. Western Blot antibody dilutions.
Immunofluorescence 1˚ 2˚
E-cadherin (CDH1) Sc7870 Pc rabbit anti-E-
cadherin 1:200
AlexaFluor 488 goat α-rabbit 
1:500
F-actin (ACTA/ACTB) A2066 Pc rabbit anti-actin 
1:400
AlexaFluor 647 goat α-rabbit
1:1000
α-tubulin (TUBA) T6199 Mc mouse anti-α-
tubulin 1:1000
AlexaFluor 547 rabbit α-
mouse 1:4000
Pericentrin (PCNT) A4448 Pc mouse anti-
pericentrin 1:1000
AlexaFluor 555 rabbit α-
mouse 1:1000
Nucleus (DAPI) Vectashield GOLD N/A
Table 5.2. Immunofluorescence antibody dilutions.
5.3. PCR primer sequences
MAST2 fwd 5' – TTG CCC TCT TCA GGA TAT GG – 3'
MAST2 rev 5' – GTG CTG AAA TGC TTC GTC AA – 3'
MAP1B fwd 5' – CCT CGA GAC GTG ATG AGT GA – 3'
MAP1B rev 5' – AAT CCG TTG AGC GGT GTA AC – 3' 
GAPDH fwd 5' – GCG CCC AAT ACG ACC AA – 3'
GAPDH rev 5' – GCT CTC TGC TCC TCC TGT T – 3'
PPIA fwd 5' – TCT TTC ACT TTG CCA AAC ACC – 3' 
PPIA rev 5' – CAT CCT AAA GCA TAC GGG TCC – 3' 
RPL13a fwd 5' – CTG GCC TCG CTT GGT TT – 3'
RPL13a rev 5' – GAT GAA CAC CAA CCC TCC CC – 3'
CDH1 fwd 5' – CTG AGG ATG GTG TAA GCG ATG – 3' 
CDH1 rev 5' – GTC TGT CAT GGA AGG TGC TC – 3' 
pGIPZ miR fwd 5' – GCA TTA AAG CAG CGT ATC – 3'
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5.4. PCR reaction mixtures
Component Volume (µL)
5X PS buffer 2
RT enzyme 0.5




Table 5.3. Reaction mixture for 10 µL PrimeScript cDNA synthesis.
Component Volume (µL) for 384-well Volume (µL) for 96-well
Evagreen master mix 3 6.5
F/R primer (300 nM) 0.0975 0.195
Template cDNA 1 2
Water 1.9025 4.305
Total 6 13
Table 5.4. Reaction mixture for 6 and 13 µL Evagreen qPCR. 
5.5. shRNAmir-30 sequences
MAST2 D9 – CCGAGACTGCCTGGATAAA
MAST2 D10 – TCTTTGTAAACATGATTCA
MAST2 D11 – TTGCTTTAAAAGCTCATCT
MAST2 D12 – TACTTGTCCGACAAAAGCT
MAST2 E1 – TGATCACTTTGTTGACAGG
MAST2 E2 – TGGACAGTCCAAAGTCCGT
MAST2 E3 – TTTATCCAGGCAGTCTCGG
MAP1B H5 – CCCTTGGCAGCTTCACCAA
MAP1B H6 – GACTCCAGTTTATCACATA
MAP1B H7 – CAAGGACTTTGAAGAGTTA
GAPDH – TGACAAAGTTGTCATTGAG
Non-silencing – CTTACTCTCGCCCAAGCGAGAG
No insert – no shRNAmir
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5.6. Neon Transfection System conditions
Conditions were initially tested with 5 µg of plasmid and 2 x 105 cells.
Condition Voltage (v) Pulse length (ms) Number (n)
T1 1200 30 2
T2 1600 10 3
T3 1700 10 3
T4 1600 20 3
T5 1600 10 2
T6 1500 10 3
T7 1500 20 2
T8 1600 30 1





Table 5.5.b. Neon transfection plasmid titre conditions.
Condition Cell number
T10 2 x 105
T11 4 x 105
T12 6 x 105
Table 5.5.c. Neon transfection cell density optimisation conditions.
5.7. Factor well size calculation
Costar 3603 well size (from catalogue) 0.3165 cm2
Eclipse Ti Inverted Microscope 10X field size (derived) 0.00684 cm2




Figure S.1. Early death following Neon transfection. Centre of well-plate (for dead cell
accumulation) for non-silencing pGIPZ condition T12. Rounded/extra bright cells are
undergoing apoptosis and necrosis in response to cellular stressors such as
electroporation, puromycin selection, and plasmid uptake and RNAi. Note, no puromycin is
added until 24 hrs, so all prior death is due only to electroporation and plasmid activity.
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Figure S.2. Expression delay in gene silencing modalities. While transfection by
electroporation leads to strong expression of GFP at 24 hrs, the signal is delayed in the
lentiviral method, likely due to extra processing (ie, reverse transcription, integration).
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Figure S.3. Effects of Aurora kinase inhibition on MCF10A nuclear morphology.
Alisertib (Aurora-A) treatment leads to improper chromosome condensation and “sickle
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The CDH1 gene, which encodes the cell-to-cell adhesion protein E-cadherin, is frequently 
mutated in lobular breast cancer (LBC) and diffuse gastric cancer (DGC). However, because 
E-cadherin is a tumor suppressor protein and lost from the cancer cell, it is not a 
conventional drug target. To overcome this, we have taken a synthetic lethal approach to 
determine whether the loss of E-cadherin creates druggable vulnerabilities. We first 
conducted a genome wide siRNA screen of isogenic MCF10A cells with and without CDH1 
expression. Gene ontology analysis demonstrated that G-protein coupled receptor (GPCR) 
signalling proteins were highly enriched amongst the synthetic lethal candidates. Diverse 
families of cytoskeletal proteins were also frequently represented. These broad classes of E-
cadherin synthetic lethal hits were validated using both lentiviral-mediated shRNA 
knockdown and specific antagonists including the JAK inhibitor LY2784544, Pertussis toxin 
and the aurora kinase inhibitors Alisertib and Danusertib. Next, we conducted a 4,057 known 
drug screen and time course studies on the CDH1 isogenic MCF10A cell lines and identified 
additional drug classes with linkages to GPCR signalling and cytoskeletal function that 
showed evidence of E-cadherin synthetic lethality. These included multiple histone 
deacetylase inhibitors including Vorinostat and Entinostat, phosphoinositide 3-kinase 
inhibitors, and the tyrosine kinase inhibitors Crizotinib and Saracatinib. Together, these 
results demonstrate that E-cadherin loss creates druggable vulnerabilities that have the 





E-cadherin is a cell-to-cell adhesion protein that is localized at the adherens junction of all 
epithelial cells (1). Other than its roles in cell adhesion, E-cadherin is involved in establishing 
and maintaining cell polarity and differentiation, the organization of cell migration and 
architecture and the mediation of signalling through various proliferation and survival 
pathways including WNT and EGFR (2, 3).  
 
Abrogation of expression of the E-cadherin gene (CDH1) by mutation, deletion or promoter 
hypermethylation is a feature common to many epithelial tumors and its downregulation is 
the hallmark of both diffuse gastric cancer (DGC) and lobular breast cancer (LBC) (1, 4-6). 
Disrupting E-cadherin’s expression or localization has a pronounced impact on a cell’s 
cytoskeletal structure, with changes including misalignment of the microtubule and actin 
cytoskeletons, defects in cell migration and irregularities in the orientation of the mitotic 
spindle (7-9).  
 
Germline CDH1 mutations are responsible for Hereditary Diffuse Gastric Cancer (HDGC), a 
cancer syndrome characterized by the highly penetrant, early onset of multifocal DGC and 
an elevated rate of LBC. In HDGC, CDH1 inactivation is an initiating event that may be 
related to abnormal mitotic spindle orientation resulting in daughter cells being displaced into 
the lamina propria, outside the epithelial plane (10-12). In other cancer types its 
downregulation is considered to be a late event that promotes increased invasive capacity, 
frequently through association with the epithelial-mesenchymal transition (13).  
 
Although E-cadherin is a tumor suppressor protein that is lost from the cancer cell and 
therefore not a conventional drug target, the downregulation of such a multifunctional protein 
during tumorigenesis would be predicted to create vulnerabilities in the cell which are 
targetable using a synthetic lethal approach. In the context of drug development, synthetic 
lethality can be defined as a drug which reduces cell viability or fitness only in cells carrying a 
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specific mutation. The utility of synthetic lethal targeting of tumor suppressor genes is well 
illustrated clinically by Olaparib, an inhibitor of the DNA repair enzyme poly-ADP ribose 
polymerase (PARP). Olaparib elicits strong clinical responses in breast and ovarian cancer 
patients who harbour inactivating mutations in the homologous recombination dsDNA repair 
genes BRCA1/2 (14, 15).  
 
In addition to providing new therapeutic avenues for the treatment of sporadic epithelial 
cancers, synthetic lethal targeting of E-cadherin-deficient cells also has the potential to 
improve the clinical management of HDGC. In order to identify druggable synthetic lethal 
vulnerabilities in E-cadherin-deficient cells, we have conducted both a genome-wide siRNA 
synthetic lethal screen and a four thousand compound known drug screen on isogenic breast 
MCF10A cells with and without CDH1 expression. Together, these screens have identified 
multiple druggable targets which suggest new therapeutic strategies for the treatment of E-
cadherin-deficient cancers and the chemoprevention of HDGC. 
 
Materials and Methods 
Cell lines and Media 
The MCF10A breast cell line and its paired isogenic MCF10A CDH1-/- line (here designated 
CDH1-/-) were obtained from Sigma Aldrich in 2011 (parental line ATCC® CRL-10317) and 
had been authenticated using short terminal repeat analysis.  CDH1-/- had been created by 
homozygous deletion of 4bp from exon 11 of the CDH1 gene. The lines were resuscitated 
within one week of receipt and early passage cells (passage 3-7) were aliquoted and frozen.  
All experiments were conducted with cells between passages 6-15 in DMEM F12 media with 
glutamate, 5% horse serum, 20 ng/mL EGF, 0.5 µg/mL hydrocortisone, 100 ng/mL cholera 





siRNA high throughput screen  
Cells were transfected with siRNAs from the Dharmacon SMARTpool whole genome protein-
coding siRNA library (RefSeq 27) housed in the Victorian Center for Functional Genomics. 
Each SMARTpool contained four siRNAs that targeted different regions of each gene in one 
well. Each reaction, in a white walled, clear bottom 384 well plate format, contained 0.125% 
DharmaFECT 3 (0.05 µL), 27.4% OptiMEM (Invitrogen) and 40 nmol/L of the siRNA 
SMARTpool (total volume 37.5 µL). Cells were reverse transfected and seeded onto the 
siRNA cocktail at a density of 700 MCF10A cells/well and 900 CDH1-/- cells/well to enable 
the two cell lines to reach confluence at the same time point (72 hours after seeding). The 
following controls were included in each plate: the death controls siEGFR and siPLK1 (4 
wells each), a synthetic lethal control siCTNNB1 (6 wells) and two negative controls, siRISC 
free and mock (lipid only, 9 wells each). After 24 hours, the media was replaced and at 72 
hours 10 μL CellTiter-Glo® was added to each well (final concentration 1/5), shaken on an 
orbital shaker for 2 minutes and incubated for a further 30 minutes at room temperature 
before measuring luminescence using a Synergy H4 microplate reader (Biotek). siRNA was 
dispensed using a Caliper Sciclone ALH3000 (PerkinElmer). All other liquid handling steps 
were performed using a Biotek406 liquid handling workstation. Primary screen analysis was 
performed by normalizing genes in each cell line individually to the average mock value 
(across all screen plates) for the respective cell line. The level of increased kill was 
determined by the ratio of CDH1-/- viability to MCF10A viability. Candidates with MCF10A 
viability ≥50% and a fold change ratio of ≤0.85 were considered synthetic lethal candidates. 
Selection of the final 500 genes chosen for secondary screening was based on further 
analysis of druggability and biological relevance. Secondary siRNA screening was performed 
using four individual siRNAs targeting each gene arrayed in individual wells, separately using 
the same transfection conditions described above with a final siRNA concentration of 25 
nmol/L. The secondary screen was analysed using the same normalization strategy and cut 




Dharmacon pGIPZ lentiviral shRNA mir30 plasmids were prepared from cultures using the 
Machery Nagel EasyPure Miniprep kit. 293FT cells were co-transfected 24hr after seeding 
with 18.6 µg pGIPZ, 9.6 µg PAX2 and 4.8 µg VSVG plasmids using 55.7 µL Lipofectamine 
2000 (Invitrogen). Media was changed at 24 hours, and after a further 24 hours viral particles 
were harvested by aspirating media, centrifugation at 3,000 rpm for 15 minutes to remove 
cellular debris and filtration through a 0.45 µM PVDF filter. Virus was aliquoted and snap 
frozen for subsequent use.  
 
Viral titer was determined by seeding MCF10A cells at 4000 cells/well and transducing with a 
1/32 dilution of virus 24 hours later. Media was changed after 24 hours, and after a further 24 
hours GFP expressing cells were quantitated over 5 fields at 10x magnification. The average 
number of transduced cells/well was used to determine the number of transducing units per 
mL.  
 
For knockdown experiments, 1000 MCF10A and 2000 CDH1-/- cells/well were seeded in 
black walled, clear bottomed 96 well plates and allowed to adhere overnight. The following 
day, virus was added at a multiplicity of infection (MOI) of 10. Media was changed at 24 
hours and 1 µg/mL puromycin added. 72 hours after transduction, media was aspirated and 
1 µg/mL Hoechst 33342 and 0.5 µg/mL propidium iodide in PBS added. After 30 minutes 
incubation plates were imaged with 4 fields/well on the Cytell (GE) at 4x magnification and 10 
fields/well at 10x magnification using the ‘Cell Viability BioApp’. CellProfiler (16) was used to 
quantitate the total nuclei, as well as the proportion stained with propidium iodide.  
 
RNA was extracted at 72 hours to determine gene knockdown using the RNAgem-PLUS kit 
(ZyGem). cDNA was synthesized using the Primescript cDNA synthesis kit (Takara), and RT-
qPCR performed using Sybr Fast kit (KAPA) on an ABI7900HT with an enzyme activation 
step of 95˚C for 3 minutes followed by 40 cycles of 95˚C for 15 seconds, 57˚C for 15 seconds 
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and 72˚C for 15 seconds. GAPDH and PPIA were used as reference genes and results were 
analysed using the efficiency method as described by Pfaffl (17). 
 
Known drug screen 
Assay ready plates containing 20 nL of 4,057 compounds diluted in DMSO at four 
concentrations (2 μmol/L, 1 μmol/L, 0.5 μmol/L and 0.25 μmol/L) were prepared by the 
Walter and Eliza Hall Institute (WEHI) High-Throughput Chemical Screening Facility. Cells 
were seeded directly onto these plates in a volume of 50 μL at a density of 1000 cells/well for 
MCF10A and 1,200 cells/well for CDH1-/- in 384 well clear bottom plates. After 48 hours, 20 
μL of CellTiter-Glo® (Promega) was added to each well, shaken for 2 minutes on an orbital 
shaker and incubated for 30 minutes before reading. Values were normalised to the average 
DMSO control value of the whole screen for each cell line at each concentration. 
 
The secondary drug screen was performed on 316 compounds selected from the primary 
screen. These were provided at 5 μmol/L and 11 1:1 dilutions were made with DMSO to 
create a 5 μmol/L to 5 nmol/L concentration range. Cells were seeded at a density of 700 
cells/well for MCF10A and 900 cells/well for CDH1-/- for 24 hours before 100 nL of each 
compound was added to the plates robotically. 32 DMSO control wells were included in each 
plate. Plates were incubated for a further 48 hours before assaying with CellTiter-Glo®.  
 
Drug titrations and time course assays 
To determine drug EC50, cells were seeded in white walled, clear bottom 384 well plates at a 
density of 800 cells/well in a volume of 45 μL. After 24 hours incubation, 5 μl of drug 
(rehydrated in DMSO to an 80 mM stock and diluted in complete media) was added to each 
well. A DMSO control and a cell only control were used on each plate. The 11 drug 
concentrations used were dependent on the individual drug. After 48 hours of treatment, cell 
viability was assayed using either the CellTiter-Glo® (Promega) or Alamar blue assay. All 
results were normalized to the average DMSO control for individual cell types. EC50 values 
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were calculated by plotting viability against the log drug concentration and fitting a nonlinear 
regression curve using Prism version 6.0 for Mac (GraphPad Software). 
 
Drug time course assays were carried out by seeding equal numbers of MCF10A or CDH1-/- 
at 4000 cells/well in xCELLigence plates (Roche), except for Crizotinib which was seeded at 
2000 cells/well. The xCELLigence system measures relative changes in electrical impedance 
in a well (‘cell proliferation index’) which can be used as a measure of cell number. After 24 
hours, three concentrations of each drug were added and growth followed in real time for a 
further 72 hours. Assays were carried out in duplicate and the data averaged. Time course 
assays were also performed on the IncuCyte imaging system (Essen Bioscience). Cells were 
seeded at 4000 cells/well in black walled clear bottom 96 well plates. After 24 hours, five 
concentrations of each drug were added and 3 fields were imaged/well at 4x magnification 
every 2 hours for 48 hours. Plates were then removed and cell numbers determined using 
metabolic assays and nuclei imaging as described above. 
 
For drug synergy studies, the combination index was determined using CompuSyn software 
(ComboSyn Inc) and the Chou-Talalay method (18). EC50 was estimated for both drugs and 
cells treated with each drug alone and in combination at this concentration and 
concentrations two and four fold higher and lower. Viability was calculated by nuclei counting 
and normalized values imported into CompuSyn.  
 
Results 
Genome-wide siRNA screen of CDH1 isogenic MCF10A cells 
To identify genes potentially involved in a synthetic lethal interaction with E-cadherin, we 
conducted a genome-wide functional screen using the Dharmacon siGENOME SMARTpool 
library targeting 18,120 genes in a pooled format, with 4 individual siRNAs targeting each 
gene. Isogenic MCF10A cells with and without CDH1 expression were screened in parallel, 
and viability was assayed 72 hours after transduction using CellTiter-Glo®. siPLK1 and 
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siEGFR were used as positive death controls (Fig. 1A) and siCTNNB1 used as a positive 
synthetic lethal control, after showing a mild synthetic lethal effect in a pilot screen 
(Supplementary Figure S1). Mock (lipid only) and RISC-free control (Dharmacon) were 
included as non-targeting controls. Little variability was observed between these controls; 
consequently we normalized the values of each gene to the average screen-wide mock value 
within each cell line.  Hits were selected based on the ratio of cell viability between the 
MCF10A and CDH1-/- cells 72 hours after transduction (Fig. 1B). We rejected siRNAs that 
were highly toxic to the MCF10A cells (a decrease in viability of ≥50%) and selected those 
for which the viability of CDH1-/- cells decreased by ≥15% more than the corresponding 
knockdown in MCF10A cells. These targets were classed as CDH1 synthetic lethal candidate 
genes (List SL1, 2,437 genes; Supplementary Table S1). From this set, 501 genes were 
manually selected for secondary screening using criteria including predicted druggability of 
the encoded proteins and biological significance. The secondary screen was performed by 
deconvoluting the four individual siRNAs that consititute the SMARTpool. Using the same 
stringent threshold as the primary screen (ie. MCF10A viability ≥50% and ≥15% more death 
in CDH1-/-), 21 genes (5%) had 3/4 or 4/4 of the individual siRNAs show a synthetic lethal 
effect. 183 genes (44%) had 1/4 or 2/4 siRNAs validate. 51% of genes were not validated 
(0/4) by this approach. Division of the selected genes into groups based on the strength of 
the synthetic lethal phenotype in the primary screen demonstrated that candidates which 
showed a greater viability differential between MCF10A and CDH1-/- cells were more likely to 
be validated in the secondary screen (Fig. 1C-D). Of the candidates that reduced CDH1-/- cell 
number by ≥25% more than MCF10A cells, 12% validated with 3/4 or 4/4 individual siRNAs, 
a validation rate comparable to other genome-wide RNAi studies (19, 20). 
 
Functional Diversity: Gene Ontology analysis  
To search for functional enrichment in the 2,437 synthetic lethal candidates identified in the 
primary screen (List SL1), we conducted a gene ontology analysis using DAVID (21). Using 
the Functional Annotation Clustering tool, the most enriched functional cluster was a group of 
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ten terms associated with G-protein coupled receptor (GPCR) signalling (Enrichment 
Score=10.01; Supplementary Table S2A). Accordingly, the two most significant biological 
process terms (Supplementary Table S2B) were ‘G-protein coupled receptor protein 
signalling pathway’ (Benjamini-adjusted p value= 4.1x10-8) and ‘cell surface receptor linked 
signal transduction’ (adj. p value=1.7x10-5). These cell signalling processes were strongly 
reflected in the DAVID gene ontology molecular function terms (Supplementary Table S2C) 
which included peptide, neuropeptide and purinergic nucleotide receptor activity and protein 
kinase activity (adj. p value 3.5x10-7 to 3.2x10-2). 
 
Because our ultimate goal is to identify targeted drugs for E-cadherin-deficient tumors that 
have minimal toxicity against non-malignant tissues, we also performed gene ontology 
analysis on a subset of genes from List SL1 whose corresponding siRNA SMARTpools had 
little or no impact on MCF10A cells (MCF10A viability ≥0.85 mock). 1,136 genes met this 
revised threshold (List SL2; Supplementary Table S3). Notably, this more stringent cut-off led 
to further enrichment of both the GPCR-associated functional cluster (Enrichment Score 
12.14) and the biological process terms ‘G-protein coupled receptor protein signalling 
pathway’ (adj. p value= 9.0x10-16) and ‘cell surface receptor linked signal transduction’ (adj. 
p value=4.8x10-10; Supplementary Table S2D). 
 
Our earlier observation of abnormal cytoskeletal organization in E-cadherin-deficient 
MCF10A cells (7) prompted us to look for specific cytoskeletal functions associated with 
synthetic lethality. Although the adjusted p-values for cytoskeletal-like terms in List SL1 and 
SL2 did not reach significance, DAVID functional clusters associated with each of cell motility, 
cell polarity and cell adhesion were amongst the top five clusters observed in the group of 
synthetic lethal candidate genes which reduced MCF10A viability to <0.85 of the mock 
controls (Enrichment Scores 2.18, 1.97 and 1.84, respectively; Supplementary Table S2E). 
This greater representation of cytoskeletal genes amongst synthetic lethal candidates which 
impact seriously on MCF10A cell viability presumably reflects the essential role of many 
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cytoskeletal proteins. Cyto- or nucleoskeletal functions that were represented in List SL1, 
often by multiple family members, included microtubule nucleation, organization and function 
(eg. TUBA1C, TUBG1, TUBB2A, MZT2A, ARPC3, NME4, NME7, MAST1, MAST2, MAST3, 
NEK1, NEK3, NEK4, NEK10, CLIP1, CLIP2, TEKT3, TEKT4, TEKT5), Rho-mediated motility 
(eg. RHOB, RHOC, RHOH, RAC1, PAK2, TIAM1), linkages between the cytoskeleton and 
nucleoskeleton (eg. SUN1, SUN2, SUN5, NSUN3, NSUN6, SYNE1), polarity (eg. DLG1, 
DLG2, DLG4, DLG5, CELSR1, CELSR3) and actin filament organization and remodelling (eg. 
AVIL, ARF6, CYTH2, CTYH3, CYTH4). 
 
E-cadherin-deficient MCF10A cells are sensitive to downregulation of microtubule 
associated genes and the aurora kinase A inhibitor Alisertib 
To validate the apparent synthetic lethal interaction between E-cadherin and the microtubule 
cytoskeleton, we selected three microtubule associated genes, MAST2, MAP1B and 
MAPRE3 for confirmation using lentiviral shRNA knockdown. MAST2 is a microtubule-
associated serine-threonine kinase (22); MAP1B is a microtubule binding and stabilizing 
protein that can also interact with actin microfilaments (23) and MAPRE3 is a microtubule 
plus end binding protein involved in regulating the dynamics of microtubules and their 
interactions with intracellular structures such as the cell cortex or mitotic kinetochore (24). 
These three genes had previously been validated in the secondary screen, with 3/4, 2/4 and 
1/4 siRNAs, respectively, decreasing the viability of CDH1-/- cells by at least 15% more than 
the MCF10A (Fig. 2A). shRNAs targeting these three genes resulted in 51-86% mRNA 
knockdown in both cell lines (Fig. 2B). 72 hours after transduction, cell viability was 
measured using nuclei counting (Fig. 2C). Knockdown of each of MAP1B, MAST2 and 
MAPRE3 resulted in 15-29% more cell death in the CDH1-/- cells compared to the MCF10A 
cells, confirming the siRNA data. 
 
To determine whether the synthetic lethal phenotype observed with downregulation of 
microtubule associated genes could be recapitulated using known inhibitors of microtubule 
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function, we treated the isogenic MCF10A cell line pair with the microtubule stabilising drug 
Taxol and inhibitors of the microtubule-associated proteins aurora kinase A and aurora 
kinase B. Increasing concentrations of Taxol (1-16 nmol/L) led to a small increase in cell 
death in CDH1-/- cells compared to MCF10A cells (Supplementary Figure S2). The aurora 
kinase A inhibitor Alisertib and the aurora kinase B inhibitor Danusertib both showed a minor 
synthetic lethal effect (Fig. 2D-E), with 18% (at 25 nmol/L) and 12% (50 nmol/L) more death 
in the CDH1-/- line, respectively. Together, the RNAi and aurora kinase inhibitor data 
demonstrate that E-cadherin-deficient MCF10A cells are more vulnerable to disruption of 
specific microtubule-related functions than E-cadherin expressing MCF10A cells. 
 
E-cadherin-deficient MCF10A cells show vulnerabilities in GPCR signalling  
Gene ontology analysis (21) identified >200 genes from our list of synthetic lethal candidates 
(List SL1) that were associated with GPCR protein signalling pathways. These candidates 
included several proteins involved in signal transduction from activated GPCRs such as the 
G protein subunits GNAS, GNAT1, GNG2 and GNG5, the membrane bound adenyl cyclase 
ADCY7 and the downstream signalling protein JAK2. ADCY7 validated in the secondary 
screen with 4/4 siRNAs recapitulating the SMARTpool phenotype (Fig. 3A). The synthetic 
lethal effect of the JAK2 siRNA SMARTpool was confirmed using lentiviral-mediated shRNA 
transduction. Both the siRNA SMARTpool and lentiviral shRNA knocked down JAK2 mRNA 
by >44% (Fig. 3B). Normalized cell numbers post transduction were significantly lower in the 
CDH1-/- cells compared to the MCF10A cells for both the siRNA pool and the shRNA (Fig. 
3C). To determine whether the synthetic lethality of JAK2 downregulation could be mimicked 
using a JAK2 antagonist, we treated the isogenic CDH1 MCF10A cell line pair with the JAK 
inhibitor LY2784544. Using the xCELLigence system to monitor cell growth in real time, 
LY2784544 had only a modest effect on MCF10A cells at 0.32, 0.63 and 1.25 μmol/L 
concentrations, however the cell proliferation index was reduced in the CDH1-/- cells in a 
concentration-dependent manner. 48 hours after drug addition, the three concentrations of 
LY2784544 resulted in a 15%, 29% and 51% reduction in CDH1-/- cell number, respectively 
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(Fig. 3D). In contrast, the three drug concentrations reduced MCF10A cell number by 0%, 
11% and 10%, respectively. A second JAK2 inhibitor, AG490, showed a similar synthetic 
lethal response in xCELLigence assays (data not shown). Further real time assays using the 
IncuCyte replicated this effect (Supplementary Figure S3). Nuclei counting confirmed a 
significant synthetic lethal effect at LY2784544 concentrations of 1.25 μmol/L (p=0.005) and 
0.63 μmol/L (p=0.03) (Fig. 3E). LY2784544 resulted in cells becoming more spindle shaped, 
with an increased number of extended filopodia; this effect was particularly marked in the 
CDH1-/- cells (Fig. 3F).  
 
The presence of G protein subunits in list SL1 prompted us to examine CDH1 synthetic 
lethality using the Gαand Gαo subunit inhibitor Pertussis toxin (25). Treatment of 
MCF10A and CDH1-/- cells with 10, 100 and 200 ng/ml of Pertussis toxin over a period of 48 
hours resulted in growth inhibition of both MCF10A and CDH1-/- cell lines in a concentration 
dependent manner (Fig. 3G). However, the MCF10A cells recovered and reached the same 
confluence as the PBS control after 48 hours, whereas the CDH1-/- cells showed 20-30% 
less confluence at that time point for the three drug concentrations.  
 
E-cadherin loss sensitises MCF10A cells to HDAC inhibitors and other drug classes  
To explore how E-cadherin loss alters sensitivity of MCF10A cells to other known drugs, we 
screened 4,057 compounds against the CDH1 MCF10A isogenic cell line pair. The 
compounds comprised the Walter and Eliza Hall Institute known drug library (3,600 
compounds from the Tocriscreen™ Total library, the Prestwick Chemical Library and the 
‘Lopac 1280’ library), the Selleck Chemistry inhibitor library (326 compounds consisting of 
approximately half known drugs and half kinase inhibitors) and a kinase inhibitor library (131 
compounds supplied by SYNthesis Medicinal Chemistry). The initial screen covered four 
drug concentrations ranging from 0.25 μmol/L to 2 μmol/L, with cell viability measured at 48 
hours after drug addition using the CellTiter-Glo® assay. Potentially synthetic lethal drugs 
were selected for further characterization if they met two criteria: (i) modest toxicity to 
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MCF10A cells (a decrease in viability of no more than 30%) and (ii) a minimum of 15% 
greater reduction in CDH1-/- viability compared to the MCF10A cells at one or more 
concentrations. 316 compounds were selected for secondary analysis using an 11 point 
serial dilution from 5 mmol/L to 5 nmol/L. 21/316 compounds in this secondary screen had 
EC50 values that were 10-50% lower in the CDH1-/- cells compared to the MCF10A cells 
(Table 1). These included multiple histone deacetylase (HDAC) and phosphoinositide 3-
kinase (PI3K) inhibitors, Crizotinib (an inhibitor of receptor tyrosine kinases c-MET, ALK and 
ROS1), CGP 71683 hydrochloride (an inhibitor of the neuropeptide receptor NPY5R) and the 
guanine nucleotide exchange factor inhibitor Brefeldin. The synthetic lethality of the majority 
of drug classes shown in Table 1 was supported by the siRNA primary screen data with one 




The E-cadherin synthetic lethal effects of Crizotinib and several HDAC inhibitors were further 
characterized in time course and direct cell counting studies. Saracatanib, a c-SRC kinase 
inhibitor not included in the 11 point screen was also further examined because of a 
borderline effect in the original four point screen. Crizotinib had little effect on the growth of 
MCF10A cells at 0.63, 1.25 and 2.50 μmol/L up to 48 hours after drug addition, as observed 
using the xCELLigence system. The same concentrations, however, reduced the growth of 
CDH1-/- cells to 86%, 76% and 46% of mock (Fig. 4A). Nuclei counting at 48 hours confirmed 
the synthetic lethal effect, although an inhibitory effect was observed on the MCF10A cells at 
all three concentrations (Fig. 4B). The difference between the nuclei counting method and 
the IncuCyte and xCELLigence methods is primarily due to cell density differences at full 
confluency which can only be determined by direct nuclei counting. 
  
Treatment with Saracatinib caused greater growth inhibition in the CDH1-/- cells compared to 
the MCF10A cells at three different concentrations in two different assay systems, cell 
confluence (IncuCyte) and direct nuclei counting. In the IncuCyte system, a dose dependent 
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inhibition was observed in both isogenic cells with the CDH1-/- cells demonstrating greater 
susceptibility (Fig. 4C). At 0.63 µmol/L, Saracatinib had negligible effect on the confluence of 
MCF10A cells but caused a 26% inhibition of CDH1-/- cells (relative to DMSO) after 48 hours. 
Similarly, differentials of 0.17 (p value=0.06), 0.30 (p value=0.02) and 0.15 (p value=0.10) 
were observed in normalized cell counts of the CDH1-/- cells compared to the MCF10A cells 
at Saracatinib concentrations of 0.63, 1.25 and 2.5 µmol/L, respectively (Fig. 4D).  
 
Entinostat selectively targets class I HDACs, in particular HDAC1-3 (26). 0.63, 1.25 and 2.5 
µmol/L Entinostat had a negligible effect on cell proliferation of MCF10A as determined using 
the xCELLigence system. In contrast, CDH1-/- cells showed 18%, 67% and 78% growth 
inhibition at these concentrations 48 hours after drug addition (Fig. 4E). Comparable results 
were obtained using the IncuCyte (Supplementary Figure S3). Nuclei counting also showed a 
significant synthetic lethal effect across the three Entinostat concentrations, although, as 
observed previously for Crizotinib, reduced nuclei count was observed in both cell lines with 
increasing drug concentration using this more direct method. At concentrations of 0.63, 1.25 
and 2.5 µmol/L, a cell viability differential of 0.13 (p-value=0.04), 0.23 (p-value=0.004) and 
0.14 (p-value=0.02) was observed between the CDH1-/- cells and the MCF10A cells (Fig. 4F). 
 
Vorinostat (SAHA) is a pan HDAC inhibitor, acting on both class I and class II HDACs (26). 
Assays using the IncuCyte system showed preferential inhibition of CDH1-/- cells over 48 
hours of drug treatment at 0.63, 1.25 and 2.5 µmol/L, with little effect on the MCF10A cells 
(Fig. 4G). This effect was confirmed on the xCELLigence system (Supplementary Figure S3). 
Similarly to Entinostat, direct nuclei counting showed a greater effect of Vorinostat on the 
MCF10A cells than was observed using the real-time proliferation assay platforms. A 
significant cell viability differential was still observed between the CDH1-/- and MCF10A cells 
with cell viability differentials of 0.21 (p-value=0.02), 0.29 (p-value=0.01) and 0.17 (p-
value=0.10) between CDH1-/- and MCF10A at concentrations of 0.63, 1.25 and 2.5 µmol/L 
(Fig. 4H). The HDAC inhibitors Mocetinostat and Pracinostat showed comparable synthetic 
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lethal effects when assayed at 0.63, 1.25 and 2.5 µmol/L on the xCELLigence system 
(Supplementary Figure S4A-B). The class I/II HDAC inhibitor valproic acid also showed a 
minor synthetic lethal effect when assayed by direct nuclei counting (Supplementary Figure 
S4C). 
 
Previous reports of synergy between HDAC inhibitors and Taxol (27-30) prompted us to test 
combinations of Taxol and each of Vorinostat and Entinostat in our isogenic cell line pair. 
CompuSyn (ComboSyn Inc) was used to calculate EC50 concentrations, and to determine 
the Combination Index. In contrast to other studies, we found no evidence for synergy 
between Taxol and these HDAC inhibitors (Supplementary Figure S2). 
 
Discussion 
Synthetic lethality provides a potential method to target cancers carrying inactivating 
mutations in tumor suppressor genes such as the E-cadherin gene, CDH1. To provide an 
initial survey of E-cadherin’s synthetic lethal interactions, we conducted a genome-wide 
functional screen of non-malignant, isogenic MCF10A cells with and without E-cadherin 
expression. 13% of the 18,120 genes in the siRNA screen met our threshold for synthetic 
lethality of at least 15% more death in the CDH1-/- cells than the wildtype MCF10A cells. 
Although this threshold is low stringency and subsequently not highly specific, it is clear that 
E-cadherin-deficiency creates large numbers of vulnerabilities in non-malignant cells which 
are exposed by genetic knockdown of additional genes. 
 
Gene ontology analysis identified a striking enrichment for GPCR signalling proteins amongst 
the synthetic lethal candidates. Notably, this enrichment was greater for hits which showed 
minimal impact on the viability of the E-cadherin-expressing MCF10A cells, suggesting that 
drug targeting of GPCR signalling in CDH1 mutant tumors may be a means to obtain clinical 
gain while minimizing collateral damage to normal tissues. The nature of the synthetic lethal 
relationship between E-cadherin and GPCR signalling is not yet known, although the 
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functional diversity of the candidate synthetic lethal GPCR signalling proteins would suggest 
that the interaction involves a common downstream mechanism such as interplay with the 
actin and microtubule cytoskeletons (31-33). The importance of cytoskeletal functions to the 
E-cadherin synthetic lethal phenotype is supported by the abundance of cytoskeletal genes 
associated with synthetic lethality in our primary siRNA screen. These genes were involved 
in all aspects of cytoskeletal function including the nucleation, organization and function of 
microtubules mitotic spindle organization and control, linkages between the cytoskeleton and 
nucleoskeleton, polarity, actin filament organization, vesicle transport, focal adhesion kinase 
signalling and Rho-mediated motility (8, 34-36). The increased vulnerability of E-cadherin-
deficient MCF10A cells to knockdown of so many diverse but inter-related functions is 
consistent with the widespread disorganization of cytoskeletal networks observed in the 
CDH1-/- cells (7). Notably, after CDH1 and TP53, RHOA is the most commonly mutated gene 
in DGC (37-39), emphasizing the importance of dysregulated cytoskeletal function to 
development of the diffuse phenotype. 
The increased vulnerability of E-cadherin-deficient MCF10A cells to RNAi knockdown of 
cytoskeletal and GPCR signalling genes was supported by the increased sensitivity of these 
cells to antagonists of multiple protein families associated with GPCR signalling and 
cytoskeletal function including HDACs (40, 41), JAK (42), aurora kinases (43), c-SRC 
tyrosine kinase (44), G-protein subunits and PI3K (45). The enrichment for GPCR signalling 
genes amongst our synthetic lethal candidates does not, however, exclude the possibility 
that other signalling functions, such as the cytokine responses of JAK2, may also be 
associated with synthetic lethality.  EC50 differences between MCF10A and CDH1-/- cells for 
these known drugs were on average only approximately 25% less in the CDH1-/- cells. This 
small differential is to be expected since neither MCF10A or CDH1-/- cells are tumorigenic 
and therefore these lines cannot be distinguished by the presence/absence of addiction to 
the targeted pathways. Synthetic lethal drugs which are significantly more potent in E-
cadherin-deficient cells will be more readily identified using fit-for-purpose, high-throughput 
compound screens across the MCF10A and other CDH1 isogenic cell line pairs. Differences 
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between the E-cadherin-expressing and E-cadherin-deficient cells may also be more 
pronounced in phenotypes other than cell viability, such as invasive capability.   
 
This research demonstrates for the first time that loss of the tumor suppressor protein E-
cadherin creates druggable vulnerabilities in cells. It remains to be determined whether any 
of the observed drug sensitivities in CDH1-/- cells will be robust to the genetic dysregulation 
of advanced tumors, and therefore able to provide additional clinical benefit in the treatment 
of sporadic CDH1-mutant tumors. Instead, the observed sensitivities may have more near 
term application to HDGC chemoprevention. The natural history of cancer development in 
CDH1 germline mutation carriers involves the development of multifocal lobular carcinoma in 
situ (46, 47) and tens to hundreds of gastric stage T1a signet ring cell carcinomas prior to the 
onset of advanced disease (11, 48, 49). The high multiplicity of these early stage foci argues 
against additional genetic hits being required for their initiation. These early breast and 
gastric cancers are therefore relatively genetically homogenous and distinguished from 
normal tissue predominantly by the cellular changes associated with deficiency of E-cadherin. 
As a consequence, the E-cadherin synthetic lethal interactions identified in the non-malignant 
breast MCF10A cells provide strong leads for drugs that may eliminate early stage disease in 
germline CDH1 mutation carriers, potentially providing a new clinical management option for 
HDGC families.  
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1.76 1.02 0.58 
Entinostat 4.31 2.50 0.58 
Quisinostat  0.05 0.04 0.72 
Pracinostat 0.73 0.54 0.74 
LAQ824 0.09 0.06 0.76 
Panobinostat 0.08 0.07 0.84 
Crizotinib 
ROS1-like tyrosine 
kinase inhibitor 5.53 3.98 0.72 
PI103 
PI3K inhibitor 
0.75 0.59 0.79 
GSK2126458  0.05 0.04 0.79 
PIK-75 
hydrochloride 0.08 0.07 0.89 
CGP 71683 
hydrochloride NPY5R inhibitor 3.92 3.47 0.89 
Tyrphostin A9 
PDGFR and 
EGFR inhibitor 1.30 0.65 0.50 
AZD8055 mTOR inhibitor 0.22 0.12 0.53 
Obatoclax 
Mesylate BCL2 inhibitor 0.63 0.47 0.74 




inhibitor 0.20 0.15 0.76 
LY2784544 
JAK family 





phosphorylation 3.74 2.90 0.78 
JNJ-7706621 
CDK and aurora 
kinase inhibitor 3.37 2.77 0.82 
Danusertib 
Inhibitor of aurora 
kinases, Bcr-Abl, 









B inhibitor 8.10 7.26 0.90 
 
Table 1. Known drugs with greater inhibitory effect on MCF10A cells compared to CDH1-/- 
cells. EC50 values were obtained from 11 point dilution curves carried out at least in 
duplicate. Cell viability was determined using the CellTiter-Glo® assay 72 hours after 
drug addition. The CDH1-/- to MCF10A ratio is a measure of the reduced viability of the 




Figure 1. siRNA screening overview of outcomes and analysis strategy 
 
(A) The resulting effect on cell viability after knockdown of each protein-coding target in 
MCF10A and CDH1-/- cells.  The positive death controls siPLK1 and siEGFR both 
consistently cause death in both cell lines. (B) The analysis workflow used to select synthetic 
lethal candidates based on MCF10A and CDH1-/- viability. (C) Correlation between primary 
and secondary screens. The dotted line marks where CDH1-/- has 15% less viability than 
MCF10A. The primary screen identified 500 candidates that were selected for validation in a 
secondary screen. 5% of these validates as with 3/4 or 4/4 individual siRNA. (D) Candidates 
tested in the secondary screen were split into two categories, based on the decrease in 
viability of CDH1-/- compared to MCF10A. Candidates with a greater differential were more 
likely to be validated in the secondary screen. 
 
Figure 2. Disruption of microtubule associated proteins induces synthetic lethal effect. 
 
(A) Bar graphs with primary and secondary screen viability normalized to mock for MAST2, 
MAP1B and MAPRE3. Each value is the average of two technical replicates. The 
arrowheads mark siRNAs that reached the synthetic lethal criteria (15% less viability in 
CDH1-/- cells). (B) Level of mRNA knockdown 72 hours after transduction with shRNA 
lentivirus constructs. Error bars show standard error of two independent experiments, except 
for MAST2 which was only assayed once. (C) Nuclei count normalized to non-silencing 
control after knockdown with MAP1B, MAST2 and MAPRE3 shRNA. Error bars show 
standard error of two independent experiments. * = p-value < 0.05 by 1 tailed, equal variance 
Students T-test. (D) Nuclei count normalized to DMSO control 48 hours after Alisertib 
treatment. Error bars show standard error of the mean of two independent experiments. (E) 
Nuclei count normalized to DMSO control 48 hours after Danusertib treatment. A single 
experiment is shown. 
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Figure 3. Disruption of GPCR associated proteins causes synthetic lethality 
 
(A) Bar graphs with primary and secondary screen viability normalized to mock for ADCY7. 
Each value is the average of two technical replicates. All siRNA reached the synthetic lethal 
criteria. (B) Normalized mRNA levels after knockdown by JAK2 shRNA and siRNA pool. (C) 
Nuclei counts normalized to non-silencing (shRNA) or mock (siRNA) controls after 
knockdown by JAK2 RNAi. (D) Representative xCELLigence experiment for cells treated with 
LY2784544. Arrow marks time when compound was added. (E) Nuclei count normalized to 
DMSO 48 hours after LY2784544 treatment. (F) Images taken 48 hours after LY2784544 
treatment showing reduced confluence and morphological changes. (G) Representative 
IncuCyte assay showing confluence over 48 hours after Pertussis toxin treatment. Error bars 
show standard error of at least two independent experiments. * = p-value < 0.05 ** = p-value 
< 0.01 by 1 tailed, equal variance Students T-test. 
 
Figure 4. Treatment with various known drugs causes CDH1 synthetic lethality 
 
(A, E), Representative xCELLigence assay of cells treated with Crizotinib (A) and Entinostat 
(E). Cells were seeded at 4000 or 2000 (Crizotinib) cells/well and drug was added at 24 
hours. Cells were grown for an additional 72 hours. (C, G), Representative IncuCyte assays 
of cells treated with Saracatinib (C) and Vorinostat (G). Cells were seeded at 4,000 cells/well 
and drug was added at 24 hours.  Cells were then grown for an additional 48 hours. (B, D, F, 
H), Nuclei counts normalized to DMSO after treatment with Crizotinib (B), Saracatinib (D), 
Entinostat (F) and Vorinostat (H). Error bars show standard error of at least two independent 
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